SG188641A1 - Matrix metalloproteinase inhibitors - Google Patents
Matrix metalloproteinase inhibitors Download PDFInfo
- Publication number
- SG188641A1 SG188641A1 SG2013021654A SG2013021654A SG188641A1 SG 188641 A1 SG188641 A1 SG 188641A1 SG 2013021654 A SG2013021654 A SG 2013021654A SG 2013021654 A SG2013021654 A SG 2013021654A SG 188641 A1 SG188641 A1 SG 188641A1
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- formula
- amino
- methylsulfonyl
- benzotriazin
- Prior art date
Links
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title description 6
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 886
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 10
- 208000006673 asthma Diseases 0.000 claims abstract description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims abstract description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 4
- 206010013774 Dry eye Diseases 0.000 claims abstract description 4
- 206010019280 Heart failures Diseases 0.000 claims abstract description 4
- 206010027476 Metastases Diseases 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 4
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 4
- 208000006011 Stroke Diseases 0.000 claims abstract description 4
- 208000007565 gingivitis Diseases 0.000 claims abstract description 4
- 230000000302 ischemic effect Effects 0.000 claims abstract description 4
- 208000017169 kidney disease Diseases 0.000 claims abstract description 4
- 230000009401 metastasis Effects 0.000 claims abstract description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 4
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 4
- 230000035755 proliferation Effects 0.000 claims abstract description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 4
- 208000037803 restenosis Diseases 0.000 claims abstract description 4
- 206010039083 rhinitis Diseases 0.000 claims abstract description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 360
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 224
- -1 formyl(4'-methylbiphenyl-4- yl)amino Chemical group 0.000 claims description 219
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 216
- 125000001072 heteroaryl group Chemical group 0.000 claims description 75
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 125000003118 aryl group Chemical group 0.000 claims description 44
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 21
- 150000002431 hydrogen Chemical group 0.000 claims description 20
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 20
- 230000008878 coupling Effects 0.000 claims description 18
- 238000010168 coupling process Methods 0.000 claims description 18
- 238000005859 coupling reaction Methods 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 238000007142 ring opening reaction Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 claims description 8
- YYEZYENJAMOWHW-UHFFFAOYSA-N 2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol Chemical compound CC1(C)OCC(CCO)O1 YYEZYENJAMOWHW-UHFFFAOYSA-N 0.000 claims description 8
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 8
- 150000001356 alkyl thiols Chemical class 0.000 claims description 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 150000003573 thiols Chemical class 0.000 claims description 8
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- FAZPVQXHUWITOS-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)-2-[4-(6-methoxypyridin-3-yl)-n-methylsulfonylanilino]butanoic acid Chemical compound C1=NC(OC)=CC=C1C1=CC=C(N(C(CCN2C(C3=CC=CC=C3C2=O)=O)C(O)=O)S(C)(=O)=O)C=C1 FAZPVQXHUWITOS-UHFFFAOYSA-N 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- 229940124761 MMP inhibitor Drugs 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 4
- 229960004699 valsartan Drugs 0.000 claims description 4
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 4
- IZSBFWXKKYQBHF-MUUNZHRXSA-N (2R)-2-[(4-ethylphenyl)carbamoyl]-2-[[4-(4-ethylphenyl)phenoxy]-formylamino]-4-hydroxybutanoic acid Chemical compound C(C)C1=CC=C(C=C1)C1=CC=C(C=C1)ON([C@@](CCO)(C(=O)O)C(NC1=CC=C(C=C1)CC)=O)C=O IZSBFWXKKYQBHF-MUUNZHRXSA-N 0.000 claims description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 3
- WLGJXUQWHZTSDT-AREMUKBSSA-N CCC(C=C1)=CC=C1C(C=C1)=CC=C1ON([C@](CCO)(C(NC(C=CC=C1)=C1F)=O)C(O)=O)C=O Chemical compound CCC(C=C1)=CC=C1C(C=C1)=CC=C1ON([C@](CCO)(C(NC(C=CC=C1)=C1F)=O)C(O)=O)C=O WLGJXUQWHZTSDT-AREMUKBSSA-N 0.000 claims description 3
- YYGYIJXVJVAZCL-AREMUKBSSA-N CCC(C=C1)=CC=C1C(C=C1)=CC=C1ON([C@](CCO)(C(NC1=CC(F)=CC=C1)=O)C(O)=O)C=O Chemical compound CCC(C=C1)=CC=C1C(C=C1)=CC=C1ON([C@](CCO)(C(NC1=CC(F)=CC=C1)=O)C(O)=O)C=O YYGYIJXVJVAZCL-AREMUKBSSA-N 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 108010061435 Enalapril Proteins 0.000 claims description 2
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 2
- 108010007859 Lisinopril Proteins 0.000 claims description 2
- 108700023400 Platelet-activating factor receptors Proteins 0.000 claims description 2
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 229960000932 candesartan Drugs 0.000 claims description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229940111134 coxibs Drugs 0.000 claims description 2
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
- 229960000873 enalapril Drugs 0.000 claims description 2
- 229960004563 eprosartan Drugs 0.000 claims description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229960002198 irbesartan Drugs 0.000 claims description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 2
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 2
- 229960002394 lisinopril Drugs 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- 102000030769 platelet activating factor receptor Human genes 0.000 claims description 2
- 150000004672 propanoic acids Chemical class 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 claims description 2
- 229960001455 quinapril Drugs 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 150000003873 salicylate salts Chemical class 0.000 claims description 2
- 229960005187 telmisartan Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 4
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 claims 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims 3
- JKSPOYJSEWDDSQ-UHFFFAOYSA-N 2-formamido-4-hydroxybutanoic acid Chemical compound OCCC(C(O)=O)NC=O JKSPOYJSEWDDSQ-UHFFFAOYSA-N 0.000 claims 2
- 229910019567 Re Re Inorganic materials 0.000 claims 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- MICKCJZTFKUVGO-UHFFFAOYSA-N 5-bromo-5-nitrocyclohexa-1,3-diene Chemical compound [O-][N+](=O)C1(Br)CC=CC=C1 MICKCJZTFKUVGO-UHFFFAOYSA-N 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 229940126657 Compound 17 Drugs 0.000 claims 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 claims 1
- 241001274216 Naso Species 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 108010033380 cathepsin-6 Proteins 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 230000002140 halogenating effect Effects 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 25
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract description 21
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract description 21
- 238000000034 method Methods 0.000 abstract description 12
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical class CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 abstract description 7
- 230000004913 activation Effects 0.000 abstract description 6
- 230000002018 overexpression Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 239000008196 pharmacological composition Substances 0.000 abstract description 2
- 206010003246 arthritis Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 305
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 156
- 239000011541 reaction mixture Substances 0.000 description 135
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 130
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- 235000019439 ethyl acetate Nutrition 0.000 description 102
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 94
- 239000012043 crude product Substances 0.000 description 86
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 85
- 238000002360 preparation method Methods 0.000 description 78
- 239000000243 solution Substances 0.000 description 78
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- 239000002904 solvent Substances 0.000 description 65
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 61
- 239000000741 silica gel Substances 0.000 description 52
- 229910002027 silica gel Inorganic materials 0.000 description 52
- 238000006243 chemical reaction Methods 0.000 description 51
- 239000012044 organic layer Substances 0.000 description 51
- 239000000047 product Substances 0.000 description 48
- 229910052938 sodium sulfate Inorganic materials 0.000 description 47
- 235000011152 sodium sulphate Nutrition 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- 239000003480 eluent Substances 0.000 description 43
- 238000003756 stirring Methods 0.000 description 43
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 42
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 38
- 239000000203 mixture Substances 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 238000010511 deprotection reaction Methods 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 20
- 229910000027 potassium carbonate Inorganic materials 0.000 description 19
- 235000011181 potassium carbonates Nutrition 0.000 description 19
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 16
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 13
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 150000007529 inorganic bases Chemical class 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- KKOIRAFXKFYZHQ-UHFFFAOYSA-N n-(4-bromophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=C(Br)C=C1 KKOIRAFXKFYZHQ-UHFFFAOYSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 6
- DMSSTTLDFWKBSX-UHFFFAOYSA-N 1h-1,2,3-benzotriazin-4-one Chemical class C1=CC=C2C(=O)N=NNC2=C1 DMSSTTLDFWKBSX-UHFFFAOYSA-N 0.000 description 6
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000012746 preparative thin layer chromatography Methods 0.000 description 6
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 5
- 239000012300 argon atmosphere Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 4
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 4
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 4
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 4
- 239000012351 deprotecting agent Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- ZDFBKZUDCQQKAC-UHFFFAOYSA-N 1-bromo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1 ZDFBKZUDCQQKAC-UHFFFAOYSA-N 0.000 description 3
- VUZNLSBZRVZGIK-UHFFFAOYSA-N 2,2,6,6-Tetramethyl-1-piperidinol Chemical group CC1(C)CCCC(C)(C)N1O VUZNLSBZRVZGIK-UHFFFAOYSA-N 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 239000005708 Sodium hypochlorite Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 3
- 229960002218 sodium chlorite Drugs 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- BSURSSXBTLDVFU-JOCHJYFZSA-N (2r)-2-[4-(3,4-difluorophenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound CS(=O)(=O)N([C@H](CCN1C(C2=CC=CC=C2N=N1)=O)C(O)=O)C(C=C1)=CC=C1C1=CC=C(F)C(F)=C1 BSURSSXBTLDVFU-JOCHJYFZSA-N 0.000 description 2
- YDHPAUDFFKHYSA-JOCHJYFZSA-N (2r)-2-[4-(3,4-dimethoxyphenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(N([C@H](CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)C=C1 YDHPAUDFFKHYSA-JOCHJYFZSA-N 0.000 description 2
- BTMRYPLBSLAAOV-HSZRJFAPSA-N (2r)-2-[4-(3-fluoro-4-methylphenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=C(F)C(C)=CC=C1C1=CC=C(N([C@H](CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)C=C1 BTMRYPLBSLAAOV-HSZRJFAPSA-N 0.000 description 2
- VQAHDWIRXNQSMA-HSZRJFAPSA-N (2r)-2-[4-(4-fluoro-3-methylphenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=C(F)C(C)=CC(C=2C=CC(=CC=2)N([C@H](CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)=C1 VQAHDWIRXNQSMA-HSZRJFAPSA-N 0.000 description 2
- TWVHTTLFDXXZAI-JOCHJYFZSA-N (2r)-2-[4-(4-fluorophenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound CS(=O)(=O)N([C@H](CCN1C(C2=CC=CC=C2N=N1)=O)C(O)=O)C(C=C1)=CC=C1C1=CC=C(F)C=C1 TWVHTTLFDXXZAI-JOCHJYFZSA-N 0.000 description 2
- LCHDMONIBANHSI-OAQYLSRUSA-N (2r)-2-[4-(6-methoxypyridin-3-yl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=NC(OC)=CC=C1C1=CC=C(N([C@H](CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)C=C1 LCHDMONIBANHSI-OAQYLSRUSA-N 0.000 description 2
- QMRJQRODOGCULH-DEOSSOPVSA-N (2s)-4-[(2,4-difluorophenyl)carbamoyloxy]-2-[4-(4-ethylphenyl)-n-formylanilino]butanoic acid Chemical compound C1=CC(CC)=CC=C1C1=CC=C(N(C=O)[C@@H](CCOC(=O)NC=2C(=CC(F)=CC=2)F)C(O)=O)C=C1 QMRJQRODOGCULH-DEOSSOPVSA-N 0.000 description 2
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 2
- BMEGKDKVYAVQFD-UHFFFAOYSA-N 2-(4-chloro-n-methylsulfonylanilino)-4-(6-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound O=C1C2=CC(OC)=CC=C2N=NN1CCC(C(O)=O)N(S(C)(=O)=O)C1=CC=C(Cl)C=C1 BMEGKDKVYAVQFD-UHFFFAOYSA-N 0.000 description 2
- KQXNXNRTALKUKO-UHFFFAOYSA-N 2-(4-chloro-n-methylsulfonylanilino)-4-(7-methyl-4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C=1C(C)=CC=C(C2=O)C=1N=NN2CCC(C(O)=O)N(S(C)(=O)=O)C1=CC=C(Cl)C=C1 KQXNXNRTALKUKO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HSOICRGLXKSGLP-UHFFFAOYSA-N 2-[4-(2,4-dimethoxyphenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound COC1=CC(OC)=CC=C1C1=CC=C(N(C(CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)C=C1 HSOICRGLXKSGLP-UHFFFAOYSA-N 0.000 description 2
- BTMRYPLBSLAAOV-UHFFFAOYSA-N 2-[4-(3-fluoro-4-methylphenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=C(F)C(C)=CC=C1C1=CC=C(N(C(CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)C=C1 BTMRYPLBSLAAOV-UHFFFAOYSA-N 0.000 description 2
- DVPZFOQSHRQKQT-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-n-methylsulfonylanilino]-4-(5-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound O=C1C=2C(OC)=CC=CC=2N=NN1CCC(C(O)=O)N(S(C)(=O)=O)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 DVPZFOQSHRQKQT-UHFFFAOYSA-N 0.000 description 2
- FYTRGZIXYMPDOI-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-n-methylsulfonylanilino]-4-(5-methyl-1,3-dioxoisoindol-2-yl)butanoic acid Chemical compound O=C1C2=CC(C)=CC=C2C(=O)N1CCC(C(O)=O)N(S(C)(=O)=O)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 FYTRGZIXYMPDOI-UHFFFAOYSA-N 0.000 description 2
- ZHKWXOHEBDNZHN-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-n-methylsulfonylanilino]-4-[4-oxo-7-(trifluoromethyl)-1,2,3-benzotriazin-3-yl]butanoic acid Chemical compound N1=NC2=CC(C(F)(F)F)=CC=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 ZHKWXOHEBDNZHN-UHFFFAOYSA-N 0.000 description 2
- GWQLSZSGHRAXLH-UHFFFAOYSA-N 2-[4-(4-ethylphenyl)-n-formylanilino]-4-(5-methyl-4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=CC(CC)=CC=C1C1=CC=C(N(C=O)C(CCN2C(C3=C(C)C=CC=C3N=N2)=O)C(O)=O)C=C1 GWQLSZSGHRAXLH-UHFFFAOYSA-N 0.000 description 2
- TWVHTTLFDXXZAI-UHFFFAOYSA-N 2-[4-(4-fluorophenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound N1=NC2=CC=CC=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C1=CC=C(F)C=C1 TWVHTTLFDXXZAI-UHFFFAOYSA-N 0.000 description 2
- OYAJVFJAJSXGNH-UHFFFAOYSA-N 2-[4-(4-methylphenoxy)-n-methylsulfonylanilino]-4-[4-oxo-7-(trifluoromethyl)-1,2,3-benzotriazin-3-yl]butanoic acid Chemical compound C1=CC(C)=CC=C1OC1=CC=C(N(C(CCN2C(C3=CC=C(C=C3N=N2)C(F)(F)F)=O)C(O)=O)S(C)(=O)=O)C=C1 OYAJVFJAJSXGNH-UHFFFAOYSA-N 0.000 description 2
- PGLLXBYTXMPJNT-UHFFFAOYSA-N 2-[4-(4-tert-butylphenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(N(C(CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)C=C1 PGLLXBYTXMPJNT-UHFFFAOYSA-N 0.000 description 2
- GEFVNTFPBQUHKC-UHFFFAOYSA-N 2-[4-[(3-fluorophenyl)carbamoyl]-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound N1=NC2=CC=CC=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C(=O)NC1=CC=CC(F)=C1 GEFVNTFPBQUHKC-UHFFFAOYSA-N 0.000 description 2
- JBCGFTKPZGJEMV-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)carbamoyl]-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound N1=NC2=CC=CC=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C(=O)NC1=CC=C(Cl)C=C1 JBCGFTKPZGJEMV-UHFFFAOYSA-N 0.000 description 2
- MRIIBPZWDVRFSG-UHFFFAOYSA-N 2-[4-[(4-methoxyphenyl)carbamoyl]-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=CC=C(N(C(CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)C=C1 MRIIBPZWDVRFSG-UHFFFAOYSA-N 0.000 description 2
- KQAIHVIRXRZREL-UHFFFAOYSA-N 2-[n-formyl-4-(4-methylphenyl)anilino]-4-(6-methyl-4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=CC(C)=CC=C1C1=CC=C(N(C=O)C(CCN2C(C3=CC(C)=CC=C3N=N2)=O)C(O)=O)C=C1 KQAIHVIRXRZREL-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- ZJNMQRXRGJHJIU-UHFFFAOYSA-N 3-(3,4-dihydroxybutyl)-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(CCC(O)CO)N=NC2=C1 ZJNMQRXRGJHJIU-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- CTYNNYZJNCYGTJ-UHFFFAOYSA-N 3-[2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl]-1,2,3-benzotriazin-4-one Chemical compound O1C(C)(C)OCC1CCN1C(=O)C2=CC=CC=C2N=N1 CTYNNYZJNCYGTJ-UHFFFAOYSA-N 0.000 description 2
- WYKODAZEHYRXSG-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)-2-(4-ethyl-n-methylsulfonylanilino)butanoic acid Chemical compound C1=CC(CC)=CC=C1N(S(C)(=O)=O)C(C(O)=O)CCN1C(=O)C2=CC=CC=C2C1=O WYKODAZEHYRXSG-UHFFFAOYSA-N 0.000 description 2
- MBOXVQDHQBYPCU-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)-2-(n-methylsulfonyl-4-phenylanilino)butanoic acid Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C1=CC=CC=C1 MBOXVQDHQBYPCU-UHFFFAOYSA-N 0.000 description 2
- HMKSXJBFBVGLJJ-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C(=O)N(CCCC(=O)O)C(=O)C2=C1 HMKSXJBFBVGLJJ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QJFMIEFKWFPMNR-UHFFFAOYSA-N 4-(5-methyl-1,3-dioxoisoindol-2-yl)-2-[4-(4-methylphenoxy)-n-methylsulfonylanilino]butanoic acid Chemical compound C1=CC(C)=CC=C1OC1=CC=C(N(C(CCN2C(C3=CC(C)=CC=C3C2=O)=O)C(O)=O)S(C)(=O)=O)C=C1 QJFMIEFKWFPMNR-UHFFFAOYSA-N 0.000 description 2
- WIGNVDLZZAMWRL-UHFFFAOYSA-N 4-(7-chloro-4-oxo-1,2,3-benzotriazin-3-yl)-2-[4-(4-chlorophenyl)-n-methylsulfonylanilino]butanoic acid Chemical compound N1=NC2=CC(Cl)=CC=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 WIGNVDLZZAMWRL-UHFFFAOYSA-N 0.000 description 2
- UKRUJPIJOJHCOB-UHFFFAOYSA-N 5-methylisoindole-1,3-dione Chemical compound CC1=CC=C2C(=O)NC(=O)C2=C1 UKRUJPIJOJHCOB-UHFFFAOYSA-N 0.000 description 2
- CEWDCEMCFUGDMG-UHFFFAOYSA-N 6-methyl-1h-1,2,3-benzotriazin-4-one Chemical compound N1=NNC(=O)C2=CC(C)=CC=C21 CEWDCEMCFUGDMG-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- LBIDHZHSONRKHK-UHFFFAOYSA-N O=C1N(C(C2=CC=CC=C12)=O)CCC(C(=O)O)N(C1=CC=C(C=C1)C(C)C)S(=O)(=O)C Chemical compound O=C1N(C(C2=CC=CC=C12)=O)CCC(C(=O)O)N(C1=CC=C(C=C1)C(C)C)S(=O)(=O)C LBIDHZHSONRKHK-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- HGZGRVDCPDIELF-UHFFFAOYSA-N benzyl 2,4-dihydroxybutanoate Chemical compound OCCC(O)C(=O)OCC1=CC=CC=C1 HGZGRVDCPDIELF-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- ZSBGJIPLRFDOJE-UHFFFAOYSA-N n-(4-phenylphenyl)methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C1=CC=CC=C1 ZSBGJIPLRFDOJE-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- LIBASNWCFRYHQB-UHFFFAOYSA-N (2,3-dichlorophenyl)-diphenylphosphane Chemical compound ClC1=CC=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1Cl LIBASNWCFRYHQB-UHFFFAOYSA-N 0.000 description 1
- BCJQCZXMZQQGDH-JOCHJYFZSA-N (2r)-2-[4-(3-fluoro-4-methoxyphenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=C(F)C(OC)=CC=C1C1=CC=C(N([C@H](CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)C=C1 BCJQCZXMZQQGDH-JOCHJYFZSA-N 0.000 description 1
- RUROLKLUQNPMIT-JOCHJYFZSA-N (2r)-2-[4-(3-fluoro-4-methoxyphenyl)-n-methylsulfonylanilino]-4-[4-oxo-7-(trifluoromethyl)-1,2,3-benzotriazin-3-yl]butanoic acid Chemical compound C1=C(F)C(OC)=CC=C1C1=CC=C(N([C@H](CCN2C(C3=CC=C(C=C3N=N2)C(F)(F)F)=O)C(O)=O)S(C)(=O)=O)C=C1 RUROLKLUQNPMIT-JOCHJYFZSA-N 0.000 description 1
- AYSZQEOHHMYYHE-HSZRJFAPSA-N (2r)-2-[4-(3-methoxyphenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound COC1=CC=CC(C=2C=CC(=CC=2)N([C@H](CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)=C1 AYSZQEOHHMYYHE-HSZRJFAPSA-N 0.000 description 1
- SWOVACJBUVNMKB-HSZRJFAPSA-N (2r)-2-[4-(4-methoxy-3-methylphenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=C(C)C(OC)=CC=C1C1=CC=C(N([C@H](CCN2C(C3=CC=CC=C3N=N2)=O)C(O)=O)S(C)(=O)=O)C=C1 SWOVACJBUVNMKB-HSZRJFAPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- RMGYQBHKEWWTOY-UHFFFAOYSA-N (3,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(F)=C1 RMGYQBHKEWWTOY-UHFFFAOYSA-N 0.000 description 1
- IILGLPAJXQMKGQ-UHFFFAOYSA-N (3-fluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1F IILGLPAJXQMKGQ-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- QXWTVLPBRHGDBI-UHFFFAOYSA-N (5-methoxypyridin-2-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)N=C1 QXWTVLPBRHGDBI-UHFFFAOYSA-N 0.000 description 1
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- DSVGFKBFFICWLZ-UHFFFAOYSA-N 1-fluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C=C1 DSVGFKBFFICWLZ-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- LYUPJHVGLFETDG-UHFFFAOYSA-N 1-phenylbutan-2-ol Chemical compound CCC(O)CC1=CC=CC=C1 LYUPJHVGLFETDG-UHFFFAOYSA-N 0.000 description 1
- NXVNBUYNOIBWFF-UHFFFAOYSA-N 2-(4-ethyl-n-methylsulfonylanilino)-4-(5-methyl-1,3-dioxoisoindol-2-yl)butanoic acid Chemical compound C1=CC(CC)=CC=C1N(S(C)(=O)=O)C(C(O)=O)CCN1C(=O)C2=CC(C)=CC=C2C1=O NXVNBUYNOIBWFF-UHFFFAOYSA-N 0.000 description 1
- ZOYNCGOZCOMUSC-UHFFFAOYSA-N 2-(4-ethyl-n-methylsulfonylanilino)-4-(7-methyl-4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound C1=CC(CC)=CC=C1N(S(C)(=O)=O)C(C(O)=O)CCN1C(=O)C2=CC=C(C)C=C2N=N1 ZOYNCGOZCOMUSC-UHFFFAOYSA-N 0.000 description 1
- 125000006516 2-(benzyloxy)ethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- BSURSSXBTLDVFU-UHFFFAOYSA-N 2-[4-(3,4-difluorophenyl)-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound N1=NC2=CC=CC=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C1=CC=C(F)C(F)=C1 BSURSSXBTLDVFU-UHFFFAOYSA-N 0.000 description 1
- BWUIKXQXGSTCSU-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-n-methylsulfonylanilino]-4-(5-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound N1=NC2=CC=CC(F)=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 BWUIKXQXGSTCSU-UHFFFAOYSA-N 0.000 description 1
- GFELLFJMBDOMBE-UHFFFAOYSA-N 2-[4-[(4-fluorophenyl)carbamoyl]-n-methylsulfonylanilino]-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoic acid Chemical compound N1=NC2=CC=CC=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C(=O)NC1=CC=C(F)C=C1 GFELLFJMBDOMBE-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- PALKPTNUIUCQQI-UHFFFAOYSA-N 2-bromo-4-(1,3-dioxoisoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C(=O)N(CCC(Br)C(=O)O)C(=O)C2=C1 PALKPTNUIUCQQI-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- NKMKDPVCESDJCN-UHFFFAOYSA-N 3-[di(propan-2-yl)carbamoylimino]-1,1-di(propan-2-yl)urea Chemical compound CC(C)N(C(C)C)C(=O)N=NC(=O)N(C(C)C)C(C)C NKMKDPVCESDJCN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
- VPCGOYHSWIYEMO-UHFFFAOYSA-N 4-(4-methylphenoxy)aniline Chemical compound C1=CC(C)=CC=C1OC1=CC=C(N)C=C1 VPCGOYHSWIYEMO-UHFFFAOYSA-N 0.000 description 1
- NQVLOHKMEASTMW-UHFFFAOYSA-N 4-(4-methylphenyl)aniline Chemical compound C1=CC(C)=CC=C1C1=CC=C(N)C=C1 NQVLOHKMEASTMW-UHFFFAOYSA-N 0.000 description 1
- ZNOKJEGZFIOFBO-UHFFFAOYSA-N 4-(5-chloro-4-oxo-1,2,3-benzotriazin-3-yl)-2-[4-(4-chlorophenyl)-n-methylsulfonylanilino]butanoic acid Chemical compound N1=NC2=CC=CC(Cl)=C2C(=O)N1CCC(C(O)=O)N(S(=O)(=O)C)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 ZNOKJEGZFIOFBO-UHFFFAOYSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- FQNFELYQJUZOCU-UHFFFAOYSA-N 5-fluoro-1h-1,2,3-benzotriazin-4-one Chemical compound N1=NNC(=O)C2=C1C=CC=C2F FQNFELYQJUZOCU-UHFFFAOYSA-N 0.000 description 1
- CSGWLWHQULZMID-UHFFFAOYSA-N 5-methoxy-1h-1,2,3-benzotriazin-4-one Chemical compound N1N=NC(=O)C2=C1C=CC=C2OC CSGWLWHQULZMID-UHFFFAOYSA-N 0.000 description 1
- RCLQFKLASUKMCG-UHFFFAOYSA-N 6-fluoro-1h-1,2,3-benzotriazin-4-one Chemical compound N1=NNC(=O)C2=CC(F)=CC=C21 RCLQFKLASUKMCG-UHFFFAOYSA-N 0.000 description 1
- ZUXOEHFEUPXHJE-UHFFFAOYSA-N 6-methoxy-1h-1,2,3-benzotriazin-4-one Chemical compound N1=NNC(=O)C2=CC(OC)=CC=C21 ZUXOEHFEUPXHJE-UHFFFAOYSA-N 0.000 description 1
- RHCFWAXSDIRFTA-UHFFFAOYSA-N 7-(trifluoromethoxy)-1h-1,2,3-benzotriazin-4-one Chemical compound N1N=NC(=O)C=2C1=CC(OC(F)(F)F)=CC=2 RHCFWAXSDIRFTA-UHFFFAOYSA-N 0.000 description 1
- YWAXHDXASAQHSY-UHFFFAOYSA-N 7-methoxy-3H-1,2,3-benzotriazin-4-one 7-(trifluoromethyl)-3H-1,2,3-benzotriazin-4-one Chemical compound FC(C1=CC2=C(C(NN=N2)=O)C=C1)(F)F.COC1=CC2=C(C(NN=N2)=O)C=C1 YWAXHDXASAQHSY-UHFFFAOYSA-N 0.000 description 1
- MNKWOUMDVCJHQD-UHFFFAOYSA-N 7-methyl-1h-1,2,3-benzotriazin-4-one Chemical compound N1N=NC(=O)C=2C1=CC(C)=CC=2 MNKWOUMDVCJHQD-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- YJZPDVBZHWFGHX-UHFFFAOYSA-N 8-methoxy-1h-1,2,3-benzotriazin-4-one Chemical compound N1=NNC(=O)C2=C1C(OC)=CC=C2 YJZPDVBZHWFGHX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910015844 BCl3 Inorganic materials 0.000 description 1
- JMGGABYYXIAEGY-XMMPIXPASA-N C(C1=CC=CC=C1)(=O)OC[C@@H](CCOCC1=CC=CC=C1)N(S(=O)(=O)C)C1=CC=C(C=C1)Br Chemical compound C(C1=CC=CC=C1)(=O)OC[C@@H](CCOCC1=CC=CC=C1)N(S(=O)(=O)C)C1=CC=C(C=C1)Br JMGGABYYXIAEGY-XMMPIXPASA-N 0.000 description 1
- LBPNELQYFJMGDZ-AREMUKBSSA-N CC(C=C1)=CC=C1C(C=C1)=CC=C1ON([C@](CCO)(C(NC1=CC=C(C)C=C1)=O)C(O)=O)C=O Chemical compound CC(C=C1)=CC=C1C(C=C1)=CC=C1ON([C@](CCO)(C(NC1=CC=C(C)C=C1)=O)C(O)=O)C=O LBPNELQYFJMGDZ-AREMUKBSSA-N 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108030001712 Macrophage elastases Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 108010076501 Matrix Metalloproteinase 12 Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000036436 Metzincins Human genes 0.000 description 1
- 108091007161 Metzincins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000350481 Pterogyne nitens Species 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- YTJQMPWJJRJYNI-SFHVURJKSA-N benzyl (2s)-4-hydroxy-2-(4-methoxy-n-methylsulfonylanilino)butanoate Chemical compound C1=CC(OC)=CC=C1N(S(C)(=O)=O)[C@@H](CCO)C(=O)OCC1=CC=CC=C1 YTJQMPWJJRJYNI-SFHVURJKSA-N 0.000 description 1
- VZWPYAZHDANELS-UHFFFAOYSA-N benzyl 2-(4-methoxy-n-methylsulfonylanilino)-4-(4-oxo-1,2,3-benzotriazin-3-yl)butanoate Chemical compound C1=CC(OC)=CC=C1N(S(C)(=O)=O)C(C(=O)OCC=1C=CC=CC=1)CCN1C(=O)C2=CC=CC=C2N=N1 VZWPYAZHDANELS-UHFFFAOYSA-N 0.000 description 1
- QAQQEKKSOHHHNA-UHFFFAOYSA-N benzyl 4-[tert-butyl(dimethyl)silyl]oxy-2-hydroxybutanoate Chemical compound CC(C)(C)[Si](C)(C)OCCC(O)C(=O)OCC1=CC=CC=C1 QAQQEKKSOHHHNA-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960000400 butamben Drugs 0.000 description 1
- KZXMLXDKKPBDBH-UHFFFAOYSA-N butane-1,2-diol Chemical compound C[CH]C(O)CO KZXMLXDKKPBDBH-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000037369 collagen remodeling Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 101150111667 dppD gene Proteins 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- AYEIJQRLYWJQHC-UHFFFAOYSA-N methylsulfanylmethane;trichloroborane Chemical compound CSC.ClB(Cl)Cl AYEIJQRLYWJQHC-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 1
- SPLQTGUKDMGUSV-UHFFFAOYSA-N n-(4-methoxyphenyl)methanesulfonamide Chemical compound COC1=CC=C(NS(C)(=O)=O)C=C1 SPLQTGUKDMGUSV-UHFFFAOYSA-N 0.000 description 1
- DZIPNNUWMDARJP-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)methanesulfonamide Chemical compound CC(C)C1=CC=C(NS(C)(=O)=O)C=C1 DZIPNNUWMDARJP-UHFFFAOYSA-N 0.000 description 1
- HFCHRQNIUUVLOT-UHFFFAOYSA-N n-[4-(4-methylphenoxy)phenyl]methanesulfonamide Chemical compound C1=CC(C)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 HFCHRQNIUUVLOT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DGOCLGVCRBDEFC-IBGZPJMESA-N prop-2-enyl (2s)-2-[4-(4-chlorophenyl)-n-methylsulfonylanilino]-4-hydroxybutanoate Chemical compound C1=CC(N([C@@H](CCO)C(=O)OCC=C)S(=O)(=O)C)=CC=C1C1=CC=C(Cl)C=C1 DGOCLGVCRBDEFC-IBGZPJMESA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- IYLFKXATVSYTQV-UHFFFAOYSA-N tert-butyl-(chloromethoxy)-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCl IYLFKXATVSYTQV-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Abstract
The present invention relates to methyl sulfonamides and N-formamides derivatives of formula (I) and to processes for their syntheses. The invention also relates to pharmacological compositions containing these derivatives and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatie arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, tumor metastasis, and other inflammatory disorders characterized by over expression and over activation of an matrix metalloproteinase using the compounds.
Description
MATRIX METALLOPROTEINASE INHIBITORS
The present invention relates to methyl sulfonamides and N-formamides derivatives and to processes for their syntheses. The invention also relates to pharmacological compositions containing these derivatives and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, tumor metastasis, and other inflammatory disorders characterized by over expression and over activation of a matrix metalloproteinase using the compounds.
Metalloproteinases (MMPs) are a naturally occurring superfamily of proteinases (enzymes) found in most mammals. The superfamily is composed of at least 26 members of zinc-containing enzymes produced by many cell types and sharing structural and functional features. Based on structural and functional considerations proteinases have been classified into different families and subfamilies (Vartak et al., J. Drug Targeting, 15, p. 1-20 (2007), and Hopper, FEBS, 354, p. 1-6 (1994)), such as collagenases (MMP-1, -8 and -13), gelatinases (MMP-2, and -9), metalloclastases (MMP-12), the MT-MMPs (MMP-14,-15, -16, -17, - 24 and 25), matrilysins (MMP-7 and -26), stromelysins (MMP- 3,-10 and -11) and sheddases such as TNF-converting enzymes (TACE and ACE).
Metalloproteinases are believed to be important in physiological disease processes that involve remodeling, such as, airway diseases, embryonic development, bone formation and uterine remodelling during menstruation. One major biological function of
MMPs is to catalyze the breakdown of connective tissues or extra-cellular matrix by their ability to hydrolyze various components of tissue or matrix. Apart from their role in degrading connective tissue, MMPs are involved in the activation of zymogen (pro) forms of other MMPs thereby inducing MMP activation. They are also involved in the biosynthesis of TNF-alpha which is implicated in many pathological conditions.
MMP-9, which belongs to the gelatinase family, plays a major role in chronic inflammatory disorders like COPD, asthma and rheumatoid arthritis. The concentration of
MMP-9 has been reported to increase in diseases like asthma, interstitial pulmonary fibrosis (IPF), adult respiratory distress syndrome (ARDS), and in chronic obstructive 5S pulmonary disease (COPD). Because of its proteolytic ability, MMP-9 has been implicated in tissue remodelling of the airways and lungs in chronic inflammatory diseases, such as severe asthma and COPD. MMP-9 is also likely to be physiologically important because of its ability to regulate the digestion of components of the extracellular matrix as well as the activity of other proteases and cytokines. MMP-9 is secreted in neutrophils, macrophages, osteoclasts, which are easily induced by cytokines and growth factors, and plays a role in various physiological and pathological processes.
MMP-12, also known as macrophage elastase or metalloelastase, is expressed in activated macrophages and has been shown to be secreted from alveolar macrophages from smokers as well as in foam cells in atherosclerotic lesions. MMP-12 knockout mouse studies have shown the development of significant emphysema, thus supporting its role in COPD. MMP-9 (gelatinase B, 92 kDa type IV collagenase) is one member of the
MMP family that is released as a proenzyme and subsequently activated via a protease cascade in vivo.
Over-expression or over-activation of an MMP, or an imbalance between an MMP and a natural, (i.e., endogenous), tissue inhibitor of a matrix metalloproteinase (TIMP) has been linked to a pathogenesis of diseases characterized by the breakdown of connective tissue or extracellular matrix.
Inhibition of the activity of one or more MMPs may be of benefit in treatment of various inflammatory, autoimmue and allergic diseases, such as, inflammation of the joint, inflammation of the GI tract, inflammation of the skin, collagen remodeling, wound healing disorders, etc.
The design and therapeutic application of MMP inhibitors have revealed that the requirement of a molecule to be an effective inhibitor of MMP class of enzymes is a functional group, (e.g., carboxylic acid, hydroxamic acid or sulphydryl) capable of chelating to the active site Zn>" ion (Whittaker et al., Chem. Rev., 99; p. 2735-76 (1999),.
WO 95/35276 discloses N-substituted arylsulphonyl amino acid and their hydroxamic acid derivatives as matrix metallo-proteinase inhibitors. WO 00/06561 discloses tricyclic sulfonamides compounds as matrix metalloproteinases. U.S. Patent No. 6,366,675 discloses N-sulphonyl-diamino: carboxylic acid derivatives used as matrix metalloprotease inhibitors. WO 2004/113279 discloses substituted glycine derivatives, useful for treating inflammatory conditions or autoimmune disorders as matrix metalloproteinase inhibitors.
Research has been carried out into the identification of inhibitors that are selective, e.g., for a few of the MMP subtypes. An MMP inhibitor of improved selectivity would avoid potential side effects associated with inhibition of MMPs that are not involved in the pathogenesis of the disease being treated.
Further, use of more selective MMP inhibitors would require administration of a lower amount of the inhibitor for treatment of disease than would otherwise be required, and after administration, partitioned in vivo among multiple MMPs. Still further, the administration of a lower amount of compound would improve the margin of safety between the dose of the inhibitor required for therapeutic activity and the dose of the inhibitor at which toxicity is observed.
Many drugs exist as asymmetric three-dimensional molecules, i.e., chiral, and will therefore have several stereoisomers depending upon the number of chiral centers present.
The importance of evaluating new chemical entities having chiral centers as single isomers is to understand their effect on pharmacological and toxicological aspects. There are often pharmacodynamic, pharmacokinetic and/or toxicological differences between enantiomers/diasterecomers. Even if natural physiological mediators are achiral, based on their target environment, their receptors/enzymes may demonstrate a preference for only one optically pure enantiomer of agonists, antagonists or inhibitors. From a pharmacokinetics point of view, chirality can have an influence on drug absorption, distribution, metabolism and elimination. Pure single isomers may also offer advantages in terms of these pharmacokinetic parameters thus enabling better developability of such molecules as drug candidates. It is also known that chirality has a significant effect of the physicochemical properties and crystallinity of a chiral molecule which in turn have profound effects on the pharmacokinetics and developability of the molecule. Besides those mentioned above, regulatory principles guide one to preferably develop single isomers as drug candidates in order to avoid any pharmacological, pharmacokinetic and toxicological problems that may arise due to interactions of an unwanted isomer with undesirable molecular targets.
In this context, synthetic strategies to produce pure single isomers offer advantages over analytical techniques of separation of isomer not only in terms of cost and efficiency but larger amounts of compound can be prepared for elaborate pharmaceutical testing.
Thus, compounds of the present invention, which are single chiral isomers, have improved potency, improved pharmacokinetics and/or improved physicochemical properties as compared to racemic compounds.
The present invention is directed to overcoming problems encountered in the art.
The present invention provides the methyl sulfonamide and formamides derivatives as matrix metalloproteinase inhibitors, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. The present invention relates to matrix metalloproteinase inhibitors useful as effective therapeutic or prophylactic agents in treatment of various inflammatory, autoimmune and allergic diseases and other inflammatory disorders characterized by the over expression and over activation of a matrix metalloproteinase using the compounds.
The present invention discloses a novel class of compounds that are dual
MMPY/12 inhibitors and have desirable activity profiles. The compounds of this invention have beneficial potency and/or selectivity.
Pharmaceutical compositions containing such compounds are provided together with the pharmaceutically acceptable carriers or diluents, which can be used for the treatment or prevention of inflammatory and autoimmune diseases. These pharmaceutical compositions may be administered or co administered by a wide variety of routes including, for example, oral, topical, rectal, intranasal or by parenteral route. The composition may also be administered or co-administered in slow-release dosage forms.
Although, specific enantiomers have been shown by way of examples, racemates, diastereomers, and pharmaceutically acceptable salts are also provided. Pharmaceutical compositions comprising the compounds, their enantiomers, racemates, diastereomers and pharmaceutically acceptable salts are also included.
The therapeutically effective amount of one or more compounds of the present invention can be used in combination with one or more other therapeutic agents, for 5 example, other anti-inflammatory agents, antihypertensive agents and immunosuppressive agents
Other objects will be set forth in accompanying description and in the part will be apparent from the description or may be by the practice of the invention.
In accordance with one aspect, there is provided compounds having structure of
Formula I:
EI ye
R2
Formula 1 including racemates, enantiomers, or diastereomers thereof; or a pharmaceutically acceptable salt thereof, wherein,
L! can be selected from bond, O, S, CH, NR? NHCO(CH3),, (CH,),CONH,
NHCONH, SO,NH, NHSO,, NHCO(0O), -O-(CHy)y, -(CH2),-O-, -OC(O)NH-, C(S)NH,
NHC(S), NHC(S)NH or -COO- wherein n can be zero or an integer between 1 and 2;
R' can be selected from hydrogen, C;-Cgalkyl, hydroxyl, C;-Ce alkoxy, cyano, nitro, halogen, halogeno C;-Cealkyl, Cs-Ci2 aryl, Cs-Ciz heteroaryl, C3-Cs cycloalkyl wherein aryl, heteroaryl, cycloalkyl is optionally substituted by one or more substitutents independently selected from R’;
R? can be CHO or SO,C alkyl;
R? can be unsubstituted or substituted heteroaryl or -OCONHR’ where R’ is Ce- Ciaaryl, heteroaryl, cycloalkyl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl,
heterocyclylalkyl each of which is optionally substituted by one or more substitutents independently selected from R’;
R* can be H or Ciealkyl;
R’ can be selected from alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-
Ci-Cg alkyl, halogeno-C;-Cs alkoxy, azido, thiol, alkylthiol, (CH2)n,-ORy, -C(=0)-R¢, -
COORy, -NRRy, -(CH),-C(=O)NRR, -(CH»),-NHC(=0)-Ry, -(CH,),- O-C(=0)-NRR, (CHz2)n NHC(=O)NRR, -(CH2),-O-C(=0)- Ry, -(CH»),-NH-C(=0)-R¢ or -(CH2),S(=0)m-NR:R, {wherein Rr and Rare independently selected from hydrogen, alkyl, alkenyl, cycloalkyl aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl, n is as defined earlier and m is an integer 0-2}.
In one aspect the invention encompasses compounds that include, for example, 2-[Formyl(4'-methylbiphenyl-4-yl)amino]-4-(6-methyl-4-oxo0-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 1); 4-(7-Chloro-4-ox0-1,2,3-benzotriazin-3(4H)-yl)-2-[ formyl(4'-methylbiphenyl-4- yl)amino Jbutanoic acid (Compound no. 2); 2-[(4'-Ethylbiphenyl-4-yl)(formyl)amino]-4-(5-methyl-4-oxo-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 3);
O-[(4-Fluorophenyl)carbamoyl]-V-formyl-N-(4'-methylbiphenyl-4-yl)homoserine (Compound no. 4);
N-Formyl-N-(4'-methylbiphenyl-4-yl)-O-[(4-methylphenyl)carbamoyl]homoserine (Compound no. 5);
O-[(3,4-Dichlorophenyl)carbamoyl]-N-formyl-N-(4'-methylbiphenyl-4- yDhomoserine (Compound no. 6);
N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O- {[4-(propan-2-y])phenyl]carbamoyl } homoserine (Compound no. 7);
N-(4'-Ethylbiphenyl-4-yl)-O-[(3-fluorophenyl)carbamoyl]- N-formylhomoserine (Compound no. 8);
O-[(2,4-Difluorophenyl)carbamoyl]-N-(4'-ethylbiphenyl-4-yl)-N- formylhomoserine (Compound no. 9);
N-(4'-Ethylbiphenyl-4-yl)-O-[(2-fluorophenyl)carbamoyl]- N-formylhomoserine (Compound no. 10);
N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O- {[4-(trifluoromethyl)phenyl]carbamoyl} homoserine (Compound no. 11);
N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O-[(2-methylphenyl)carbamoyl homoserine (Compound no. 12);
N-(4'-Ethylbiphenyl-4-yl)-O-[(4-ethylphenyl)carbamoyl]-N-formylhomoserine (Compound no. 13);
N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O-[(4-methoxyphenyl)carbamoyllhomoserine (Compound no. 14);
O-[(2,6-Dichlorophenyl)carbamoyl]-N-(4'-ethylbiphenyl-4-y1)- N- formylhomoserine (Compound no. 15); 2-[Biphenyl-4-yl(methylsulfonyl)amino]-4-(1,3-dioxo-1,3-dihydro-2 H-isoindol-2- yDbutanoic acid (Compound no. 16); 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-yl)-2- {[4-(6-methoxypyridin-3- yl)phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 17); 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-y1)-2-[ (4'-methoxybiphenyl-4- yl)(methylsulfonyl)amino]butanoic acid (Compound no. 18); 2-{[4-(6-Methoxypyridin-3-yl)phenyl](methylsulfonyl)amino} -4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 19); 4-(7-Methoxy-4-oxo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {[4-(6-methoxypyridin-3- yl)phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 20); 2-{[4-(6-Methoxypyridin-3-yl)phenyl](methylsulfonyl)amino} -4-[4-ox0-7- (trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]butanoic acid (Compound no. 21); 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-yl)-2- {[4-(6-methoxypyridin-3- yl)phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 22); 4-(6-Methoxy-4-oxo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {[4-(4- methylphenoxy)phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 23); 4-(7-Methyl-4-oxo0-1,2,3-benzotriazin-3(4H)-yl)-2- {[4-(4-methylphenoxy) phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 24); 2-{[4-(4-Methylphenoxy)phenyl](methylsulfonyl)amino} -4-[4-oxo-7- (trifluoromethyl)-1,2,3-benzotriazin-3(4 H)-yl]butanoic acid (Compound no. 25); 2- {[4-(4-Methylphenoxy)phenyl](methylsulfonyl)amino} -4-(4-o0xo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 26); 2-[(3',4'-Difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 27); 2-[(4'-Ethylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 28); 2-{[4-(2-Methoxypyrimidin-5-yl)phenyl](methylsulfonyl)amino } -4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 29); 2-[(3'-Fluoro-4'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 30); 2-[(2',4'-Dimethoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 31);
2-[(4-Methoxyphenyl)(methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)- yDbutanoic acid (Compound no. 32); 4-(7-Methoxy-4-oxo0-1,2,3-benzotriazin-3(4H)-yl)-2-[(4- methoxyphenyl)(methylsulfonyl)amino]butanoic acid (Compound no. 33);
4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-y1)-2-[(4-methoxyphenyl) (methylsulfonyl)amino]butanoic acid (Compound no. 34); 2-[(4-Methoxyphenyl)(methylsulfonyl)amino]-4-(5-methyl-1,3-dioxo-1,3-dihydro- 2H-isoindo-2-yl)butanoic acid (Compound no. 35); 4-(7-Methoxy-4-oxo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {[4-(4-
methylphenoxy)phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 36); 4-(5-Methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2- {[4-(4-methylphenoxy) phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 37); 2-[(3'-Methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 38);
2-[(4'-Fluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 39);
2- {(Methylsulfonyl)[4'-(propan-2-yl)biphenyl-4-yl]Jamino } -4-(4-ox0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 40); 2-[Biphenyl-4-yl(methylsulfonyl)amino]-4-(4-oxo-1,2,3-benzotriazin-3(4 H)-
yl)butanoic acid (Compound no. 41); 2-{[4-(6-Methylpyridin-3-yl)phenyl]|(methylsulfonyl)amino} -4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 42); 2-{(Methylsulfonyl)[4-(pyrimidin-5-yl)phenyl]amino} -4-(4-o0xo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 43);
2- {(Methylsulfonyl)[4-(pyridin-3-yl)phenyl]amino} -4-(4-ox0-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 44);
2- {(Methylsulfonyl)[4'-(trifluoromethyl)biphenyl-4-yl]amino} -4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 45); 2- {(Methylsulfonyl)[4-(pyridin-4-yl)phenyl]amino} -4-(4-ox0-1,2,3-benzotriazin-
3(4H)-yl)butanoic acid (Compound no. 46); 2-[(3',4'-Dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 47); 2-[(4'-tert-Butylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 48);
2-[(2',3"-Difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 49); 2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 50);
4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-y1)-2- {(methylsulfonyl)[4-(propan-2- yl)phenyl] amino} butanoic acid (Compound no. 51); 4-(6-Methoxy-4-0x0-1,2,3-benzotriazin-3(4H)-yl)-2- {(methylsulfonyl)[4-(propan- 2-yl)phenyl]amino } butanoic acid (Compound no. 52);
4-(7-Methyl-4-oxo0-1,2,3-benzotriazin-3(4H)-yl)-2- {(methylsulfonyl)[4-(propan-2- yl)phenyl]amino } butanoic acid (Compound no. 53); 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-yl)-2-[(4-ethylphenyl) (methylsulfonyl)amino ]butanoic acid (Compound no. 54); 2-[(4-Ethylphenyl)(methylsulfonyl)amino]-4-(5-methyl-1,3-dioxo-1,3-dihydro-2 H-
isoindol-2-yl)butanoic acid (Compound no. 55); 2-[(4-Ethylphenyl)(methylsulfonyl)amino]-4-(7-methyl-4-oxo0-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 56); 2-[(4-Ethylphenyl)(methylsulfonyl)amino]-4-(6-methoxy-4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 57);
2-[(Methylsulfonyl)(phenyl)amino]-4-(4-o0xo- 1,2,3-benzotriazin-3(4 H)-yl)butanoic acid (Compound no. 58); 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-methyl- 1,3-dioxo-1,3- dihydro-2H-isoindol-2-yl)butanoic acid (Compound no. 59); 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-chloro-4-oxo-1,2,3-
benzotriazin-3(4H)-yl)butanoic acid (Compound no. 60); 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(7-chloro-4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 61); 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(7-methyl-4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 62);
2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-[4-oxo-7-(trifluoromethyl)- 1,2,3-benzotriazin-3(4H)-yl]butanoic acid (Compound no. 63); 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-methoxy-4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 64); 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-fluoro-4-oxo-1,2,3-
benzotriazin-3(4H)-yl)butanoic acid (Compound no. 65); 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(1-methyl-2.,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl)butanoic acid (Compound no. 66); 4-{(Methylsulfonyl)[ 1-ox0-4-(4-0x0-1,2,3-benzotriazin-3(4H)-yl)-1-(prop-2-en-1- yloxy)butan-2-yl]amino } benzoic acid (Compound no. 67);
2-[ {4-[(4-Methylphenyl)carbamoyl|phenyl} (methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 68);
2-[ {4-[(4-Chlorophenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 69);
2-{(Methylsulfonyl)[4-(phenylcarbamoyl)phenyl]amino} -4-(4-ox0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 70); 2-[{4-[(3-Fluorophenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 71);
2-[(Methylsulfonyl)(4- {[4-(propan-2-yl)phenyl]carbamoyl} phenyl)amino]-4-(4- 0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 72); 2-[{4-[(4-Methoxyphenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 73); 2-[{4-[(4-Fluorophenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo-
1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 74); 2-[(Methylsulfonyl)(4- {[4-(trifluoromethyl)phenyl] carbamoyl} phenyl) amino]-4- (4-ox0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 75); (2R)-2-[(4'-Fluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 76);
(2R)-2- {(Methylsulfonyl)[4-(pyrimidin-5-yl)phenyl]amino } -4-(4-ox0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 77);
(2R)-2- {(Methylsulfonyl)[4'-(propan-2-yl)biphenyl-4-yl]amino} -4-(4-0xo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 78); (2R)-2-[(3',4'-Dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3-
benzotriazin-3(4H)-yl)butanoic acid (Compound no. 79); (2R)-2-[(3',4'-Difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 80); (2R)-2-[(3'-Fluoro-4'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 81);
(2R)-2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 82); (2R)-2-[(3'-Methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 83); (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-
1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 84); (2R)-2-[Biphenyl-4-yl(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin-3(4 H)- yDbutanoic acid (Compound no. 85);
(2R)-2- {[4-(6-Methoxypyridin-3-yl)phenyl](methylsulfonyl)amino} -4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 86);
(25)-2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 87); (25)-2-[(3',4'-Dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 88);
(28)-2-[(3'-Fluoro-4'-methylbiphenyl-4-yl)(methylsul fonyl)amino]-4-(4-oxo-1,2,3- benzo triazin-3(4H)-yl)butanoic acid (Compound no. 89); (25)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 90);
(2R)-2-[(3',4'-Dimethoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 91); (2R)-2-{[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)phenyl] (methylsulfonyl)amino } -4- (4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 92); (2R)-2-[(4'-Methoxy-3'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-
1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 93); (2R)-2-[(4'-Fluoro-3'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 94);
(2R)-2- {(Methylsulfonyl)[4'-(trifluoromethoxy)biphenyl-4-ylJamino } -4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 95);
(2R)-2-{[4'-Chloro-3'-(trifluoromethyl)biphenyl-4-yl](methylsulfonyl)amino} -4- (4-ox0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 96); (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-[4-oxo-7- (trifluoro methyl)-1,2,3-benzotriazin-3(4H)-yl]butanoic acid (Compound no. 97); (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(8-methyl-
4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 98); (2R)-4-(7-Chloro-4-oxo0-1,2,3-benzotriazin-3(4H)-yl)-2-[(3'-fluoro-4'- methoxybiphenyl-4-yl)(methylsulfonyl)amino]butanoic acid (Compound no. 99); (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(7- methoxy-4-o0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 100);
(2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(6-methyl- 4-o0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 101); (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(8- methoxy-4-o0xo0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 102); (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(6-fluoro-4-
oxo0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 103); 4-(5-Chloro-4-ox0-1,2,3-benzotriazin-3(4H)-yl)-2-[(4-chlorophenyl) (methylsulfonyl)amino ]butanoic acid (Compound no. 104); 2-[(4-Bromophenyl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin-3(4H)- yDbutanoic acid (Compound no. 105);
2-[(4-Chlorophenyl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin-3(4H)- yDbutanoic acid (Compound no. 106); 2-[(4-Chlorophenyl)(methylsulfonyl)amino]-4-(7-methyl-4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 107);
2-[(4-Chlorophenyl)(methylsulfonyl)amino]-4-(6-methoxy-4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 108).
In another aspect, provided herein are pharmaceutical compositions comprising therapeutically effective amounts of one or more compounds, described herein, together with one or more pharmaceutically acceptable carriers, excipients or diluents.
In another aspect, provided herein, are methods for treating or prophylaxis of an animal or a human suffering from various inflammatory or allergic diseases, comprising administering to a mammal in need thereof therapeutically effective amount of one or more compounds of Formula 1, described herein.
In one embodiment, the diseases or conditions of inflammation and associated pathologies are selected from asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, tumor metastasis, and other inflammatory disorders
In yet another aspect, the present invention relates to the therapeutically effective amount of compounds of Formula I in combination with one or more of other therapeutic agents used in treating various inflammatory and allergic diseases. Examples of such therapeutic agents includes, but are not limited to, 1) anti-inflammatory agents, experimental or commercial (i) such as nonsteroidal anti-inflammatory agents piroxicam, diclofenac, propionic acids, fenamates, pyrazolones, salicylates, PDE-4/p38 MAP Kinase/Cathepsin inhibitors, (ii) leukotrienes LTC4/LTD4/LTE4/LTB4-Inhibitors, 5- lipoxygenase inhibitor and PAF-receptor antagonists, (iii) Cox-2 inhibitors, (iv) MMP inhibitors, and (v) interleukin-I inhibitors; 2) antihypertensive agents, (i) ACE inhibitors, e.g., enalapril, lisinopril, valsartan, telmisartan and quinapril, (ii) angiotensin II receptor antagonists and agonists, e.g., losartan, candesartan, irbesartan, valsartan, and eprosartan, (iii) B-blockers, and (iv) calcium channel blockers. 3) immunosuppressive agents such as cyclosporine, azathioprine and methotrexate, and anti inflammatory corticosteroids.
The following definitions apply to terms, as used herein.
The term “alkyl”, unless otherwise specified, refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms. This term can be exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-decyl, tetradecyl, and the like.
The term “alkenyl”, unless otherwise specified, refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group having from 2 to 20 carbon atoms with cis, trans or geminal geometry.
The term “alkynyl”, unless otherwise specified, refers to a monoradical of an unsaturated hydrocarbon, having from 2 to 20 carbon atoms.
The term “cycloalkyl”, unless otherwise specified, refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings, which may optionally contain one or more olefinic bonds, unless otherwise constrained by the definition. Such cycloalkyl groups can include, for example, single ring structures, including cyclopropyl, cyclobutyl, cyclooctyl, cyclopentenyl, and the like or multiple ring structures, including adamantanyl, and bicyclo [2.2.1] heptane or cyclic alkyl groups to which is fused an aryl group, for example, indane, and the like. Spiro and fused ring structures can also be included.
The term “aryl”, unless otherwise specified, refers to aromatic system having 6 to 14 carbon atoms, wherein the ring system can be mono-, bi- or tricyclic and are carbocyclic aromatic groups. For example, aryl groups include, but are not limited to, phenyl, biphenyl, anthryl or naphthyl ring, and the like.
The term “aryloxy” denotes the group O-aryl wherein aryl is the same as defined above.
The term “heteroaryl”, unless otherwise specified, refers to an aromatic ring structure containing 5 or 6 ring atoms or a bicyclic or tricyclic aromatic group having from 8 to 10 ring atoms, with one or more heteroatom(s) independently selected from N, O or S and optionally are benzofused or fused heteroaryl having 5-6 ring members.
The term “heterocyclyl”, unless otherwise specified, refers to a non-aromatic monocyclic or bicyclic cycloalkyl group having 5 to 10 atoms wherein 1 to 4 carbon atoms in a ring are replaced by heteroatoms selected from O, S or N, and optionally are benzofused or fused heteroaryl having 5-6 ring members.
The terms “cycloalkylalkyl”, “arylalkyl”, “heteroarylalkyl”, “heterocyclylalkyl” refers respectively to cycloalkyl, aryl, heteroaryl or heterocyclyl group linked to the remainder of the molecule via an alkyl group.
The term “amino” refers to —NH,
The term “halogen” refers to fluorine, chlorine, bromine or iodine;
The term “leaving group” refers to groups that exhibit or potentially exhibit the properties of being labile under the synthetic conditions and also, of being readily separated from synthetic products under defined conditions. Examples of leaving groups include, but are not limited to, halogen (e.g., F, Cl, Br, I), triflates, tosylate, mesylates, alkoxy, thioalkoxy, or hydroxy radicals, and the like.
The term “protecting groups” refers to moieties that prevent chemical reaction at a location of a molecule intended to be left unaffected during chemical modification of such molecule. Unless otherwise specified, protecting groups may be used on groups, such as hydroxy, amino, or carboxy. Examples of protecting groups are found in T.W. Greene and
P.G.M. Wuts, “Protective Groups in Organic Synthesis”, 2° Ed., John Wiley and Sons,
New York, N.Y. The species of the carboxylic protecting groups, amino protecting groups or hydroxy protecting groups employed are not critical, as long as the derivatised moiety/moieties is/are stable to conditions of subsequent reactions and can be removed without disrupting the remainder of the molecule.
The compounds of this invention can contain one or more asymmetric carbon atom and thus may occur as racemic mixtures, enantiomers and diasteromers. These compounds can also exist as conformers/rotamers. All such isomeric forms of these compounds are included in the present invention. Each stereogenic carbon atom may be of the R or §S configuration. Although the specific compounds exemplified in this application may be depicted in a particular sterochemical configuration, compounds having either the opposite stereochemistry at any given chiral center or mixture thereof are envisioned as part of the invention.
The term “pharmaceutically acceptable salts” forming part of this invention includes the salts of carboxylic acids moiety, which can be prepared by reacting the compound with appropriate base to provide corresponding base addition salts. Examples of such base are alkali metal hydroxide including potassium hydroxide, sodium hydroxide, and lithium hydroxide; alkaline earth metal hydroxides such as magnesium hydroxide and calcium hydroxide. Further, the salts of organic bases, such as lysine, arginine, guanidine, ethanolamine, choline and the like, inorganic bases, e.g., ammonium or substituted ammonium salts are also included. Wherever appropriate, compounds with pharmaceutically acceptable organic and inorganic acids, e.g., hydro halides, such as hydrochloride, hydrobromide, hydroiodide; other mineral acids and their corresponding salts, such as sulphate, nitrate, phosphate, ¢tc.; and alkyl and mono-arylsulphonates, such as ethane sulphonate, toluene sulphonate and benzene sulphonate; and other organic acids and their corresponding salts, such as acetate, tartaratae, maleate, succinate, citrate, etc.
In another aspect, the compounds, disclosed herein, may be prepared by following reaction sequences as depicted in Schemes I, 11, III, IV, V and VI.
Scheme 1
HO, OH ‘B 0 H
NH, e Q * "Cy Or
JO RS — a
Br —_— R R R
Formula 2
Formula 3 Formula 4 Formula 5
HO . wo
N oR YY © Hp® o
RS -————— I p
RS -— : OH (=) Formula 8 R R
RS Path A Formula 6
Formula 9 Formula 7 path B | RCO
Formula 11
HO H._O
Hp o ¥ ¥ 0
R R 0 R 0
NHR' NHR’
R35
Formula 10 Formula 12 Formula 13 {Formula | when R? is {Formula 1 when R? is heteroaryl, L! is bond} OCONHR', L! is bond}
The compound of Formula 10 (Path A) and Formula 13 (Path B) can be prepared according to Scheme I. Thus, reacting 4-bromo-nitrobenzene with a compound of
Formula 2 (wherein O& is aryl or heteroaryl ring and R® is hydrogen, alkyl, halogen, alkoxy or halogeno-C:-Cs alkyl) gives a compound of Formula 3 which on reduction forms a compound of Formula 4. The reaction of a compound of Formula 4 with alpha- bromolactone gives a compound of Formula 5 which on upon formylation forms a compound of Formula 6. The compound of Formula 6 on ring opening forms a compound of Formula 7 (wherein R;, is carboxy protecting group, such as methyl, ethyl, allyl, benzyl, t-butyl, silyl, BOC-anhydride) which on reaction with a compound of Formula 8 (wherein (=X is a heteroaryl ring, R’ is same as defined earlier) gives a compound of Formula 9 which finally on deprotection gives a compound of Formula 10. The reaction of a compound of Formula 7 with a compound of Formula 11 (where R’ is same as defined earlier) gives a compound of Formula 12 which on deprotection give a compound of
Formula 13.
The coupling of 4-bromo-nitrobenzene with a compound of Formula 2 to give a compound of Formula 3 can be carried out in the presence of inorganic base selected from, for example, potassium carbonate, sodium carbonate, sodium acetate, potassium acetate in presence of a solvent selected from, tetrahydrofuran, N,N’ -dimethylformamide, dimethylsulfoxide, toluene, or mixture(s) thereof.
The reduction of a compound of Formula 3 to give a compound of Formula 4 can be carried out using reducing agent selected from, for example, Raney Nickel in hydrazine hydrate or ammonium formate, zinc, tin or iron in the presence of hydrochloric acid or lithium aluminum hydride, Pd/C in Hj in the presence of a solvent, for example, tetrahydrofuran, methanol, ethanol, diethyl ether, dioxane, or mixture(s) thereof.
The coupling of a compound of Formula 4 with alpha-bromolactone to give a compound of Formula 5 can be carried out using inorganic base selected from, for example, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium bicarbonate using solvent selected from, for example, acetonitrile, water, or mixture(s) thereof.
The formylation of a compound of Formula 5 to give a compound of Formula 6 can be carried out using formylating agent selected from, for example, formic acid, acetic formic anhydride, chloral, activated formic acid using , N'-dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI), activated formic ester, ammonium formate in the presence of a solvent selected from, for example, toluene, dimethoxymethane, xylene, or mixture(s) thereof.
The ring opening of a compound of Formula 6 to give a compound of Formula 7 can be carried out with alkyl/aryl halide in the presence of 18-crown-6 using one or more inorganic base selected from sodium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide in the presence of a solvent, for example, N, N’-dimethylformamide, methanol, ethanol, propanol, butanol, tetrahydrofuran, acetonitrile, water, or mixture(s) thereof.
The coupling of a compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9 can be carried out in the presence of redox couple. The oxidizing part of the redox couple is selected from, for example, 1,1°-(azodicarbonyl)piperidine (ADDP), 4,7-dimethyl-3,5,7-hexahydro-1,2,4,7-tetrazocin-3,8-dione (DHTD), NNN ,N’- tetramethylazodicarboxamide (TMAD), N,N,N’, N’-tetraisopropylazodicarboxamide (TIPA), diethyl azodicarboxylate (DEAD), di-#-butylazodicarboxylate or diisopropylazodicarboxylate (DIAD). The reducing part of the redox couple is selected from, for example, tributylphosphine, triphenylphosphine, p-(dimethylaminophenyl) or triscyclohexylphosphine in the presence of a solvent, for example, tetrahydrofuran, dimethylsulfoxide, N,N’ -dimethylformamide, acetonitrile, or mixture(s) thereof.
The deprotection of a compound of Formula 9 to give a compound of Formula 10 can be carried out can be carried out in the presence of mineral acid, for example, hydrochloric, hydrobromic, hydroiodic acid in a solvent selected from dichloromethane, chloroform, carbon tetrachloride, dichloroethane, methanol, ethanol, acetonitrile, tetrahydrofuran, or mixture(s) thereof.
Or alternatively, the deprotection of a compound of Formula 9 to give a compound of Formula 10 can be carried out in the presence of one or more organic acid(s), for example, trifluoroacetic acid, p-toluenesulphonic acid or camphor sulphonic acid, in a solvent selected from dichloromethane, chloroform, carbon tetrachloride, dichloroethane, methanol, ethanol, acetonitrile, tetrahydrofuran, or mixture(s) thereof.
Or alternatively, the deprotection of a compound of Formula 9 to give a compound of Formula 10 can be carried out in the presence of inorganic base, for example, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, potassium carbonate in a solvent selected from dichloromethane, chloroform, carbon tetrachloride, dichloroethane, methanol, ethanol, acetonitrile, tetrahydrofuran, or mixture(s) thereof.
Or alternatively, the deprotection of a compound of Formula 9 to give a compound of Formula 10 can be carried out in the presence of deprotecting agent, for example, Pd/C in presence of Hj, Pd/C with ammonium formate, Pd/C in presence of tricthylsilane, ozone, boron trichloride dimethylsulfide (BCl3.SMe,), 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ), tetrakis triphenylphosphine in the presence of morpholine using solvent selected from dichloromethane, chloroform, carbon tetrachloride, dichloroethane, methanol, ethanol, acetonitrile, tetrahydrofuran, or mixture(s) thereof.
The reaction of a compound of Formula 7 with a compound of Formula 11 to give a compound of Formula 12 can be carried out in the presence of base selected from, for example, tricthylamine, N,N’-dimethylaminopyridine, 2,6-lutidine, 1-methylpiperidine, N- ethyldiisoproylamine, N,V’ -diisopropylethylamine or N-methylmorpholine in a solvent selected from, tetrahydrofuran, », N’-dimethylformamide, dimethylsulfoxide, acetonitrile, or mixture(s) thereof.
The deprotection of a compound of Formula 12 to give a compound of Formula 13 can be carried out under similar conditions as described for the compound of Formula 9 to give a compound of Formula 10.
Scheme II
N
5 5 ™~S50,-Ak
Dene Dora Org OH
Hal Hal k
Formula 14 Formula 15 Formula 16 Formula 17
When R, is aryl/heteroaryl when R, is halogen substituted with RS
Path C
Path D ak Ak HO_ OH Ax
B
SO
0; o SO; QO 22
I
Nv" on Ny orp Re Ir Com -————— Hal
R® N RO N Formula 2 N (=) (=) Het
RS RS iS
Formula 20 Formula 19 Formula 18 [Formula 1 when R3 is heteroaryl and L! is bond]
The compound of Formula 20 can be prepared according to Scheme II. Thus, the alpha halogenation of a compound of Formula 14 (wherein is a heteroaryl ring, R” is same as defined earlier) to give a compound of Formula 15 (wherein Hal is F, Cl, Br, I) which upon protection gives a compound of Formula 16 (wherein R,, is the same as defined earlier). The reaction of a compound of Formula 16 with a compound of Formula 17 (wherein Ak is Ci.salkyl and Ry is alkyl, halogen, aryl, heteroaryl) can take place in two ways.
Path C (when Ry is halogen): The compound of Formula 16 react with a compound of Formula 17 to form a compound of Formula 18 which upon coupling with a compound of Formula 2 (wherein 4 is aryl or heteroaryl ring and R® is the same as defined earlier) gives a compound of Formula 19. The compound of Formula 19 on deprotection gives a compound of Formula 20.
Path D (when Ry is aryl/heteroaryl substituted with R®): The compound of Formula 16 on reaction with a compound of Formula 17 gives a compound of Formula 19 which upon deprotection gives a compound of Formula 20.
The alpha halogenation of a compound of Formula 14 to form a compound of
Formula 15 can be carried out in the presence of red phosphorous/Brs, in the presence of a solvent selected from, for example, carbon tetrachloride, chloroform, dichloromethane, dichloroethane, or mixture(s) thereof.
The O-protection of a compound of Formula 15 to give a compound of Formula 16 can be carried out with carboxy protecting group, for example, methyl, benzyl, allyl, butyl, silyl, BOC anhydride in the presence of organic base selected from, for example, triethylamine, N,N’-dimethylaminopyridine, 2,6-Iutidine, 1-methylpiperidine, N- ethyldiisoproylamine, N,N -diisopropylethylamine or N-methylmorpholine using solvents selected from, tetrahydrofuran, », N’-dimethylformamide, dimethylsulfoxide, acetonitrile, or mixture(s) thereof.
Or alternatively, the O-protection of a compound of Formula 15 to give a compound of Formula 16 can be carried out with carboxy protecting group, for example, methyl, benzyl, allyl, t-butyl, silyl, BOC anhydride in the presence of inorganic base selected from, sodium bicarbonate, lithium bicarbonate, potassium bicarbonate in one or more solvents selected from, for example, V, MN’ -dimethylformamide, acetonitrile, dimethylsulfoxide, tetrahydrofuran, methanol, ethanol, water, or mixture(s) thereof.
The reaction of a compound of Formula 16 with a compound of Formula 17 (Path
C) to give a compound of Formula 18 can be carried out in the presence of inorganic base selected from, for example, lithium carbonate, sodium carbonate, potassium carbonate, magnesium carbonate, barium carbonate using solvent, for example, acetonitrile, tetrahydrofuran, dioxane, N,N’ -dimethylformamide, dimethylsulfoxide, or mixture(s) thereof.
The coupling of a compound of Formula 18 with a compound of Formula 2 to give a compound of Formula 19 can be carried out in the presence of inorganic catalyst selected from, for example, bis-(diphenylphosphino)ferrocence palladium II dichloride (Pd(dppD)Clp), tetrakis(triphenylphosphine) palladium (0) [Pd(PhsP).], palladium acetate or dichlorotriphenylphosphine palladium (II), with suitable base selected from, for example, potassium carbonate, sodium acetate, potassium acetate in the presence of solvent selected from, tetrahydrofuran, N,N’ -dimethylformamide, dimethylsulfoxide, toluene, or mixture(s) thereof.
The deprotection of a compound of Formula 19 to give a compound of Formula 20 can be carried out under similar conditions as described for the compound of Formula 9 to give a compound of Formula 10.
The reaction of a compound of Formula 16 with a compound of Formula 17 (Path
D) to give a compound of Formula 19 can be carried out in the presence of inorganic base selected from, for example, potassium carbonate, sodium carbonate, lithium carbonate, barium carbonate in a solvent, for example, acetonitrile, tetrahydrofuran, N,N - dimethylformamide, dimethylsulfoxide, or mixture(s) thereof.
Scheme III
Ak Ak \ .
SO.
SO 2 { N WM ~ N. cr SOA HOS ir 0 - ry OH
Ry R, R, © ,
Formula 17a OH
Formula 21 Formula 22
Ak ! . % | - -
N. when R, is 1 x~r ORp halogen 50; Rr fred 80, Q 1 N.
Hal N. ORp
ORp' TT JO ORp Formula 27 JO Y —» RpOOC
Formula 24 Path E R when R, is COOR, P & OH & N aN OH Path H Het of Formula 23 “Eo ! oy RS Lior NH Formula 27 Formula 32
RE Ak ° when R, is aryl/heteroaryl
Formula 24a so, Formula 27 Path G substituted with halogen, Ak
N. when Ris alkoxy/ Ry is allyl group I
ORp aryloxy/halogen/ Ak Jl Q hydrogen | N.
R® SO, ORp
O ORp' 1
Path F N oF HOOC
Formula 25 ~C
Ak N 1 Het
SO, Hal N () ~ (=) Formula 33 IS
OR;
Ak J P RS 1 Ry NH,
SO, ) N Formula 30 by & Q
P R3 Formula 34 R
RE Formula 28 Ak tO OH
Ak SO, o
I
Formula 26 so, RS N oe : H res A, Ox
Ak
Formula 27 | A o N
Ak SO, Hal N Het 1 N Het 50, §f OH Formula 35 R3 1 RS
N. R
ORp ® N Formula 31 Ak
Bh
RY
~0 ) 7 {Formula 1 when R3 is heteroaryl, L! SO, 0
Het is bond and R! is aryl/heteroaryl . x
Xs Formula 29 substituted withhalogen} ¥ Cy OH
Formula 26a N {Formula 1 when R? is heteroaryl, L! is o bond and R! is halogen/hydrogen, N
Ak lkoxy/aryloxy'} Her 1 50: o RS
N. of Formula 36 {Formula 1 when R3 is heteroaryl, L.! is
RS CONHaryl/heteroayl} ~ 0 N
R® Formula 26b {Formula 1 when R’® is heteroaryl, L! is bond and R! is aryl/heteroaryl substituted with OR6'}
The compound of Formula 26b (Path E), Formula 29 (Path F), Formula 31 (Path
G), Formula 36 (Path H) can be prepared according to Scheme III. Thus reacting a compound of Formula 17a (wherein Ris hydrogen, halogen, alkoxy, aryloxy, aryl, carboxy) with alpha-hydroxy lactone gives a compound of Formula 21 which upon ring opening gives a compound of Formula 22. The carboxy-protection of compound of
Formula 22 gives a compound of Formula 23 (wherein R,, is same as defined earlier).
Path E (when Ry is halogen): the compound of Formula 23 upon hydroxy protection gives a compound of Formula 24 (wherein R,,> is hydroxy protecting group).
The coupling of a compound of Formula 24 with a compound of Formula 24a (wherein R® is alkyl, aryl, heteroaryl) gives a compound of Formula 25 which upon deprotection gives a compound of Formula 26. The reaction of a compound of Formula 26 with a compound of Formula 27 gives a compound of Formula 26a. The deprotection of a compound of
Formula 26a gives a compound of Formula 26b.
Path F (when Ry is alkoxy/aryloxy/halogen/hydrogen): the reaction of a compound of Formula 23 with a compound of Formula 27 gives a compound of Formula 28 which upon deprotection gives a compound of Formula 29.
Path G: (when Ry is aryl substituted with halogen and R,, is allyl): the reaction of a compound of Formula 23 with a compound of Formula 27 gives a compound of Formula 30 which upon deprotection gives a compound of Formula 31.
Path H: (when Ry is COOR,): the coupling of a compound of Formula 23 with a compound of Formula 27 gives a compound of Formula 32 which upon deprotection gives a compound of Formula 33. The coupling of a compound of Formula 33 with a compound of Formula 34 gives a compound of Formula 35 which finally upon deprotection forms a compound of Formula 36.
The reaction of a compound of Formula 17a with o-hydroxy lactone to give a compound of Formula 21 can be carried out under similar conditions as described for the reaction of a compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The ring-opening of a compound of Formula 21 to give a compound of Formula 22 can be carried out as described for the compound of Formula 6 to give a compound of
Formula 7.
The carboxy-protection of a compound of Formula 22 to give a compound of
Formula 23 can be carried out under similar conditions as described for the compound of
Formula 15 to give a compound of Formula 16.
The hydroxy-protection of a compound of Formula 23 to give a compound of
Formula 24 (Path E) can be carried out using protecting group selected from, for example, tert-butyldimethylsilylchloride (TBDMSCI), trimethylsilylchloride (TMSCI), tert- butyldimethylsilyloxymethylchloride (TOMCI), triisopropylsilylchloride (TIPSCI), benzoyl chloride in the presence of base, for example, imidazole, N-methylimidazole, triethylamine, pyridine, diisopropylethylamine, N,N’ dimethylaminopyridine in the presence of solvent, for example, VV, N’-dimethylformamide, toluene, acetonitrile, dichloromethane, or mixture thereof.
The coupling of a compound of Formula 24 with a compound of Formula 24a to give a compound of Formula 25 can be carried out under similar conditions as for the reaction of a compound of Formula 18 with a compound of Formula 2 to give a compound of Formula 19.
The deprotection of a compound of Formula 25 to give a compound of Formula 26 can be carried out using deprotecting agent selected from, for example, boron trifluoride ethearte (BF3.0Et,), HF-pyridine, boron trichloride, boron tribromide, cesium fluoride (CsF), potassium fluoride (KF), n-tetrabutylammonium fluoride, Pd/C in Hj, potassium carbonate in presence of solvent, for example, dichloromethane, », N’-dimethylformamide, acetonitrile, methanol, ethanol, acetone, tetrahydrofuran, or mixture thereof.
The reaction of a compound of Formula 26 with a compound of Formula 27 to give a compound of Formula 26a can be carried out under similar conditions as described for the reaction of a compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The deprotection of a compound of Formula 26a to give a compound of Formula 26b can be out under similar conditions as described for the deprotection of a compound of Formula 9 to give a compound of Formula 10.
The reaction of a compound of Formula 23 (Path F) with a compound of Formula 27 to give a compound of Formula 28 can be carried out under similar condition as described for the reaction of a compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The deprotection of a compound of Formula 28 to give a compound of Formula 29 can be out under similar conditions as described for the deprotection of a compound of
Formula 9 to give a compound of Formula 10.
The reaction of a compound of Formula 23 (Path G) with a compound of Formula 27 to give a compound of Formula 30 can be carried out under similar conditions as described for reaction of a compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The deprotection of a compound of Formula 30 to give a compound of Formula 31 can be carried out under similar conditions as described for the deprotection of a compound of Formula 9 to give a compound of Formula 10.
The reaction of a compound of Formula 23 (Path H) with a compound of Formula 27 to give a compound of Formula 32 can be carried out under similar conditions as described for the compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The deprotection of a compound of Formula 32 to give a compound of Formula 33 can be carried out as described for the compound of Formula 9 to give a compound of
Formula 10.
The coupling of a compound of Formula 33 with a compound of Formula 34 to give a compound of Formula 35 can be carried out using base selected from triethylamine,
N,N-dimethylaminopyridine, 2,6-lutidine, 1-methylpiperidine, N-ethyldiisoproylamine,
N,N-diisopropylethylamine or N-methylmorpholine, in the presence of a additives for example hydroxybenzotriazole, 3-hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine, 2- hydroxypyridine, N-hydroxysuccinimide or 1-hydroxy-7-azabenzotriazole, with a suitable condensing agent, for example, dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride, chlorotripyrrolidinophosphonium hexafluorophosphate or (benzotriazol-1-yloxy)#ris-(dimethylamino)phosphonium hexafluorophosphate in the presence of a solvent selected from, for example, N,N’ dimethylformamide, dimethylsulfoxide, acetonitrile, or mixture(s) thereof.
The deprotection of a compound of Formula 35 to give a compound of Formula 36 can be carried out under similar condition as described for the compound of Formula 9 to give a compound of Formula 10.
Scheme IV
Ak
Ak 1 i ys Ak SO 0 S0r
HO HO 2 " 2 ! ye yo Re RL yo 5 Re Oyo
Formula 39
OH ORp Formula 17 OR... OH when R, is alkyl P Formula 41
Formula 37 Formula 38 Formula 40 H
N
RS
Formula 27
Ak Ak ! 80; 50,
N 0
RE OH " Lv OR
N
N
Q 8
RS ”
Formula 43 Formula 42 {Formula 1 when R? is heteroaryl, L! is bond and R! is aryl/heteroaryl}
The compound of Formula 43 can be prepared according to Scheme IV. Thus, protecting a compound of Formula 37 (wherein R;, is same as defined earlier) gives a compound of Formula 38 (wherein R,- is same as defined earlier) which on reaction with a compound of Formula 39 (Wherein R® is alkyl and Ak is same as defined earlier) gives a compound of Formula 40. The compound of Formula 40 on deprotection gives a compound of Formula 41 which on reaction with a compound of Formula 27 (wherein R’
is same as defined earlier) forms a compound of Formula 42. The deprotection of a compound of Formula 42 gives a compound of Formula 43.
The protection of a compound of Formula 37 to give a compound of Formula 38 can be carried out under similar conditions as described for the compound of Formula 23 to give a compound of Formula 24.
The reaction of a compound of Formula 38 with a compound of Formula 39 to give a compound of Formula 40 can be carried out under similar conditions as described for the reaction of a compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The deprotection of a compound of Formula 40 to give a compound of Formula 41 can be carried out under similar conditions as described for the compound of Formula 25 to give a compound of Formula 26.
The reaction of a compound of Formula 41 with a compound of Formula 27 to give a compound of Formula 42 can be carried out under similar conditions as described for the reaction of a compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The deprotection of a compound of Formula 42 to give a compound of Formula 43 can be carried as described for the compound of Formula 9 to give a compound of
Formula 10.
Scheme V
H Se NHSO,-Ak S0,-Ak go% Mm we oor — 3 — Hal Hal
Formula 44 N N Ne > : N
OH Formula 27 when I'd H Formula 48 Het
RS is hydrogen Het ot Het Formula 17
When R, is halogen Formula 49
Formula 45 Formula 46 Formula 47 Ho. OH
Ng”
RS
Formula 2
S0,-Ak S0,-Ak SOAK
AA OH Ngo Yow oe LQ
Het
RS ©, RS (ier) RS
Formula 52 Formula 51 Formula 50
Formulal [when R3 is heteroaryl,
L! is bond and R' is aryl/heteroaryl]
The compound of Formula 52 can be prepared according to Scheme V. Thus reacting 4-(2-hydroxyethyl)-2,2-dimethyl 1,3-dioxolane with a compound of Formula 44 gives a compound of Formula 45 which upon ring opening gives a compound of Formula 46. The compound of Formula 46 on O-protection gives a compound of Formula 47 (wherein R;; is same earlier) which upon reaction with a compound of Formula 48 (wherein Hal and Ak are same as defined earlier) gives a compound of Formula 49. The coupling of a compound of Formula 49 with a compound of Formula 2 gives a compound of Formula 50. The compound of Formula 50 on deprotection forms a compound of
Formula 51 which finally on oxidation gives a compound of Formula 52.
The reaction of 4-(2-hydroxyethyl)-2,2-dimethyl 1,3-dioxolane with a compound of Formula 44 form a compound of Formula 45 can be carried out under similar condition as for the compound of Formula 7 with a compound of Formula 8 to give a compound of
Formula 9.
The ring opening of a compound of Formula 45 to give a compound of Formula 46 can be carried out in the presence of mineral acids selected from, for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, or in the presence of catalytic amount of cerium(IV) ammonium nitrate (CAN), cerium(I1I) trifluoromethane sulfonate using solvent, for example, acetone, nitromethane, acetonitrile, water, or described thereof.
The protection of a compound of Formula 46 to give a compound of Formula 47 can be carried out under similar conditions as described for the compound of Formula 23 to give a compound of Formula 24.
The reaction of a compound of Formula 47 with a compound of Formula 48 to give a compound of Formula 49 can be carried out under similar conditions as described for the reaction of a compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The coupling of a compound of Formula 49 with a compound of Formula 2 to give a compound of Formula 50 can be carried out under similar conditions as described for coupling of a compound of Formula 18 with a compound of Formula 2 to give a compound of Formula 19.
The deprotection of a compound of Formula 50 to give a compound of Formula 51 can be carried out under similar condition as described for the deprotection of a compound of Formula 25 to give a compound of Formula 26.
The oxidation of a compound of Formula 51 to give a compound of Formula 52 can be carried using oxidizing agent, for example, sodium chlorite and sodium hypochlorite in presence of 2,2,6,6-tetramethylpiperidine-N-oxyl) (TEMPO), sodium periodate in presence of ruthenium trichloride, potassium dichromate, potassium permanganate, using a solvent selected from, acetonitrile, carbon tetrachloride, water, or mixture(s) thereof.
Scheme VI
NHSO,-Ak Ak >< Rp" H 2) SO, > H H p i o Cn — — —_— - p a
ORo' Formula 48
OH ORyp' OR’ ’ ORp'
Formula 53 Formula 54 Formula 55 p
Formula 56 oN ©
Formula 2
Ak Ak
SO H Ak 2 N So, 1
N. " et) ! 80,
ORp N. ORp" 1
RS TL p No ORp"
RE Formula 27 OH
Formula 59 RS Formula 58
Formula 57 “
Ak
I
SO, 50;
N OH N OH
—_—
N 5 N
RS RS
Formula 60 Formula 61 [Formula I whenR3 is heteroaryl
L! is bond,R! is aryl/heteroaryl]
The compound of Formula 61 can be prepared according to Scheme VI. Thus, protecting 4-(2-hydroxyethyl)-2,2-dimethyl 1,3-dioxolane gives a compound of Formula 53 (wherein R;, is same as defined earlier) which upon ring opening forms a compound of
Formula 54. The compound of Formula 54 upon further protection gives a compound of
Formula 55 (wherein Rp’ is same as defined earlier) which on reaction with a compound of Formula 48 (wherein Hal is same as defined earlier) gives a compound of Formula 56.
The coupling of a compound of Formula 56 with a compound of Formula 2 gives a compound of Formula 57 which on deprotection forms a compound of Formula 58. The reaction of a compound of Formula 58 with a compound of Formula 27 (wherein R is same as defined earlier) gives a compound of Formula 59. The compound of Formula 59 on deprotection gives a compound of Formula 60 which on oxidation forms a compound of Formula 61.
The protection of 4-(2-hydroxyethyl)-2,2-dimethyl 1,3-dioxolane to give a compound of Formula 53 can be carried out using alkyl/aryl halides using inorganic base selected from lithium hydride, sodium hydride or organic base selected from pyridine, triethylamine, trimethylamine, tributylamine, N-ethyldiisopropylamine, 4-V,N- dimethylaminopyridine, N-methylmorpholine or 2,6-lutidine in the presence of a solvent, for example, N,N’ -dimethylformamide, dimethylsulfoxide, acetonitrile, or mixture(s) thereof.
The ring opening of a compound of Formula 53 to give a compound of Formula 55 can be carried out under similar conditions as described for compound of Formula 45 to give a compound of Formula 46.
The protection of a compound 54 to give a compound of Formula 55 can be carried out under similar conditions as described for the protection of compound of Formula 23 to give a compound of Formula 24.
The reaction of a compound of Formula 55 with a compound of Formula 48 to give a compound of Formula 56 can be carried out under similar conditions as described for the compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The coupling of a compound of Formula 56 with a compound of Formula 2 to give a compound of Formula 57 can be carried out under similar conditions as described for coupling of a compound of Formula 18 with a compound of Formula 2 to give a compound of Formula 19.
The deprotection of a compound of Formula 57 to give a compound of Formula 58 can be carried out as described for the deprotection of a compound of Formula 9 to give a compound of Formula 10.
The coupling of a compound of Formula 58 with a compound of Formula 27 to gives a compound 59 can be carried out under similar conditions as described for the compound of Formula 7 with a compound of Formula 8 to give a compound of Formula 9.
The deprotection of a compound of Formula 59 to give a compound of Formula 60 can be carried out under similar conditions as described fro the compound of Formula 25 to give a compound of Formula 26.
The oxidation of a compound of Formula 60 to give a compound of Formula 61 can be carried out under similar condition as described for the compound of Formula 51 to give a compound of Formula 52.
In the above schemes, where specific reagents, for example, bases, acids, solvents, condensing agents, reducing agent, deprotecting agent, hydrolyzing agents, catalysts, etc., as mentioned, is to be understood that other reagents, e.g., other acids, bases, solvents, condensing agents, reducing agent, deprotecting agent, hydrolyzing agents, catalysts, etc., known to one of ordinary skill in the art may be used. Similarly, reaction temperatures and durations may be adjusted according to the desired needs without undue experimentation and well within the abilities of one of ordinary skill in the art.
The compounds described herein may be administered to an animal for treatment orally, topically, rectally, internasally or by parenteral route. Pharmaceutical compositions disclosed herein comprise pharmaceutically effective amounts of compounds described herein formulated together with one or more pharmaceutically acceptable carriers, excipients or diluents.
Solid form preparations for oral administration include capsules, tablets, pills, powder, granules, lozenges, troches, cachets and suppositories. For solid form preparations, active compounds can be mixed with one or more inert, pharmaceutically acceptable excipients or carrier. Tablets and capsules for oral administration may contain conventional excipients, such as binding agents and/or dissolution enhancers, for example, polyvinyl pyrrolidine, cellulose, mucilage of starch, gelatin, sorbitol, syrup, acacia or tragacanth; fillers or bulking agents, for example, microcrystalline cellulose, sugar, maize-starch, calcium phosphate, sorbitol or lactose; lubricants, for example, talc, silica, polyethyleneglycol, magnesium stearate or stearic acid; disintegrating agents and binder, for example, croscarmellose sodium, pregelatinized starch, sodium starch gylcollate or potato starch; glidants, for example, colloidal silicon dioxide or talc; antiadherents, for example, magnesium stearate or sodium luaryl sulfate and coating materials.
Capsules, tablets or pills may also comprise buffering agents.
Tablets, capsules, pills or granules can be prepared using one or more coatings or shells to modulate the release of active ingredients, for example, enteric coatings or other coatings known to one of ordinary skill in the art.
General Example
A formulation of a tablet could typically contain from 0.01 mg to 500 mg of active compound while tablet fill weight may range from 50 mg to 1000 mg. An example is illustrated below:
Liquid form preparations for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs. In such liquid form preparations, active compounds can be mixed with water or one or more non-toxic solvents, solubilizing agents or emulsifiers, for example, water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, for example, cottonseed, groundnut, corn, germ, olive, castor and sesame oil, glycerol, fatty acid esters of sorbitan, or mixtures thereof. Oral compositions can also include one or more adjuvants, for example, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, or mixtures thereof.
Injectable preparations, for example, sterile injections, and aqueous suspensions may be formulated according to methods known to one of ordinary skill in the art, and in particular, using one or more suitable dispersing or wetting and suspending agents.
Acceptable vehicles and solvents that may be employed include one or more of water,
Ringer’s solution, isotonic sodium chloride, or mixtures thereof.
Suppositories for rectal administration of the compound of this invention can be prepared by mixing the drug with suitable nonirritating excipients, such as cocoa butter and polyethylene glycols, which are solid at ordinary temperatures but liquid at body temperature and which therefore melt in the rectum and release the drug.
Dosage forms for topical or transdermal administration of a compound of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. Active compounds can be admixed under sterile condition with one or more pharmaceutically acceptable carriers and optionally any preservatives or buffers as may be required. Ophthalmic formulations, eardrops, eye ointments, powders and solutions are also encompassed within the scope of this invention.
Pharmaceutical preparations may be in unit dosage form. In unit dosage form, the preparations can be subdivided into unit doses containing appropriate quantities of active components. Unit dosage forms can be packaged preparations containing discrete capsules, powders, in vials or ampoules, ointments, capsules, sachets, tablets, gels, creams or any combination and number of such packaged forms.
Table I
A DN BN
©
R2
Formula 1
Cc |R L' R’ R’
No.
Ny,
2 HC a bond -CHO 0
Ns Cl 3 0 bond -CHO :
Ce bond -CHO \ ne Toa
CL, [1 _ \ { ) bond -CHO \ a bond -CHO \
IES a bond -CHO \
Ce 11 a bond -CHO No
IE
12 b -CH \
Ce es
HN. 13 a -CH Yeo
CT ee 14 bond -CHO “o_o
NE
{ 3 -CH Yo 0
Ce tx oo 17 J ) bond -SO,CHj;
HC’ N= 0 18 ¢ bond -SO,CHj; s 19 J 3 bond -SO,CHj; / 3 bond -SO,CHj
Ny, or 21 / 3 bond -SO,CHj 22 / 3 bond -SO,CHj; S co oo
Ny,
Co oo
NS CH,
IEE oo i= oo oo
F I
28 { ) bond -SO,CH
Cle te 29 N bond -SO,CH
ENE bond -SO,CHj3 “oO ne —
F Ny 31 bond -SO,CHj; und > ct oo ct oo
Ny, Ih te oo
CH; -SO,CHj; >” —N, 0 ii oO
Ny, ors 37 HC 0 -S0O,CHj; Seo fl 0 oo oo 40 LG OY bond -SO,CHj; 41 as bond -SO,CHj; 42 7 \ bond -SO,CHj;
C
43 N 3 bond -SO,CHj3 44 7 \ bond -SO,CHj;
45 CF; { 3 bond -SO,CHj; VO
Nay, 46 NO) bond -SO,CHj;
Ny, 47 al ( 3 bond -SO,CHj; 0 cl Sy 48 ne) { 3 bond -SO,CHj;
Ny, 49 ( bond -SO,CH3 Vo
F F Ny 50 oo bond -SO,CHj;
Ny, oo 52 -CH(CHj3), bond -SO,CHj; or
I , or aE
CH,
EEE
55 -CH,CHs; bond -SO,CHj; oo” —N,
oo oo
A CH, 57 -CH,CHj; bond -SO,CHj; reo
I
58 H bond -SO,CHj; VO
Ny, 59 al a bond -SO,CH; ” 0 cle oo oo
Ns Cl oo
N CH, oo oo oo / 3 bond -SO,CHj; i
WY o a aE a
78 LG OY bond -SO,CHj; 79 al ( 3 bond -SO,CHj; Xo cl Rh
F { 3 bond -SO,CHj; VO
F R
81 HC ( 3 bond -SO,CHj; Vo
F 5 84 bond -SO,CHj;
BC (
F Na, ol ) bond -SO,CHj; 88 al ( 3 bond -SO,CHj; VO cl R
HC { 3 bond -SO,CHj; VO
F Ny, ~~ bond -SO,CH; Yr
BC
F Ny, 91 5 { ) bond -SO,CH;3 0 / ’ Q Ny, 92 bond -SO,CH;3 0 os 1S
Hd
HC Ny 94 v ( 3 bond -SO,CH3 VO
EAS a 95 bond -SO,CH ar on 2 WO
Ny, a ( 3 bond -SO,CHj; 0
CF! Ng, 97 ~ bond -S0,CH; “ou
HC
F Ny, CF, ~ bond -SO,CHj3
HC
F Ny
CH, ~ bond -SO,CHj;
HC
F Ny a
100 5 { ) bond -SO,CHj3
HC
F Ny CH, le oo
HC :
F Ny 102 bond -SO,CHj;
HC (
F Ny, 103 4 - bond -SO,CHj3
HC
¥ Ny oo 105 | Br bond -SO,CHj3
Ny, 106 | Cl bond -SO,CHj;
Ny, 107 | Cl bond -SO,CHj3 oL
A CH, 108 | Cl bond -SO,CHj3 x :
The following examples are set forth to demonstrate general synthetic procedures for the preparation of representative compounds of the present invention. The examples are provided to illustrate particular aspect of the disclosure and do not limit the scope of the present invention.
Experimental
Various solvents, for example, dimethylformamide, benzene, tetrahydrofuran, etc., were dried using various drying reagents according to procedure as described in the literature.
Synthesis of intermediate
Synthesis of 6-methyl-1.2.3-benzotriazin-4(3H)-one
The title compound was prepared following the procedure outlined in J. Med.
Chem., 35(14), p. 2626-2630 (1992).
The following analogues of benzotriazin-4(3 H)-one were prepared analogously: 7-Methoxy-1,2,3-benzotriazin-4(3 H)-one 7-(Trifluoromethyl)-1,2,3-benzotriazin-4(3 H)-one; 7-Methyl-1,2,3-benzotriazin-4(3 H)-one; 6-Methoxy-1,2,3-benzotriazin-4(3 H)-one; 5-Chloro-1,2,3-benzotriazin-4(3H)-ong; 7-Chloro-1,2,3-benzotriazin-4(3H)-ong; 5-Methoxy-1,2,3-benzotriazin-4(3 H)-one; 5-Fluoro-1,2,3-benzotriazin-4(3 H)-one; 8-Methoxy-1,2,3-benzotriazin-4(3 H)-one; 6-Fluoro-1,2,3-benzotriazin-4(3 H)-one.
Synthesis of 5-methyl-1H-isoindole-1,3(2H)-dione
The title compound was prepared following the procedure outline in Chem. Ber. 1877,10, 1163.
Synthesis of 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butanoic acid
To a solution of y-aminobutyric acid (20.68 g, 0.199 moles) and phthalic anhydride (29.6 g, 0.199 moles) in toluene (300 mL) was added triethylamine (3 mL, 0.0215 moles) and heated at 110°C for about18 hours. After completion, the reaction mixture was allowed to cool to room temperature. The reaction mixture was washed with IN HCI solution (20 mL) at 40°C and solid was crystallized out from organic layer. The residues was filtered, washed with water and dried under vacuum overnight to get desired product.
Yield: 31.64 g
LCMS: 234.2 (M+1)
Synthesis of N-(4-bromophenyl)methane sulfonamide
To a solution of 4-bromoaniline (100 g, 581 mmoles) in dichloromethane (75 mL) and pyridine (75 mL) was slowly added methanesulphonyl chloride (99 g, 872 mmoles).
The reaction mixture was allowed to stir for about one hour at the same temperature.
After one hour, dilute hydrochloric acid was added to the reaction mixture to remove pyridine. The organic layer was collected, dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain a crude product. The crude product was purified on a silica gel column using 60% ethyl acetate: hexane as eluent to afford a desired compound.
Yield: 110g
LCMS: 267.03, 268.97 (M+Na)
Synthesis of N-[4-(4-methylphenoxy)phenyl]methane sulfonamide
To a solution of 4-(4-methylphenoxy)aniline (3.5 g, 17.6 mmoles) in pyridine (20 mL) and dichloromethane (20 mL) at 0°C was added methanesulfonyl chloride (2.2 mL, 26.4 mmoles). The reaction mixture was allowed to stir at room temperature for about 2 hours. After completion of reaction, pyridine was evaporated and the reaction mixture was extracted with ethyl acetate. The organic layer was collected, washed with water, dried over anhydrous sodium sulphate and evaporated to get a crude product. The crude product obtained was purified on silica gel column using 25% ethyl acetate: hexane as eluent to get desired compound.
Yield: 3.1g
The following compound can be prepared accordingly: N-(4-Methoxyphenyl) methanesulfonamide.
Synthesis of benzyl 2.4-dihydroxybutanoate
To a solution of a-hydroxylactone (10 g, 0.098 moles) in methanol (50 mL) was added sodium hydroxide (5.88 g, 0.147 moles) in water (10 mL) and allowed to stir at room temperature for about one hour. The reaction mixture was concentrated and taken in
NN, N’-dimethylformamide (40 mL) and benzyl bromide (14 mL, 0. 117 moles) was added drop wise. The reaction mixture was again allowed to stir for overnight at room temperature. After completion of reaction, solvent was evaporated under vacuum and the reaction mixture was extracted with ethyl acetate. The organic layer was washed with water, brine and dried over anhydrous sodium sulphate and evaporated under vacuum to obtain a crude product. The crude product was purified on silica gel column using 80% ethyl acetate: hexane as eluent to afford the title compound.
Yield: 10.4 g
LCMS: 211.47 (M+1), 233.5 (M+Na)
Synthesis of N-(biphenyl-4-yl)methanesulfonamide
To the solution of 4-biphenyl amine (1 g, 0.0059 moles) in dimethylformamide (10 mL) was added potassium carbonate (1.63 g, 0.0118 moles) and stirred for about 10 minutes and then methanesulfonyl chloride (3.64 mL, 0.0472 moles) was added slowly.
The reaction mixture was allowed to stir at room temperature for about 30 minutes. After completion, the reaction mixture was extracted with ethyl acetate while washing with water. The organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product which was purified on silica gel column to get desired product.
Yield: 0.75 g
Synthesis of tert-butyl 4- {[4-hydroxy-1-o0xo0-1-(prop-2-en-1-yloxy)butan-2-yl] (methyl sulfonyl)amino} benzoate
Step a: Preparation of fert-butyl 4-nitrobenzoate
To a solution of p-nitrophenol (10 g, 59.88 mmoles) in fert-butanol (100 mL) and tetrahydrofuran (100 mL) were added N,N’-dimethylaminopyridine (1.4 g, 11.97 mmoles) and Boc anhydride (38.4 mL, 179.64 mmoles) at room temperature. The reaction mixture was allowed to stir for about 10 hours at room temperature. The temperature was increased slowly to 35°C and reaction mixture was stirred for about 6 hours. After completion, solvent was evaporated under reduced pressure and reaction mixture was extracted with ethyl acetate. The organic layer was washed with water, brine and evaporated under vacuum to get a crude product. The crude product was purified on silica gel column using 20% ethyl acetate: hexane as eluent to get desired compound.
Yield 12 g
Step b: Preparation of zert-butyl 4-aminobenzoate
To a solution of compound obtained from Step a (11 g) in tetrahydrofuran (50 mL) and methanol (50 mL) was added 10% Pd/C (3 g) and H, was supplied at 60 psi in Parr apparatus for about 2 hours. After completion, reaction mixture was filtered through celite pad and residue was washed with ethyl acetate. The filtrate obtained was concentrated under vacuum to get the desired compound.
Yield: 10 g.
LCMS: 194.47 (M+1)
Step c: Preparation of zert-butyl 4-[(methylsulfonyl)amino] benzoate
To an ice cooled solution of compound obtained from Step b (10 g, 51.81 mmoles) in pyridine (50 mL) and dichloromethane (50 mL) was added methanesulphonyl chloride (8.86 g, 77.72 mmoles). The reaction mixture was allowed to stir for about one hour at same temperature. After one hour, HCI (11 N) solution was added to bring the pH of the reaction mixture to neutral and then extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated under vacuum to get crude product. The crude product obtained was purified on silica gel column using 50% ethyl acetate: hexane as eluent to get desired product.
Yield: 10 g
LCMS: 293.76 (M+Na)
Step d: Preparation of tert-butyl 4-[(methylsulfonyl)(2-oxotetrahydrofuran-3- yl)amino] benzoate
To an ice cooled solution alpha-hydroxy lactone (1 g, 9.80 mmoles) in tetrahydrofuran (30 mL) were added compound obtained from Step ¢ (2.6 g, 9.80 mmoles) and triphenylphosphine (13.6 g, 14.70 mmoles). The reaction mixture was stirred for about 15 minutes and diisopropylazodicarboxylate (DIAD) (2.9 g, 14.70 mmoles) was added at same temperature. The reaction mixture was allowed to stir for about 2 hours at room temperature. After complete conversion of starting material, solvent was evaporated under vacuum to obtain a crude compound. The crude compound was purified on silica gel column using 30% ethyl acetate: hexane as elutent to get the desired product.
Yield: 6g
LCMS: 354.82 (M).
Step e: Preparation of N-[4-(tert-butoxycarbonyl)phenyl]-/NV-(methylsulfonyl) homoserine
To an ice-cooled solution of compound obtained from Step d (4 g, 11.26 mmoles) in ethanol (30 mL) and methanol (10 mL) was added sodium hydroxide (0.495 g, 12.39 mmoles) in water (5 mL). The reaction mixture was allowed to stir at same temperature for about 30 minutes. After 30 minutes, solvent was evaporated and reaction mixture was extracted with ethyl acetate while washing with water. The aqueous layer was acidified with aqueous solution of sodium bisulfate and extracted with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulphate and evaporated to get desired compound.
Yield: 3g
Step f: Preparation of tert-butyl 4-{[4-hydroxy-1-oxo-1-(prop-2-en-1-yloxy)butan-2- yl](methylsulfonyl)amino}benzoate
To a solution of compound obtained from step ¢ (3 g, 8.04 mmoles) in NV, N’- dimethylformamide (25 mL) were added sodium bicarbonate (1 g, 12.06 mmoles) and allyl bromide (1.07 g, 8.84 mmoles) at room temperature. The reaction mixture was allowed to stir at room temperature for about 12 hours. After completion of reaction, solvent was evaporated and reaction mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated to get crude product. The crude product was purified on silica gel column using 40% ethyl acetate: hexane to get the desired compound.
Yield: 1.4 g.
LCMS: 413.87 (M+1).
Synthesis of prop-2-en-1-yl N-(4'-chlorobiphenyl-4-yl)-N-(methylsulfonyl)homoserinate
Step a: Preparation of /N-(4'-chlorobiphenyl-4-yl)methanesulfonamide
To a solution of N-(4-bromophenyl)methanesulfonamide (2 g, 0.008 moles) in N,
N’-dimethylformamide (15 mL) and water (15 mL) were added 4-chlorophenylboronic acid (2.49 g, 0.016 moles), potassium carbonate (3.3 g, 0.024 moles) and tetrakis triphenylphosphine (277 mg, 0.002 moles). The reaction mixture was heated upto 100°C for about 14 hours. After completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain a crude product. The crude product was purified on silica gel column using 25% ethyl acetate: hexane as eluent to get title compound.
Yield: 1.8 g
Step b: Preparation of N-(4'-chlorobiphenyl-4-yl)-/V-(2-oxotetrahydrofuran-3- yl)methane sulfonamide
To a compound obtained from step a (10 g, 0.035 moles) in tetrahydrofuran (70 mL) were added o-hydroxy lactone (8.8 g, 0.05 moles) and triphenylphosphine (13.9 g, 0.05 moles) at 0°C. The reaction mixture was allowed to stir for about 10 minutes and diisopropylazodicarboxylate DIAD (10.7 mL, 0.05 moles) was added to it at 0°C. The reaction mixture was again stirred for about 2 hours at room temperature. After completion, solvent was evaporated to obtain a crude product which was purified on silica gel column using 20% ethyl acetate: hexane as eluent to get the desired product.
Yield: 10g
LCMS: 365.71 (M+1)
Step c: Preparation of N-(4'-chlorobiphenyl-4-yl)-N-(methylsulfonyl)homeoserine
To a solution of compound obtained from step b (10 g, 0.0273 moles) in ethanol: water mixture (10:1) (100ml: 10mL) at 0°C was added sodium hydroxide (1.2g, 0.037 moles) in water (2 mL). The reaction mixture was allowed to stir for about 2 hours at 0°C.
After 2 hours, solvent was evaporated under reduced pressure and residues obtained were taken in water and extracted with ethyl acetate. The aqueous layer obtained was acidified by aqueous solution of sodium bisulphite and then extracted with ethyl acetate. The combined organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get title compound.
Yield: 10g
Step d: Preparation of prop-2-en-1-yl N-(4'-chlorobiphenyl-4-yl)-V-(methylsulfonyl) homoserinate
To a compound obtained from step ¢ (10 g, 0.026 moles) in ethanol: water: DMF mixture (60 mL: 6 mL: 60 mL) at room temperature was added sodium bicarbonate (2.1 g, 0.026 moles). The reaction mixture was allowed to stir at room temperature for about 30 minutes. After 30 minutes, the reaction mixture was concentrated under reduced pressure and treated with toluene. The toluene was evaporated and residue so obtained was taken in dry N, N’-dimethylformamide (20 mL) at room temperature. To this reaction mixture was slowly added allyl bromide (3.4 g, 0.028 moles) and stirred for overnight at room temperature. After completion, water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was collected, washed with water, brine, dried over anhydrous sodium sulphate solution and evaporated under reduced pressure to obtain a crude product. The crude product was purified on silica gel column using 30% ethyl acetate: hexane as eluent to get title compound.
Yield: 5.2 g
Example 1: Synthesis of 2-[formyl(4'-methylbiphenyl-4-yl)amino]-4-(6-methyl-4-oxo- 1.2.3-benzo triazin-3(4H)-yl)butanoic acid (Compound no. 1) (Scheme [, Path A)
Step a: Preparation of 4-methyl-4'-nitrebiphenyl
To a solution of 4-bromo-nitrobenzene (5 g, 0.0247 moles) in N,N’- dimethylformamide (25 mL) were added potassium carbonate (10.2 g, 0.0741 moles) and 4-methylboronic acid (4 g, 0.0297 moles) under argon atmosphere and heated at 100°C for about 3 hours. After completion, reaction mixture was quenched by addition of water and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulphate and concentrated under vacuum to get a crude product which was purified on silica gel column using 15% ethyl acetate: hexane as eluent to obtain desired compound.
Yield: 53 ¢g
LCMS: 236.07 (M+23)
Step b: Preparation of 4'-methylbiphenyl-4-amine
To a solution of compound obtained from Step a (5.2 g, 0.0244 moles) in tetrahydrofuran (25 mL) and methanol (25 mL) was added 10% Pd/C (5.2 g) under vacuum and then hydrogen gas was supplied by balloon. The reaction mixture was allowed to stir for about 2 hours at room temperature. After completion, reaction mixture was filtered through celite pad and filtrate was concentrated under vacuum to obtained title compound. Yield: 5 g
LCMS: 184.01 (M+1)
Step c: Preparation of 3-[(4'-methylbiphenyl-4-y)amino]dihydrofuran-2(3 H)-one
To alpha-bromo lactone (3 g, 0.018 moles) was added compound obtained from
Step b (4.9 g, 0.027 moles) and heated to 100°C to 110°C for about 3 hours. After completion consumption of starting material, reaction mixture was evaporated under reduced pressure and purified on silica gel column using 20% ethyl acetate: hexane as eluent to get desired compound.
Yield: 4 g
LCMS: 268.11 (M+1)
Step d: Preparation of /V-(4'-methylbiphenyl-4-yl)-/V-(2-oxotetrahydrofuran-3- yhformamide
To a solution of compound obtained from Step ¢ (2 g, 0.00749 moles) in toluene (30 mL) was added formic acid (0.4 g, 0.0089 moles) and reflux for about 9 hours. After complete, reaction mixture was evaporated under reduced pressure to get a crude product which was purified over silica gel column using 15% ethyl acetate: hexane as eluent to obtain title compound.
Yield: 19g
LCMS: 295.94 (M+1)
Step e: Preparation of methyl /V-formyl-/V-(4'-methylbiphenyl-4-yl)homoserinate
To a solution of compound obtained from Step d (1.9 g, 0.0064 moles) in N,N’- dimethylformamide (4 mL) and water (1 mL) was added sodium hydroxide (0.309 g, 0.0077 moles) and stirred for about 30 minutes at room temperature. After 30 minutes sodium bicarbonate (0.624 g, 0.0074 moles), 18-crown-6 (0.168 g, 0.00064 moles) amd methyl iodide (1.3 g, 0.0914 moles) was added to the reaction mixture and again stirred for overnight at room temperature. After completion, reaction mixture was quenched by addition of water and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulphate and concentrated under reduced pressure to get crude product which was purified on silica gel column using 8% ethyl acetate: hexane as eluent.
Yield: 2.1g
Step f: Preparation of methyl 2-[formyl(4'-methylbiphenyl-4-yl)amino]-4-(6-methyl- 4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoate
To a compound obtained from step ¢ (0.3 g, 0.0009 moles) in tetrahydrofuran (5 mL) were added 6-methylbenzotriazinone (0.177 g, 0.0011 moles) and triphenyl phosphine (0.353 g, 0.0013 moles) under argon atmosphere. The reaction mixture was allowed to cool to 0°C and to it was added diisopropylazodicarboxylate (0.272 g, 0.0013 moles) and stirred for about 30 minutes at room temperature. After completion, reaction mixture was quenched by addition of water and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get crude compound which was purified on silica gel column using 7% ethyl acetate: hexane as eluent to get desired product.
Yield: 0. 15 g
LCMS: 470 (M+1)
Step g: Preparation of 2-[formyl(4'-methylbiphenyl-4-yl)amino]-4-(6-methyl-4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid
To a compound obtained from Step f (0.15 g, 0.0003 moles) in tetrahydrofuran (5 mL) and methanol (5 mL) was added solution of lithium hydroxide (0.018 g, 0.0004 moles) in water (1 mL). The reaction mixture was allowed to stir for about one hour at room temperature. After completion, the reaction mixture was acidified with sodium bisulphate solution (pH~2) and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate and concentrated under vacuum to get crude compound which was purified by preparative TLC using 10% methanol: dichloromethane as mobile phase. Yield: 0.030 g
LCMS-455.35 (M-1) 'H NMR (400 MHz) 5 8.40 (1H, s), 8.03-8.05 (1H, m), 7.87 (2H, m), 7.61-7.63 (2H, m), 7.52-7.54 (2H, m), 7.40-7.42 (2H, m), 7.24-7.26 (2H, m), 4.84 (1H, m), 4.39 (2H, m), 2.51 (2H, m), 2.28-2.33 (6H, m).
The following compounds can be prepared by following the above synthetic route. 4-(7-Chloro-4-ox0-1,2,3-benzotriazin-3(4H)-yl)-2-[ formyl(4'-methylbiphenyl-4- yl)amino Jbutanoic acid (Compound no. 2);
LCMS-447.23 (M-28) 2-[(4'-Ethylbiphenyl-4-yl)(formyl)amino]-4-(5-methyl-4-oxo-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 3).
LCMS-469.34 (M-1)
Example 2: Synthesis of O-[(4-fluorophenyl)carbamoyl]-N-formyl-N-(4-methylbiphenyl- 4-yl)homoserine (Compound no. 4) (Scheme 1, Path B)
Step a: Preparation of methyl O-[(4-fluorophenyl)carbamoyl]-/V-formyl-V-(4'-methyl biphenyl-4-yl)homeoserinate
To a solution of methyl N-formyl-N-(4"-methylbiphenyl-4-yl)homoserinate (0.3 g, 0.0009 moles) in tetrahydrofuran (5 mL) was added triethylamine (0.272 g, 0.0027 moles) and 1-fluoro-4-isocyanatobenzene (0.147 g, 0.0010 moles) under argon atmosphere at room temperature. The reaction mixture was allowed to stir for about 2 hours at room temperature. After completion, the reaction mixture was quenched by addition of water and extracted with ethyl acetate. The organic layer obtained was dried over anhydrous sodium sulphate and concentrated under reduced pressure to get crude compound. The crude compound was purified on silica gel column using 15% ethyl acetate: hexane as eluent to obtain desired product.
Yield: 0.15 ¢g
LCMS: 464.93 (M+1)
Step b: Preparation of O-[(4-fluorophenyl)carbamoyl]-V-formyl-V-(4'- methylbiphenyl-4-yl)homoserine
To a compound obtained from Step a (0.15 g, 0.0003 moles) in tetrahydrofuran (5 mL) and methanol (5 mL) was added solution of lithium hydroxide (0.018 g, 0.0004 moles) in water and stirred for about one hour at room temperature. After completion, the reaction mixture was acidified with sodium bisulfite (pH~2) and extracted with ethyl acetate. The organic layer was separated and dried over anhydrous sodium sulphate and concentrated under vacuum to get crude compound which was purified by preparative
TLC using 10% methanol: dichloromethane as mobile phase to obtain a desired product.
Yield: 0.03 g
LCMS-449.28 (M-1) 'H NMR (400 MHz)-3 9.63 (1H, s), 8.45(1H, 5), 7.67-7.69 (2H, m), 7.53-7.55 (4H, m), 7.26-7.28 (2H, m), 7.12-7.14 (4H, m), 4.89-4.93 (1H, m), 4.06-4.10 (2H, s), 2.45 (2H, m), 2.41-2.43 (3H, m).
The following compounds can be prepared by following the above synthetic route.
N-Formyl-N-(4'-methylbiphenyl-4-yl)-O-[(4-methylphenyl)carbamoyl homoserine (Compound no. 5);
LCMS-417.27 (M-28)
O-[(3,4-Dichlorophenyl)carbamoyl]-N-formyl-N-(4'-methylbiphenyl-4- yDhomoserine (Compound no. 6);
LCMS-501.15 (M)
N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O- {[4-(propan-2- yl)phenyl]carbamoyl} homoserine (Compound no. 7);
LCMS-487.35 (M-1)
N-(4'-Ethylbiphenyl-4-yl)-O-[(3-fluorophenyl)carbamoyl]- N-formylhomoserine (Compound no. 8);
LCMS-463.33 (M-1)
O-[(2,4-Difluorophenyl)carbamoyl]-N-(4'-ethylbiphenyl-4-yl)-N- formylhomoserine (Compound no. 9);
LCMS-481.32 (M-1)
N-(4'-Ethylbiphenyl-4-yl)-O-[(2-fluorophenyl)carbamoyl]- N-formylhomoserine
Compound no. 10);
LCMS-463.33 (M-1)
N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O- {[4- (trifluoromethyl)phenyl]carbamoyl } homoserine (Compound no. 11);
LCMS-513.32 (M-1)
N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O-[(2-methylphenyl)carbamoyl homoserine (Compound no. 12);
LCMS-459.33 (M-1)
N-(4'-Ethylbiphenyl-4-yl)-O-[(4-ethylphenyl)carbamoyl]-N-formylhomoserine (Compound no. 13);
LCMS-473.30 (M-1)
N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O-[ (4-methoxyphenyl)carbamoyl] homoserine (Compound no. 14);
LCMS-475.35 (M-1)
O-[(2,6-Dichlorophenyl)carbamoyl]-N-(4'-ethylbiphenyl-4-y1)- N- formylhomoserine (Compound no. 15);
LCMS-515.29 (M-1)
Example 3: Synthesis of 4-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-y1)-2-[(4'- methoxybiphenyl-4-yl) (methyl) amino]butanoic acid (Compound no. 18); (Scheme II,
Path C)
Step a: Preparation of 2-bromo-4-(1,3-dioxo-1,3-dihydro-2 H-isoindol-2-yl)butanoic acid
To a solution of 4-(1,3-dioxo-1,3-dihydro-2 H-isoindol-2-yl)butanoic acid (11.7 g, 0.050 moles) in carbon tetrachloride (60 mL) was added red phosphorous (5.2 g, 0.167 mole) and heated at about 60°C. To this reaction mixture, bromine (40 mL, 0.792 mole) was added slowly over a period of about one hour and again heated up to 60°C for about 8 5S hours then cooled to 0°C. After that, water (50 mL) was added to the reaction mixture.
The reaction mixture was solidified and extracted with ethyl acetate. The organic layer was washed with aqueous solution of sodium bicarbonate. The obtained aqueous layer was acidified (pH~2) using aqueous solution of hydrochloric acid and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulphate and evaporated to get desired product.
Yield: 10.8 g
LCMS: 313.4 (M+1)
Step b: Preparation of tert-butyl 2-bromo-4-(1,3-dioxo-1,3-dihydro-2 H-isoindol-2-yl) butanoate
To a solution of compound obtained from Step a (180 mg, 0.576 mmoles) in tetrahydrofuran (5 mL) was added Boc anhydride (1 mL, 0.461 mmoles) and N,N’- dimethylaminopyridine (7 mg, 0.057 mmoles). The reaction mixture was allowed to stir at room temperature for about 18 hours. After completion of reaction, solvent was azeotropically distilled using toluene and ethyl acetate to obtain a crude product. The crude product was purified on silica gel column using 20% ethyl acetate: hexane as eluent to get the desired product.
Yield: 180 mg
Step c¢: Preparation of zer-butyl 2-[(4-bromophenyl)(methylsulfonyl)amino]-4-(1,3- dioxo-1,3-dihydro-2H-isoindol-2-yl)butanoate
To a solution of N-(4-bromophenyl)methanesulfonamide (1 g, 0.04 moles) in acetonitrile (20 mL) was added potassium carbonate (0.276 g, 0.002 moles) at room temperature. The reaction mixture was allowed to stir for about 15 minutes and then compound obtained from Step b (1.472 g, 0.004 moles) was added. The reaction mixture was heated at about 80°C for about 56 hours. After completion, the reaction mixture was concentrated and residue obtained was taken in ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product was purified by preparative
TLC using 30% cthyl acetate: hexane as mobile phase to get the desired product.
Yield: 1.7 g
LCMS: 555.9 (M+NH,")
Step d: Preparation of tert-butyl 4-(1,3-dioxo-1,3-dihydro-2 H-isoindol-2-yl)-2-[(4'- methoxy biphenyl-4-yl)(methylsulfonyl)amino]butanoate
To a solution of a compound obtained from Step ¢ (0.205 g, 0.381 moles) in dry
N,N’ -dimethylformamide (5 mL) were added tetrakistriphenylphosphine (8 mg, 0.007 moles), potassium carbonate (0.21g, 1.527 moles) and 4-methoxyphenylboronic acid (0.191 g, 1.259 moles) at room temperature. The reaction mixture was heated to 105°C for about 4.5 hours. After 4.5 hours, it was allowed to cool to room temperature and N,
N’-dimethylformamide was evaporated and residues obtained were taken in ethyl acetate.
The organic layer was washed with water, brine and evaporated under vacuum to get crude product which was purifiedby preparative TLC using 30% ethyl acetate: hexane as mobile phase to get desired product.
Yield: 0.161 g
LCMS: 587.1 (M+Na)
Step e: Preparation of 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-[(4'- methoxybiphenyl-4-yl)(methylsulfonyl)amino|butanoic acid
To a solution of compound obtained from step d (0.144 g, 0.00025 moles) in dichloromethane (5 mL) was added trifluoroacetic acid (1.2 mL) at 0°C. The reaction mixture was allowed to stir for about 3 hours at 0°C and then at room temperature for about 4 hours. After completion, the reaction mixture was extracted with dichloromethane, washed with water and brine. The organic layer was evaporated under reduced pressure to get a crude product which was purified on silica gel column using 50% ethyl acetate: hexane as eluent to get desired product.
Yield: 0.113 g
LCMS: 509.1 (M+1)
'H NMR (CDCls, 400 MHz) &: 7.84 (2H, m), 7.71 (2H, m), 7.62 (4H, m), 7.51 (2H, d, J = 8 Hz), 6.97 (2H, d, J=8 Hz), 5.04 (1H, m), 4.12 (2H, m), 3.85 (3H, s), 3.13 (3H, 5), 2.36 (1H, m), 1.95 (1H, m).
Example 4: Synthesis of 2-[biphenyl-4-yl(methylsulfonyl)amino]-4-(1,3-dioxo-1,3- dihydro-2H-isoindol-2-yl)butanoic acid (Compound no. 16) (Scheme II, Path D)
Step a: Preparation of tert-butyl 2-[biphenyl-4-yl(methylsulfonyl)amine]-4-(1,3- dioxo-1,3-dihydro-2H-isoindol-2-yl)butanoate
To a solution of tert-butyl 2-bromo-4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) butanoate (300 mg, 0.815 mmoles) in &, N’-dimethylformamide (5 mL) were added N- (biphenyl-4-yl)methanesulfonamide (161 mg, 0.652 mmoles) and potassium carbonate (112 mg, 0.815 mmoles). The reaction mixture was heated at 80°C for about 7.5 hours.
After completion, reaction mixture was allowed to cool to room temperature and water was added to it. The reaction mixture was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain a crude product. The crude product was purified on silica gel column using 40% ethyl acetate: hexane as eluent to get desired product.
Yield: 152 mg
LCMS: 552.1 (M+NH,")
Step b: Preparation of 2-[biphenyl-4-yl(methylsulfonyl)amino]-4-(1,3-dioxo-1,3- dihydro-2H-isoindol-2-yl)butaneic acid
To an ice-cooled solution of compound obtained from Step a (152 mg, 0.0002 moles) in dichloromethane (10 mL) was added trifluoroacetic acid (0.7 mL) and stirred for about 2.5 hrs at room temperature. After completion of reaction, the solvent was evaporated and the reaction mixture was taken in dichloromethane and washed with water.
The organic layer was separated, dried over anhydrous sodium sulphate and concentrated to get crude product. The crude product was purified on silica gel column using 40% ethyl acetate: hexane as eluent to get desired product.
Yield: 41.6 mg
LCMS: 479.0 (M+1) 'H NMR (MeOH-de, 400 MHz): § 7.85 (4H, m), 7.78 (4H, m), 7.63 (2H, m), 7.45 (2H, m), 7.36 (1H, m), 4.88 (1H, m), 3.86 (2H, m), 3.15 (3H, s), 2.36 (1H, m), 1.89 (1H, m).
The following compounds can be prepared by following the above synthetic route. 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-yl)-2- {[4-(6-methoxypyridin-3- yl)phenyl](methylsulfonyl)amino} butanoic acid (Compound no. 17);
LCMS: 510.1(M+1)
Example 5: Synthesis of 2-{[4-(6-methoxypyridin-3-yl)phenyl](methylsulfonyl)amino}- 4-(4-ox0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 19) (when Ry is halogen) (Scheme III, Path E)
Step a: Preparation of N-(4-bromophenyl)-/V-(2-oxotetrahydrofuran-3- yl)methanesulfonamide
To a solution of a-hydroxy lactone (673 mg, 0.0072 moles) at 0°C were added N- (4-bromophenyl)methanesulfonamide (1.5 g, 0.006 moles) and triphenylphosphine (2.35 g, 0.009 moles). The reaction mixture was allowed to stir for about15 minutes at 0°C and diisopropylazodicarboxylate (1.8 g, 0.0009 moles) was added. The reaction mixture was again stirred for about 30 minutes at 0°C. After completion, the reaction mixture was concentrated to get a crude product which was purified on silica gel column using 40% ethyl acetate: hexane as eluent to get the desired compound.
Yield: 920 mg
LCMS: 351.18 and 353.12 (M+NH,")
Step b: Preparation of sodium 2-[(4-bromophenyl)(methylsulfonyl)amino]-4-hydroxy butanoate
To a solution of compound obtained from Step a (1.5g, 0.0044 moles) in methanol (10 mL) was added sodium hydroxide (79 mg, 0.0044 moles) and stirred for about one hour at room temperature. After completion, the reaction mixture was concentrated and cthyl acetate was added and decanted to get the desired product.
Yield: 850 mg.
Step c: Preparation of benzyl N-(4-bromophenyl)-/V-(methylsulfonyl)homoserinate
To a solution of compound obtained from Step b (800 mg, 0.0022 moles) in N, N’- dimethylformamide (5 mL) at 0°C was added benzyl bromide (388 mg, 0.0022 moles).
The reaction mixture was allowed to stir for overnight at room temperature. After completion, reaction mixture was extracted with ethyl acetate while washing with water.
The combined organic layer was dried over anhydrous sodium sulphate and concentrated to get crude product. The crude product so obtain was purified on silica gel column using 70% ethyl acetate: hexane to get desired product.
Yield: 850 mg.
Step d: Preparation of benzyl N-(4-bromophenyl)-O-[tert-butyl(dimethyl)silyl]-/V- (methylsulfonyl)homoserinate
To a solution of compound obtained from Step ¢ (800 mg, 0.0018 moles) in N,N’- dimethylformamide (8 mL) were added tert-butyldimethylsilylchloride (325 mg, 0.0021 moles) and imidazole (369 mg, 0.0054 moles). The reaction mixture was allowed to stir for about one hour at room temperature. After completion, reaction mixture was quenched by addition of water and extracted with ethyl acetate. The organic layer was collected, dried over anhydrous sodium sulphate and evaporated under reduced pressure to afford the desired product.
Yield: 1.2 g LCMS: 556.77 and 558.78 (M+1)
Step e: Preparation of benzyl O-[fert-butyl(dimethyl)silyl]-/V-[4-(6-methoxypyridin-3- yDphenyl]-/V-(methylsulfonyl)homoserinate
To a solution of compound obtained from Step d (1.7 g, 0.0045 moles) in N, N’- dimethylformamide (20 mL) were added 5-methoxypyridineboronic acid (929 mg, 0.0061 moles), tetrakis triphenylphosphine palladium (0) (176 mg, 0.0008 moles) and potassium carbonate (1.26 g, 0.0091 moles). After completion of addition, reaction mixture was heated up to 110°C for about 3 hours. After 3 hours, solvent was evaporated and reaction mixture was extracted with ethyl acetate while washing with water. The combined organic layer was collected, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product obtained was purified on silica gel column using 40% ethyl acetate to get desired product.
Yield: 1.3 g
Step f: Preparation of benzyl NV-[4-(6-methoxypyridin-3-yl)phenyl]-/V- (methylsulfonyl) homo serinate
To a solution of compound obtained from Step ¢ (1.1 g, 0.0019 moles) in dichloromethane (20 mL) was added boron trifluoride etherate BF3;.0Ft (1.1 g, 0.0095 moles) slowly at room temperature. The reaction mixture was allowed to stir at room temperature for about one hour. After completion, reaction mixture was quenched with saturated solution of sodium bicarbonate and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated to get crude product. The crude product was purified on silica gel column using 40% ethyl acetate: hexane as eluent to get desired product.
Yield: 750 mg
LCMS: 471.30 (M+1)
Step g: Preparation of benzyl 2-{[4-(6-methoxypyridin-3- yD)phenyl](methylsulfonyl)amine}-4-(4-0x0-1,2,3-benzotriazin-3(4 H)-yl)butanoate
To a solution of compound obtained from Step f (250 mg, 0.531 mmoles) in tetrahydrofuran (15 mL) at 0°C were added benzotriazinone (78 mg, 0.531 mmoles) and triphenylphosphine (278 mg, 1.063 mmoles). The reaction mixture was allowed to stir for about 15 minutes at 0°C and diisopropylazodicarboxylate (161 mg, 0.797 mmoles) was added at same temperature. The reaction mixture was again stirred for about one hour at same temperature. After completion of reaction, solvent was evaporated under reduced pressure to obtain a crude product. The crude product was purified on silica gel column using 40% ethyl acetate: hexane to get desired product.
Yield: 200 mg.
LCMS: 600.88 (M+1)
Step h: Preparation of 2-{[4-(6-methoxypyridin-3-yl)phenyl](methylsulfonyl)amino}- 4-(4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid
To a solution compound obtained from Step g (200 mg) in tetrahydrofuran (10 mL) was added 10% Pd/C (200 mg) and hydrogen was supplied at 55 psi in Parr apparatus for about 8 hours at room temperature. After completion, reaction mixture was filtered through celite pad and residue was washed with 20% methanol: dichloromethane. The filtrate was concentrated to get solid material which was treated with ethyl acetate. The ethyl acetate layer was decanted to get desired product.
Yield: 18 mg
LCMS: 510.70 (M+1) 'H NMR (DMSO-d, 400 MHz) &: 8.52 (1H, 5), 8.25 (1H, d, J = 8 Hz), 8.18 (1H, d, J= 8
Hz), 8.05 (2H, m), 7.92 (1H, m), 7.76 (2H, d, J= 8 Hz), 7.66 (2H, d, J=8Hz), 6.92 (1H, d,
J=38 Hz), 4.48 (3H, m), 3.90 (3H, s), 3.29 (3H, s), 2.3 (1H, m), 1.90 (1H, m).
The following compounds can be prepared by following the above synthetic route. 4-(7-Methoxy-4-oxo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {[4-(6-methoxypyridin-3- yl)phenyl](methylsulfonyl)amino} butanoic acid (Compound no. 20);
LCMS: 540.71 (M+1) 2-{[4-(6-Methoxypyridin-3-yl)phenyl](methylsulfonyl)amino} -4-[4-ox0-7- (trifluoro methyl)-1,2,3-benzotriazin-3(4H)-yl]butanoic acid (Compound no. 21);
LCMS: 578.74 (M+1)
Example 6: Synthesis of 2-[(4-methoxyphenyl)(methylsulfonyl)amino]-4-(4-0x0-1.2.3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 32) (Scheme III, Path F)
Step a: Preparation of benzyl 2-[(4-methoxyphenyl)(methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoate
To a solution of benzyl N-(4-methoxyphenyl)-N-(methylsulfonyl)homoserinate (200 mg, 0.508 moles) in tetrahydrofuran (15 mL) were added triphenylphosphine (200 mg, 0.763 moles) and benzotriazinone (82 mg, 0.550 moles) at 0°C. The reaction mixture was stirred for about 15 minutes and diisopropylazodicarboxylate (154 mg, 0.763 moles) was added to it at 0°C. The reaction mixture was again stirred for about 2 hours at room temperature. After completion, solvent was evaporated to get a crude product which was purified on silica gel column using 30% ethyl acetate: hexane as eluent to get desired compound.
Yield: 180 mg
Step b: Preparation of 2-[(4-methoxyphenyl)(methylsulfonyl)amine]-4-(4-0x0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid
To a compound obtained from Step a (180 mg) in tetrahydrofuran (10 mL) and methanol (10 mL) was added 10% Pd/C (60 mg) and hydrogen gas was supplied on Parr apparatus at 50 psi for about one hour at room temperature. After one hour, the reaction mixture was filtered through celite pad and residue obtained was washed with 10% methanol: dichloromethane. The filtrated was concentrated under reduced pressure to get desired compound.
Yield: 24 mg
LCMS: 433. 69 (M+1) 'H NMR (MeOD, 400 MHz): & 8.31 (1H, d, J= 8 Hz), 8.14 (1H, d, J = 8 Hz), 8.03 (1H, m), 7.88 (1H, m), 7.58 (2H, d, J =8 Hz), 6.92 (2H, d, /=8 Hz), 4.92 (1H, m), 4.57-4.67 (2H, m), 3.79 (3H, s), 3.14 (3H, s), 2.48 (1H, m), 2.02 (1H, m).
The following compounds can be prepared by following the above synthetic route. 4-(6-Methoxy-4-oxo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {[4-(4-methylphenoxy) phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 23);
LCMS: 539.84 (M+1) 4-(7-Methyl-4-oxo0-1,2,3-benzotriazin-3(4H)-yl)-2- {[4-(4-methylphenoxy) phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 24);
LCMS: 523.78 (M+1) 2-{[4-(4-Methylphenoxy)phenyl](methylsulfonyl)amino} -4-[4-oxo-7- (trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]butanoic acid (Compound no. 25);
LCMS: 572.86 (M+1) 2- {[4-(4-Methylphenoxy)phenyl](methylsulfonyl)amino} -4-(4-o0xo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 26);
LCMS: 509.74 (M+1) 4-(7-Methoxy-4-o0x0-1,2,3-benzotriazin-3(4 H)-yl)-2-[ (4-methoxyphenyl) (methylsulfonyl)amino]butanoic acid (Compound no. 33);
LCMS: 463.79 (M+1)
4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-y1)-2-[(4- methoxyphenyl)(methylsulfonyl)amino]butanoic acid (Compound no. 34);
LCMS: 433.63 (M+1) 2-[(4-Methoxyphenyl)(methylsulfonyl)amino]-4-(5-methyl-1,3-dioxo-1,3-dihydro- 2H-isoindol-2-yl)butanoic acid(Compound no. 35);
LCMS: 469.70 (M+1) 4-(7-Methoxy-4-oxo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {[4-(4-methylphenoxy) phenyl] (methylsulfonyl)amino } butanoic acid (Compound no. 36);
LCMS: 539.84 (M+1) 4-(5-Methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2- {[4-(4- methylphenoxy)phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 37);
LCMS: 523.85 (M+1) 2-[(Methylsulfonyl)(phenyl)amino]-4-(4-o0xo- 1,2,3-benzotriazin-3(4 H)-yl)butanoic acid (Compound no. 58);
LCMS: 402.85 (M+1) 4-(5-Chloro-4-o0x0-1,2,3-benzotriazin-3(4H)-yl)-2-[ (4- chlorophenyl)(methylsulfonyl)amino]butanoic acid (Compound no. 104);
LCMS: 473.67 (M+1) 2-[(4-Bromophenyl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin-3(4H)- yDbutanoic acid (Compound no. 105);
LCMS: 481.54 and 483.51 (M+1) 2-[(4-Chlorophenyl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin-3(4H)- yDbutanoic acid (Compound no. 106);
LCMS: 437.33 (M+1) 2-[(4-Chlorophenyl)(methylsulfonyl)amino]-4-(7-methyl-4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 107);
LCMS: 451.70 (M+1) 2-[(4-Chlorophenyl)(methylsulfonyl)amino]-4-(6-methoxy-4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 108);
LCMS: 467.75 (M+1)
Example 7: Synthesis of 2-[(4'-chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-methyl- 1,3-dioxo0-1,3-dihydro-2 H-isoindol-2-yl)butanoic acid (Compound no. 59) (Scheme III,
Path G)
Step a: Preparation of prop-2-en-1-yl 2-[(4'-chlorobiphenyl-4- yD(methylsulfonyl)amino]-4-(5-methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2- yl)butanoate
To a solution of hydroxyl derivative (0.250 g, 0.591 moles) in tetrahydrofuran (10 mL) were added triphenylphosphine (0.232 g, 0.88 moles) and 4-methyl phthalimide (0.104 g, 0.65 moles) at 0°C. The reaction mixture was stirred for about 15 minutes and diisopropylazodicarboxylate (0.179 g, 0.0.88moles) was added to it at 0°C. The reaction mixture was again stirred for about 2 hours at room temperature. After completion, solvent was evaporated to get a crude product which was purified on silica gel column using 30% ethyl acetate: hexane as eluent to get desired compound.
Yield: 0.25 g.
Step b: Preparation of 2-[(4'-chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5- methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butanoic acid
To a compound obtained from Step a (250 mg, 0.441 moles) in acetonitrile (10 mL) at 0°C was added tetrakis triphenylphosphine (51 mg, 0.044 moles) and morpholine (384 mg, 4.4 moles). The reaction mixture was allowed to stir for about 3 hours at 0°C.
After 3 hours, the reaction mixture was diluted by addition of water and extracted with cthyl acetate. The aqueous layer obtained was acidified with sodium bisulphite and extracted with ethyl acetate. The combined organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product was purified on preparative TLC using 10% methanol: dichloromethane as mobile phase to get desired product.
Yield: 35mg
LCMS: 526.84 (M+1) 'H NMR (MeOH-ds, 400 MHz) &: 7.78 (2H, d, J = 8 Hz), 7.70 (1H, d, J = 4Hz), 7.61 (6H, m), 7.43 (2H, m), 4.73 (1H, m), 3.72-3.90 (2H, m), 3.20 (3H, s), 2.48 (3H, 5), 2.31 (1H, m), 1.77 (1H, m).
The following compounds can be prepared by following the above synthetic route. 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-chloro-4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 60);
LCMS: 546.66 (M) 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(7-chloro-4-oxo-1,2,3- benzotriazin-3 (4H)-yl)butanoic acid (Compound no. 61);
LCMS: 546.73 and 548.68 (M+1 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(7-methyl-4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 62);
LCMS: 526.70 and 528.72 (M+1) 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-[4-oxo-7-(trifluoromethyl)- 1,2,3-benzo triazin-3(4H)-yl]butanoic acid (Compound no. 63);
LCMS: 580.74 (M+1) 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-methoxy-4-oxo-1,2,3- benzotriazin-3 (4H)-yl)butanoic acid (Compound no. 64);
LCMS: 542.76 (M+1) 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-fluoro-4-oxo-1,2,3- benzotriazin-3 (4H)-yl)butanoic acid (Compound no. 65);
LCMS: 530.73 (M+1) 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(1-methyl-2.,4-dioxo-1,4- dihydro quinazolin-3(2H)-yl)butanoic acid (Compound no. 66);
LCMS: 543.6 (M+1)
Example 8: Synthesis of 2-[ {4-[(4-methylphenyl)carbamoyl]phenyl} (methylsulfonyl) amino]-4-(4-oxo0-1.2,3-benzotriazin-3(4 H)-yl)butanoic acid (Compound no. 68) Scheme 111, Path H)
Step a: Preparation of fer-butyl 4-{(methylsulfonyl)[1-0x0-4-(4-0x0-1,2,3- benzotriazin-3(4H)-yl)-1-(prop-2-en-1-yloxy)butan-2-ylJamino} benzoate
To a solution of hydroxyl derivative (1.4 g, 3.389 mmoles) in tetrahyrofuran (20 mL) at 0°C were added triphenylphosphine (1.77g, 6.779 mmole) and 1,2,3-benzotriazin- 4(3H)-one (0.498 g, 3.389 mmole) after 5S minutes at the same temperature diisopropylazodicarboxylate (1.027 g, 5.084 mmole) was added. Then, the reaction mixture was stirred for 30 minutes at the same temperature. Solvent was evaporated and purification was performed on silica gel 60-120 mesh column using 40% EtOAc:Hexane as eluent to get 3 gm of product.
LCMS: 542.83 (M+1)
Step b: Preparation of 4-{(methylsulfonyl)[1-0x0-4-(4-0x0-1,2,3-benzotriazin-3(4H)- yD)-1-(prop-2-en-1-yloxy)butan-2-yl]amino} benzoic acid
To a solution of compound obtained from Step a (3 g, 5.535 mmoles) in dichloromethane (30 mL) was added trifluoroacetic acid (6 mL, 28.782 mmol) at room temperature. The reaction mixture was allowed to stir for about 2 hours at the same temperature. After 2 hours, the solvent was evaporated and the reaction mixture was neutralized by aqueous solution of sodium bicarbonate. The reaction mixture was extracted with ethyl acetate, dried over anhydrous sodium sulphate and evaporated under 5S vacuum to get desired product.
Yield: 1g
LCMS: 486.78 (M+1)
The following compounds can be prepared by following the above synthetic route. 4-{(Methylsulfonyl)[ 1-ox0-4-(4-0x0-1,2,3-benzotriazin-3(4H)-yl)-1-(prop-2-en-1- yloxy)butan-2-yl]amino} benzoic acid (Compound no. 67);
LCMS: 486.78 (M+1)
Step c: Preparation of prop-2-en-1-yl 2-[{4-[(4-methylphenyl)carbamoyl] phenyl} (methyl sulfonyl)amino]-4-(4-0x0-1,2,3-benzotriazin-3(4H)-yl) butanoate
To an ice-cooled solution of compound obtained from Step b (400 mg, 0.823 mmoles) in N, N’-dimethylformamide (20 mL) were added p-toludine (88 mg, 0.823 mmoles), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (236 mg, 1.234 mmoles), N, N’-dimethylaminopyridine (20 mg, 0.164 mmoles) and hydroxybenzotriazole (111 mg, 0.823 mmoles). The reaction mixture was allowed to stir at room temperature for 12 hours. After completion, the solvent was evaporated and the reaction mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated under vacuum to get crude product. The crude product obtained was purified on silica gel column using 80% ethyl acetate: hexane as cluent to get the desired compound.
Yield: 520 mg
Step d: Preparation of 2-[{4-[(4-methvlphenvl)carbamoyl]phenvl}(methylsulfonyl) amino]-4-(4-0x0-1,2,3-benzotriazin-3(4H)-vl)butaneic acid
To an ice-cooled solution of compound obtained from Step ¢ (520 mg, 0.904 mmoles) in acetonitrile (25 mL) were added tetrakis triphenylphosphine palladium (0) (208 mg, 0.180 mmoles) and morpholine (786 mg, 9.043 mmoles). The reaction mixture was allowed to stir at same temperature for about 30 minutes. After 30 minutes, the solvent was evaporated and the reaction mixture was acidified using aqueous solution of sodium bisulphate and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated to get crude product. The crude product was purified on preparative TLC using 10% methanol: dichloromethane as mobile phase to get desired compound.
Yield: 250 mg.
LCMS: 535.84 (M+1), 557.82 (M+Na) 'H NMR (DMSO-ds, 400 MHz): 8 10.3 (1H, s), 8.25 (2H, m), 8.20 (1H, m), 8.06-8.10 (3H, m), 7.96 (4H, m), 7.15 (2H, d, J = 8 Hz), 4.78 (1H, m). 4.51 (2H, m), 3.16 (3H, s), 2.42 (1H, m), 2.20 (3H, s), 1.95 (1H, m).
The following compounds can be prepared by following the above synthetic route. 2-[ {4-[(4-Chlorophenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound no. 69);
LCMS: 555.74 and 557.72 (M+1) 2-{(Methylsulfonyl)[4-(phenylcarbamoyl)phenyl]amino} -4-(4-0xo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 70);
LCMS: 521.80 (M+1) 2-[{4-[(3-Fluorophenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound no. 71);
LCMS: 539.74 (M+1) 2-[(Methylsulfonyl)(4- {[4-(propan-2-yl)phenyl] carbamoyl} phenyl)amino]-4-(4- 0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 72);
LCMS: 563.80 (M+1) 2-[{4-[(4-Methoxyphenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound no. 73);
LCMS: 551.77 (M+1) 2-[{4-[(4-Fluorophenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound no. 74);
LCMS: 539.74 (M+1) 2-[(Methylsulfonyl)(4- {[4-(trifluoromethyl)phenyl]carbamoyl} phenyl)amino]-4- (4-o0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 75).
LCMS: 589.75 (M+1)
Example 9: Synthesis of 4-(1.3-dioxo-1.3-dihydro-2H-isoindol-2-yl)-2- {(methylsulfonyl)[4-(propan-2-yl)phenyl]amino } butanoic acid (Compound no. 51)
Scheme IV
Step a: Preparation of benzyl 4-{[tert-butyl(dimethyl)silyl]oxy}-2-hydroxybutanoate
To an ice-cooled solution of benzyl 2,4-dihydroxybutanoate (10.4 g, 49.52 mmoles) in dichloromethane (100 mL) were added triethylamine (8.3 mL, 59.42 mmoles) followed by tert-butyldimethylsilyl chloride (8.20 g, 54.47 mmoles) and N, N’- dimethylaminopyridine (241 mg, 1.98 mmoles). The reaction mixture was allowed to stir at room temperature for about one hour. After completion, reaction mixture was quenched by addition of water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under vacuum to afford the crude compound. The crude compound obtained was purified on column chromatography using silica gel and eluting with 10% ethyl acetate: hexane as eluent to get the desired compound. Yield: 9.6 g
LCMS: 325.67 (M+1), 347.64 (M+Na)
Step b: Preparation of benzyl O-|tert-butyl(dimethyl)silyl]-V-(methylsulfonyl)-/V-[4- (propan-2-yl)phenyllhomoserinate
To an ice-cooled solution of compound obtained from Step a (1 g, 3.08 mmoles) in tetrahydrofuran (5 mL) were added N-[4-(propan-2-yl)phenyl]methanesulfonamide (722 mg, 3.39 mmoles) and triphenylphosphine (1.21 g, 4.62 mmoles) under argon atmosphere.
Diisopropylazodicarboxylate (0.67 mL, 3.39 mmoles) was added dropwise and the reaction mixture was allowed to stir at the same temperature for about 30 minutes. After completion, solvent was evaporated under vacuum and crude compound obtained was purified on silica gel using 20% ethyl acetate: hexane as eluent to get desired compound.
Yield: 1.7 g.
Step c: Preparation of benzyl N-(methylsulfonyl)-/V-[4-(propan-2-yl)phenyl] homoserinate
To a solution of compound obtained from Step b (1.7 g, 3.27 mmoles) in dichloromethane (10 mL) was added borane trifluoride ethearte BF;.OEt, (2 mL, 16.35 mmoles) slowly at room temperature. The reaction mixture was allowed to stir at room temperature for about one hour. After completion, reaction mixture was quenched with saturated solution of sodium bicarbonate and extracted with dichloromethane. The organic layer was washed with water, brine and dried over anhydrous sodium sulphate and concentrated under vacuum to get a crude compound. The crude compound obtained was purified on silica gel column and eluting with 40% ethyl acetate: hexane as eluent to get the desired product.
Yield: 510 mg
Step d: Preparation of benzyl 4-(1,3-dioxo-1,3-dihydro-2 H-isoindol-2-yl)-2-{(methyl sulfonyl) [4-(propan-2-yl)phenyl]amino}butanoate
To an ice-cooled solution of compound obtained from Step ¢ (170 mg, 0.41 mmoles) in tetrahydrofuran (10 mL) were added phthalimide (67 mg, 0.46 mmoles) and triphenylphosphine (161 mg, 0.61 mmoles). Diisopropylazodicarboxylate (0.09 mL, 0.46 mmoles) was added to the reaction mixture and stirred for about 30 minutes at the same temperature. After completion, solvent was evaporated and crude product obtained was purified on silica gel column chromatography using 50% ethyl acetate: hexane as eluent to get desired product.
Yield: 150 mg
Step e: Preparation of 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-{(methylsulfonyl) [4-(propan-2-yl)phenyl]amino}butanoic acid
To a solution of compound obtained from Step d (150 mg, 0.280 mmoles) in tetrahydrofuran (10 mL) at room temperature was added 10% Pd/C (100 mg) and hydrogen gas was supplied by balloon. The reaction mixture was allowed to stir for about 30 minutes at the same temperature. After completion, the reaction mixture was filtered using celite pad and residue obtained was washed with 10% methanol: dichloromethane solution. The filtrate was concentrated and purification was performed on preparative
TLC using 10% methanol: dichloromethane as mobile phase to afford desired product.
Yield: 30 mg.
LCMS: 445.79 (M+1), 467.75 (M+Na)
'H NMR (MeOD-dj, 400 MHz) &: 7.78-7.85 (2H, m), 7.52 (1H, d, J = 8 Hz), 7.29 (1H, d,
J=8 Hz), 4.90 (1H, m), 3.74-3.91 (2H, m), 3.29 (3H, s), 2.93 (1H, m), 2.20 (1H, m), 1.79 (1H, m), 1.25 (6H, dd, J=8 Hz).
The following compounds can be prepared by following the above synthetic route. 4-(6-Methoxy-4-o0xo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {(methylsulfonyl)[4-(propan- 2-yl) phenyl]amino } butanoic acid (Compound no. 52);
LCMS: 475.82 (M+1) 4-(7-Methyl-4-oxo0-1,2,3-benzotriazin-3(4H)-yl)-2- {(methylsulfonyl)[4-(propan-2- yl) phenyl]amino } butanoic acid (Compound no. 53);
LCMS: 459.83 (M+1) 4-(1, 3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-[(4- ethylphenyl)(methylsulfonyl)amino] butanoic acid (Compound no. 54);
LCMS: 431.75 (M+1) 2-[(4-Ethylphenyl)(methylsulfonyl)amino]-4-(5-methyl-1,3-dioxo-1,3-dihydro-2 H- isoindol-2-yl)butanoic acid (Compound no. 55);
LCMS: 445.79 (M+1) 2-[(4-Ethylphenyl)(methylsulfonyl)amino]-4-(7-methyl-4-oxo-1,2,3-benzotriazin- 3(4H)-yl) butanoic acid (Compound no. 56);
LCMS: 445.79 (M+1) 2-[(4-Ethylphenyl)(methylsulfonyl)amino]-4-(6-methoxy-4-oxo0-1,2,3- benzotriazin-3(4H)-yl) butanoic acid (Compound no. 57);
LCMS: 461.79 (M+1)
Example 10: Synthesis of 2-[(3'.4'-difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4- 0x0-1,2.3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 27) (Scheme V)
Step a: Preparation of 3-[2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl]-1,2,3-benzotriazin- 4(3H)-one
To an ice-cooled solution of 4-(2-hydroxyethyl)-2,2-dimethyl 1,3-dioxolane (3.8 g, 0.025 moles) in tetrahydrofuran (50 mL) were added benzotriazinone (4.2 g, 0.028 moles) and triphenylphosphine (13.6 g, 0.051 moles). The reaction mixture was allowed to stir for about 15 minutes at 0°C and diisopropylazodicarboxylate (7.3 mL, 0.038 moles) was added to it. The reaction mixture was again stirred for about 2 hours at room temperature.
After completion of reaction, solvent was evaporated under vacuum to obtain a crude product which was purified on silica gel column using 30% ethyl acetate: hexane as eluent to get desired product.
Yield: 11g
LCMS: 294.99 (M+Na)
Step b: Preparation of 3-(3,4-dihydroxybutyl)-1,2,3-benzotriazin-4(3H)-one
To a solution of compound obtained from Step a (11 g, 39.954 mmoles) in acetone (60 mL) was added concentrated HCI (12 mL) and reaction mixture was allowed to stir at room temperature for about one hour. After one hour, the solvent was evaporated under reduced pressure and reaction mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated under vacuum to get crude compound. The crude compound obtained was purified on silica gel column using 70% ethyl acetate: hexane as eluent to get desired product.
Yield: 45g
LCMS: 236.49 (M+1)
Step c: Preparation of 2-hydroxy-4-(4-0x0-1,2,3-benzotriazin-3(4H)-yl)butyl benzoate
To an ice-cooled solution of compound obtained from Step b (1 g, 0.0042 moles) in dichloromethane (150 mL) were added triethylamine (1.1 mL, 0.0085 moles) and benzoyl chloride (0.5 mL, 0.0042 moles) and stirred at same temperature for about 2 hours and at room temperarure for about 3 hours. After completion, reaction mixture was diluted with water and extracted with dichloromethane. The organic layer was collected, dried over anhydrous sodium sulphate and evaporated under vacuum to get crude product.
The crude product was purified on silica gel column using 70% ethyl acetate: hexane as cluent to get desired product.
Yield: 1.8 g
LCMS: 340.59 (M+1)
Step d: Preparation of 2-[(4-bromophenyl)(methylsulfonyl)amino]-4-(4-0x0-1,2,3- benzotriazin-3(4H)-yl)butyl benzoate
To an ice-cooled solution of compound obtained from Step ¢ (1.8 g, 0.0053 moles) in tetrahydrofuran (20 mL) were added triphenylphosphine (2.78 g, 0.0161 moles) and N- (4-bromophenyl)methanesulfonamide (1.46 g, 0.00584 moles). The reaction mixture was allowed to stir for about 15 minutes and then diisopropylazodicarboxylate (1.5 mL, 0.00796 moles) was added at same temperature. The reaction mixture was again stirred at room temperature for about one hour. After one hour, solvent was evaporated under reduced pressure to obtain a crude product. The crude product obtained was purified on silica gel column using 30% ethyl acetate: hexane as eluent to get desired product.
Yield: 1.3 g.
Step e: Preparation of 2-[(3',4'-difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4- 0x0-1,2,3-benzotriazin-3(4H)-yl) butyl benzoate
To a solution of compound obtained from Step d (400 mg, 0.0007 moles) in N, N’- dimethylformamide (15 mL) were added tetrakis triphenylphosphine palladium (0) (40 mg, 0.000035 moles), potassium carbonate (290 mg, 0.0021 moles) and 3, 4-difluorobenzene boronic acid (221 mg, 0.0014 moles). The reaction was heated upto 110°C for about 3 hours. After 3 hours, solvent was evaporated and reaction mixture was taken in ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product was purified on silica gel column using 50% ethyl acetate: hexane to get desired product.
Yield: 300 mg
LCMS: 606.27 (M+2).
Step f: Preparation of N-(3',4'-difluorobiphenyl-4-yl)-N-[1-hydroxy-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butan-2-yllmethanesulfonamide
To a solution of compound obtained from Step e (300 mg, 0.496 moles) in methanol (10 mL) and tetrahydrofuran (10 mL) was added potassium carbonate (102 mg, 0.745 moles) and stirred for about one hour at room temperature. After one hour, solvent was evaporated and reaction mixture was taken in ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain a crude product. The crude product obtained was purified on silica gel column using 60% ethyl acetate: hexane as eluent to get the desired product.
Yield: 200 mg
LCMS: 501.81 (M+1)
Step g: Preparation of 2-[(3',4'-difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4- 0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid
To a solution of compound obtained from Step f (200 mg, 0.4 moles) in acetonitrile (10 mL) were added 2,2,6,6-tetramethylpiperidine-N-oxyl (6 mg, 0.04 moles), sodium chlorite (72 mg, 0.8 moles) and 5% aqueous solution of sodium hypochlorite (59 mg, 0.8 moles). The reaction was heated up to 35°C for about 6 hours. After 6 hrs, the solvent was evaporated and reaction mixture was taken in ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product was purified on preparative
TLC using 10% methanol: dichloromethane as mobile phase to get desired product.
Yield: 30 mg.
LCMS: 515.72 (M+1) 'H NMR (DMSO-d, 400 MHz): § 8.28 (2H, d, J = 4 Hz), 8.22 (1H, d, J= 8 Hz), 8.12 (1H, dd, J=8 and 4 Hz), 7.96 (1H, m), 7.85 (4H, m), 7.58 (2H, m), 4.74 (1H, d, J = 8 HZ), 4.56 (2H, m, -NCH,), 3.21 (3H, s), 2.48 (2H, m).
The following compounds can be prepared by following the above synthetic route. 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-yl)-2- {[4-(6-methoxypyridin-3- yl)phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 22);
LCMS: 510.69 (M+1) 2-[(4'-Ethylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 28);
LCMS: 507.79 (M+1) 2-{[4-(2-Methoxypyrimidin-5-yl)phenyl](methylsulfonyl)amino} -4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 29);
LCMS: 511.76(M+1) 2-[(3'-Fluoro-4'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 30);
LCMS: 511.76 (M+1) 2-[(2',4'-Dimethoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 31);
LCMS: 539.84 (M+1) 2-[(3'-Methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 38);
LCMS: 509.81 (M+1) 2-[(4'-Fluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 39);
LCMS: 497.78 (M+1) 2- {(Methylsulfonyl)[4'-(propan-2-yl)biphenyl-4-yl]Jamino } -4-(4-ox0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 40);
LCMS: 521.82 (M+1) 2-[Biphenyl-4-yl(methylsulfonyl)amino]-4-(4-oxo-1,2,3-benzotriazin-3(4 H)- yDbutanoic acid (Compound no. 41);
LCMS: 479.78 (M+1) 2-{[4-(6-Methylpyridin-3-yl)phenyl]|(methylsulfonyl)amino} -4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 42);
LCMS: 494.83 (M+1) 2-{(Methylsulfonyl)[4-(pyrimidin-5-yl)phenyl]amino} -4-(4-o0xo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 43);
LCMS: 481.79 (M+1) 2- {(Methylsulfonyl)[4-(pyridin-3-yl)phenyl]amino} -4-(4-ox0-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 44);
LCMS: 480.79 (M+1) 2- {(Methylsulfonyl)[4'-(trifluoromethyl)biphenyl-4-yl]amino} -4-(4-oxo0-1,2,3- benzotriazin-3 (4H)-yl)butanoic acid (Compound no. 45);
LCMS: 547.83 (M+1) 2- {(Methylsulfonyl)[4-(pyridin-4-yl)phenyl]amino} -4-(4-ox0-1,2,3-benzotriazin- 3(4H)-yl)butanoic acid (Compound no. 46);
LCMS: 480.7969 (M+1) 2-[(3',4'-Dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 47);
LCMS: 547.76 and 549.71 (M+1) 2-[(4'-tert-Butylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 48);
LCMS: 535.87 (M+1)
2-[(2',3"-Difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 49);
LCMS: 515.79 (M+1) 2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 50).
LCMS: 527.81 (M+1)
Example 11: Synthersis of (2R)-2-[(3'.4'-Dichlorobiphenyl-4-yl)(methylsulfonyl)amino]- 4-(4-o0x0-1.2.3-benzotriazin-3 (4H)-yl)butanoic acid (Compound no. 79); Scheme V
Step a: Preparation of 3-[2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl]-1,2,3-benzotriazin- 4(3H)-one
To an ice-cooled solution of 4-(2-hydroxyethyl)-2,2-dimethyl 1,3-dioxolane (20 g, 0.136 mole) in tetrahydrofuran (200 mL) were added benzotriazinone (22 g, 0.150 mole) and triphenylphosphine (71 g, 0.273 mole). The reaction mixture was allowed to stir for about 15 minutes at 0°C and diisopropylazodicarboxylate (41.5 g, 0.205 mole) was added toit. The reaction mixture was again stirred for 2 hours at room temperature. After completion of reaction, solvent was evaporated under vacuum to obtain a crude product which was purified on silica gel column using 30% ethyl acetate: hexane as eluent to get desired product.
Yield: 69 g
Step b: Preparation of 3-(3,4-dihydroxybutyl)-1,2,3-benzotriazin-4(3H)-one
To a solution of compound obtained from Step a (69 g, 0.250 moles) in acetone (200 mL) was added concentrated HCI (70 mL) and reaction mixture was allowed to stir at room temperature for about one hour. After one hour, the solvent was evaporated under reduced pressure and reaction mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated under vacuum to get crude compound. The crude compound obtained was purified on silica gel column using 70% ethyl acetate: hexane as eluent to get desired product.
Yield: 21 g
Step c: Preparation of 2-hydroxy-4-(4-0xo-1,2,3-benzotriazin-3(4H)-yl)butyl benzoate
To an ice-cooled solution of compound obtained from Step b (21 g, 0.089 mole) in dichloromethane (100 mL) were added triethylamine (27 g, 0.268 mole) and benzoyl chloride (15.5 mL, 0.134 mole) and stirred at same temperature for about 3 hours. After completion, the reaction mixture was diluted with water and extracted with dichloromethane. The organic layer was collected, dried over anhydrous sodium sulphate and evaporated under vacuum to get crude product. The crude product was purified on silica gel column using 70% ethyl acetate: hexane as eluent to get desired product.
Yield: 16 g
Step d: Preparation of 2-[(4-bromophenyl)(methylsulfonyl)amino]-4-(4-0xo0-1,2,3- benzo triazin-3(4 H)-yl)butyl benzoate
To an ice-cooled solution of compound obtained from Step ¢ (11 g, 0.032 mole) in tetrahydrofuran (100 mL) were added triphenylphosphine (17 g, 0.064 mole) and N-(4- bromophenyl)methane sulfonamide (8.95 g, 0.035 mole). The reaction mixture was allowed to stir for about 15 minutes and then diisopropylazodicarboxylate (9.8 g, 0.048 mole) was added at the same temperature. The reaction mixture was again stirred at room temperature for about one hour. After one hour, solvent was evaporated under reduced pressure to obtain a crude product. The crude product obtained was purified on silica gel column using 30% ethyl acetate: hexane as eluent to get desired product.
Yield: 1.3 g.
Step e: Preparation of 2-[(3',4'-dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4- 0x0-1,2,3-benzotriazin-3(4 H)-yl)butyl benzoate
To a solution of compound obtained from Step d (0.8g, 0.0014 mole) in N, NV’- dimethylformamide (20 mL) were added tetrakis triphenylphosphine palladium (0) (0.08 g, 0.00007 mole), potassium carbonate (.58 g, 0.0042 mole) and 3,4-chlorobenzene boronic acid (0.535 g, 0.0028 mole). The reaction was heated up to 110°C for about 3 hours.
After 3 hours, the solvent was evaporated and the reaction mixture was taken in ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product was purified on silica gel column using 50% ethyl acetate: hexane to get desired product.
Yield: 850 mg
Step f: Preparation of N-(3',4'-dichlorobiphenyl-4-yl)-V-[1-hydroxy-4-(4-oxo-1,2,3- benzotriazin-3(4 H)-yl)butan-2-yl|methanesulfonamide
To a solution of compound obtained from Step ¢ (0.85 g, 0.00133 mole) in methanol (15 mL) was added potassium carbonate (0.276 g, 0.0020 mole) and stirred for about one hour at room temperature. After one hour, the solvent was evaporated and the reaction mixture was taken in ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain a crude product. The crude product obtained was purified on silica gel column using 60% ethyl acetate: hexane as eluent to get the desired product.
Yield: 0.430 g.
LCMS: 533.13 (M+)
Step g: Preparation of 2-[(3',4'-dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4- 0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid
To a solution of compound obtained from Step f (0.43 g 0.0008 mole) in acetonitrile (15 mL) were added 2,2,6,6-tetramethylpiperidine-N-oxyl (0.012 g, 0.000007 mole), sodium chlorite (0.145 g, 0.0016 mole) and 5% aqueous solution of sodium hypochlorite (0.12 g, 0.0016 moles). The reaction was heated up to 35°C for about 6 hours. After 6 hours, the solvent was evaporated and the reaction mixture was taken in ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product was purified on preparative TLC using 10% methanol: dichloromethane as mobile phase to get desired product.
Yield: 0.15 g.
HNMR (DMSO-ds, 400 MHz): 8.22 (2H, m), 8.16 (1H, m), 8.03 - 8.05 (2H, m), 7.67 - 7.71 (6H, m), 4.63 (1H, m), 4.55 (2H, m), 3.15 (3H,s), 2.14 (1H, m), 1.99 (1H, m)
LCMS: 547.11 (M+1)
The following compounds can be prepared by following the above synthetic route.
(2R)-2-[(4'-Fluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 76);
LCMS: 497.19 (M+1) (2R)-2- {(Methylsulfonyl)[4-(pyrimidin-5-yl)phenyl]amino } -4-(4-ox0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 77);
LCMS: 481.21 (M+1) (2R)-2- {(Methylsulfonyl)[4'-(propan-2-yl)biphenyl-4-yl]amino} -4-(4-0xo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 78);
LCMS: 521.29 (M+1) (2R)-2-[(3',4'-Difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 80);
LCMS: 515.22 (M+1) (2R)-2-[(3'-Fluoro-4'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 81);
LCMS: 511.32 (M+1) (2R)-2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 82);
LCMS: 513.71 (M+1) (2R)-2-[(3'-Methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 83);
LCMS: 509.25 (M+1) (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 84);
LCMS: 527.22 (M+1) (2R)-2-[Biphenyl-4-yl(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin-3(4 H)- yDbutanoic acid (Compound no. 85);
LCMS: 479.25 (M+1) (2R)-2- {[4-(6-Methoxypyridin-3-yl)phenyl](methylsulfonyl)amino} -4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 86);
LCMS: 510.169 (M+1) (25)-2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 87);
LCMS: 513.23 (M+1) (25)-2-[(3',4'-Dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 88);
LCMS: 547.22 and 549.11 (M+1)
(28)-2-[(3'-Fluoro-4'-methylbiphenyl-4-yl)(methylsul fonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 89);
LCMS: 511.27 (M+1) (28)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 90);
LCMS: 527.28 (M+1) (2R)-2-[(3',4'-Dimethoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 91);
LCMS: 537.5 (M-1) (2R)-2-{[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)phenyl] (methylsulfonyl)amino } -4- (4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 92);
LCMS: 537.30 (M+1) (2R)-2-[(4'-Methoxy-3'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 93);
LCMS: 545.22 (M+1) (2R)-2-[(4'-Fluoro-3'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- benzotriazin-3(4H)-yl)butanoic acid (Compound no. 94);
LCMS: 533.27 (M+1) (2R)-2- {(Methylsulfonyl)[4'-(trifluoromethoxy)biphenyl-4-ylJamino } -4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 95);
LCMS: 563.16 (M+1) (2R)-2-{[4'-Chloro-3'-(trifluoromethyl)biphenyl-4-yl](methylsulfonyl)amino} -4- (4-ox0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 96);
LCMS: 581.9 (M+1)
Example 12: Synthesis of (2R)-2-[(3'-fluoro-4'-methoxybiphenyl-4- yD(methylsulfonyl)amino]-4-[4-oxo -7-(trifluoromethyl)-1.2.3-benzotriazin-3(4H)- yl]butanoic acid (Compound no. 97) (Scheme VI)
Step a: Preparation of (45)-4-[2-(benzyloxy)ethyl]-2,2-dimethyl-1,3-dioxolane
To an ice-cooled solution of 2-[(45)-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol (5 g, 34.24 mmoles) in N,N’ -dimethylformamide (50 mL) was added sodium hydride (1.06 g, 44.52 mmoles) and stirred for about 15 minutes. After 15 minutes, benzyl bromide (7.02 g, 41.09 mmole) was added and again stirred for about one hour at the same temperature.
After completion of reaction, aqueous solution of ammonium chloride was added and the solvent was evaporated under vacuum. The reaction mixture was taken in ethyl acetate and washed with water. The organic layer was collected, dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain a crude product. The crude product was purified on silica gel column using 20% ethyl acetate: hexane as eluent to get the desired product.
Yield: 8 g
LCMS: 237.30 (M+1)
Step b: Preparation of (25)-4-(benzyloxy)butane-1,2-diol
To a solution of compound obtained from Step a (8 g) in acetone (50 mL) was added hydrochloric acid (12 mL, 11 N) at room temperature and stirred for about 3 hours at room temperature. After completion of reaction, the solvent was evaporated under reduced pressure and pH was adjusted to neutral by addition of aqueous solution of sodium bicarbonate. The reaction mixture was extracted with ethyl acetate while washing with water. The combined organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product was purified on silica gel column using 20% ethyl acetate: hexane as eluent to get desired compound.
Yield: 5g
LCMS: 197.24 (M+1)
Step c: Preparation of (25)-4-(benzyloxy)-2-hydroxybutyl benzoate
To an ice-cooled solution of compound obtained from Step b (5 g, 31.05 mmoles) in dichloromethane (100 mL) were added triethylamine (9.4 g, 93.16 mmoles) and benzoyl chloride (3.9 g, 27.95 mmoles). The reaction mixture was allowed to stir for about 45 minutes at the same temperature. After 45 minutes, the reaction mixture was extracted with dichloromethane while washing with water. The combined organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product was purified on silica gel column using 60% ethyl acetate: hexane as eluent to get desired compound.
Yield: 5g
LCMS: 301.25 (M+1)
Step d: Preparation of (2R)-4-(benzyloxy)-2-[(4-bromophenyl)(methylsulfonyl) amino]butyl benzoate
To a solution of compound obtained from Step ¢ (5 g, 16.66 mmole) in tetrahydrofuran (100 mL) at 0°C were added triphenyl phosphine (8.7 g, 33.33 moles), N- (4-bromophenyl)methanesulfonamide (4.58 g, 18.33 mmoles) and diisopropylazodicarboxylate (5 g, 25 mmoles). The reaction mixture was allowed to stir for about one hour at same temperature. After that the reaction mixture was concentrated to obtain a crude product which was purified on column chromatography on silica gel column using 60% ethyl acetate: hexane as eluent to get desired product.
Yield: 14 g
LCMS: 534.04 (M+2)
Step e: Preparation of (2R)-4-(benzyloxy)-2-[(3'-fluoroe-4'-methoxybiphenyl-4-yl) (methyl sulfonyl)amino] butyl benzoate
To a solution of compound obtained from Step d (5 g, 9.398 mmoles) in N, N’- dimethylformamide (50 mL) were added 3-fluoro-4-methoxyphenylboronic acid (3.19 g, 18.796 mmoles), potassium carbonate (3.89 g, 28.195 mmoles) and tetrakistriphenyl phosphine palladium (0) (542 mg, 0.469 mmoles). The reaction mixture was heated upto 110°C for about 3 hours. After 3 hours, the solvent was evaporated and the reaction mixture was extracted with ethyl acetate while washing with water. The combined organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain a crude product. The crude product was purified on silica gel column using 30% ethyl acetate hexane as eluent to get desired product.
Yield: 43 ¢g
Step f: Preparation of (2R)-2-[(3'-fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl) amino|-4-hydroxybutyl benzoate
To a solution of compound obtained from Step e (4.39 g, 0.008 moles) in tetrahydrofuran (60 mL) and methanol (40 mL) was added Pd/C (2.5 g) in the presence of hydrogen gas supplied using balloon. The reaction mixture was allowed to stir for overnight at room temperature. After completion, reaction mixture was filtered through celite and residue so obtained was washed with 10% methanol: dichloromethane (200 mL).
The filtrate was collected and dried to get desired compound.
Yield: 2.5¢g
LCMS: 488.16
Step g: Preparation of (2R)-2-[(3'-fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl) amino]-4-[4-0x0-7-(trifluoromethyl)-1,2,3-benzotriazin-3(4 H)-yl| butyl benzoate
To a solution of compound obtained from Step (2.5 g, 0.0051 moles) in tetrahydrofuran (30 mL) were added 7-trifluoromethoxy benzotriazinone (1.21 g, 0.00564 moles) and triphenyl phosphine (2.68 g, 0.010 moles) at room temperature under nitrogen atmosphere. After 5 minutes, diisopropylazodicarboxylate (1.55 g, 0.0077 moles) was added under nitrogen atmosphere and the reaction mixture was stirred at the same temperature for about one hour. After completion, the reaction mixture was extracted with ethyl acetate and washed with water. The combined organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to get crude product.
The crude product was purified on silica gel column using 30% ethyl acetate: hexane as eluent to get desired product.
Yield: 4.2 g
LCMS: 685.15 (M+1)
Step h: Preparation of N-(3'-fluoro-4'-methoxybiphenyl-4-yI)- V-{(2R)-1-hydroxy-4- [4-0x0-7-(trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl|butan-2- yl}methanesulfonamide
To a solution of compound obtained from Step g (4.2 g, 0.00614 moles) in methanol (40 mL) at room temperature was added potassium carbonate (1.27 g, 0.00921 moles) under argon atmosphere. The reaction mixture was allowed to stir for about one hour at same temperature. After completion, solvent was evaporated and the reaction mixture was extracted with ethyl acetate while washing with water. The combined organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to get crude product. The crude product was purified on silica gel column using 40% ethyl acetate: hexane as eluent to obtain a desired compound.
Yield: 3.1g
LCMS: 581.04
Step i: Preparation of (2R)-2-[(3'-fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl) amino]-4-[4-0x0-7-(trifluoromethyl)-1,2,3-benzotriazin-3(4 H)-yl|butanoic acid
To a solution of compound obtained from Step h (900 mg, 1.552 mmoles) in acetonitrile:carbon tetrachloride: water (12ml:12ml:16ml) at room temperature were added ruthenium trichloride (13 mg, 0.062 mmoles) and sodium periodate (996 mg, 4.66 mmoles). The reaction mixture was allowed to stir for about 30 minutes at same the temperature. After completion, solvent was evaporated and the reaction mixture was extracted with ethyl acetate while washing with water. The combined organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to get a crude product. The crude product was purified on preparative TLC using 10% methanol: dichloromethane as mobile phase to get the desired product.
Yield: 107 mg.
LCMS: 595 (M+1) 'H NMR (DMSO-ds, 400 MHz): § 8.59 (1H, 5), 8.44 (1H, d, J = 8 Hz), 8.22 (1H, d, J=8
Hz), 7.71 (2H, d, J=8 Hz), 7.59 ( 3H, m), 7.50 (1H, d, J=8 Hz), 7.25 (1H, t, J = 8 Hz), 4.82 (1H, m), 4.55 (2H, m), 3.88 (3H, s, -OCH3), 3.17 (3H, s, S-CH3), 2.4 (1H, m), 1.90 (1H, m).
The following compounds can be prepared by following the above synthetic route. (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(8-methyl- 4-o0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 98);
LCMS: 541.11 (M+1) (2R)-4-(7-Chloro-4-ox0-1,2,3-benzotriazin-3(4H)-yl)-2-[(3'-fluoro-4'- methoxybiphenyl-4-yl)(methylsulfonyl)amino]butanoic acid (Compound no. 99);
LCMS: 561.00 (M+1) (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(7- methoxy-4-o0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 100);
LCMS: 557.10 (M+1) (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(6-methyl- 4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 101);
LCMS: 541.05 (M+1) (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(8- methoxy-4-o0xo0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 102);
LCMS: 557.10 (M+1) (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(6-fluoro-4- 0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 103).
Assay for Matrix Metallo Proteinases (MMPs)
New chemical entities (NCEs) of the present invention and corresponding standards used in the present invention were prepared (stock 10 mM) in 100% DMSO and subsequent dilutions were made in 50% DMSO-50% TCNB (50 mM Tris, 10 mM CaCl,, 150 mM NaCl, 0.05% Brij-35, pH 7.5). 1 ul of the compound and 88 pl of TCNB was added to wells of 96 well plate to achieve the desired final concentration of NCE (final
DMSO concentration should not exceed 0.5%). 1 pl of activated, recombinant MMPs was added to each well (20-100 ng/100 pl reaction mixture) except the “negative well”. (MMP-1, 9 &14 enzymes require prior activation. For this, supplied enzyme was incubated with either APMA, final concentration 1 mM, for a time period of 1 hour at 37°C). Incubation was done at room temperature (~ 25°C) for 4 minutes to 5 minutes.
The Reaction was initiated with 10 pl of 100 uM substrate (ES001: Aliquots were freshly diluted in TCNB; stock: 2 mM) and increase in florescence was monitored at excitation wave length 320 nm followed by emission at 405 nm for 25-30 cycles. Increase in florescence (RFU) was calculated for positive, negative and NCE/standard wells. The percent inhibition compared to controls was calculated and ICs values determined using
Graph-prism software.
Activities for MMP9 provided ICs values below 10 micromolar. Activities for MMP12 provided ICs values 35 nanomolar to 10 micromolar.
Claims (1)
- We Claim:1 1. A compound of Formula I: A £1 0 ye 2 R? 3 Formula 1 4 including racemates, enantiomers or diastereomers thereof; or a pharmaceutically acceptable salt thereof, wherein, 6 Lis selected from bond, O, S, CH, NR*, NHCO(CHa),, (CH,),CONH, NHCONH, 7 SO,NH, NHSO,, NHCO(O), -O-(CH3)y, -(CH2),-O-, -OC(O)NH-, C(S)NH, 8 NHC(S), NHC(S)NH or -COO- wherein n is zero or an integer between 1 and 2; 9 R' is selected from hydrogen, C1-Ce alkyl, hydroxyl, C,-Cg alkoxy, cyano, nitro, halogen, halogeno C;-Cgalkyl, Cs-C; aryl, Cs-C1; heteroaryl, Cs-Cecycloalkyl 11 wherein aryl, heteroaryl, cycloalkyl is optionally substituted by one or more 12 substitutents independently selected from R; 13 R? is CHO or SO,C 1 alkyl; 14 Ris unsubstituted or substituted heteroaryl or -OCONHR’ where R’ is Ce-Ci aryl, heteroaryl, cycloalkyl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, 16 heterocyclylalkyl each of which is optionally substituted by one or more 17 substitutents independently selected from R; 18 R*is H or Cy¢alkyl; 19 R’ is selected from alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C;-Cs alkyl, halogeno-C;-Cs alkoxy, azido, thiol, alkylthiol, -(CH,),-OR¢ -C(=0)-Rg, - 21 COORy, -NRRy, -(CH»),-C(=O)NRR, -(CH»),-NHC(=0)-Rs, -(CH»),- O- 22 C(=0)-NRR,, (CHz)n NHC(=0)NRR, -(CH2)n-O-C(=0)- Ry, -(CHy)n-NH-C(=0)- 23 Rror -(CH2)nS(=0)m-NRR {wherein Rr and Rg are independently selected from 24 hydrogen, alkyl, alkenyl, cycloalkyl aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl, n is as define earlier and m is an integer 0-2}.1 2. A compound of Formula I, which is: 2 2-[Formyl(4'-methylbiphenyl-4-yl)amino]-4-(6-methyl-4-oxo0-1,2,3-benzotriazin- 3 3(4H)-yl)butanoic acid (Compound no. 1); 4 4-(7-Chloro-4-ox0-1,2,3-benzotriazin-3(4H)-yl)-2-[ formyl(4'-methylbiphenyl-4- yl)amino Jbutanoic acid (Compound no. 2); 6 2-[(4'-Ethylbiphenyl-4-yl)(formyl)amino]-4-(5-methyl-4-oxo-1,2,3-benzotriazin- 7 3(4H)-yDbutanoic acid (Compound no. 3); 8 O-[(4-Fluorophenyl)carbamoyl]-V-formyl-N-(4'-methylbiphenyl-4-yl)homoserine 9 (Compound no. 4); N-Formyl-N-(4'-methylbiphenyl-4-y1)-O-[(4-methylphenyl)carbamoyl homoserine 11 (Compound no. 5); 12 O-[(3,4-Dichlorophenyl)carbamoyl]-N-formyl-N-(4'-methylbiphenyl-4- 13 yDhomoserine (Compound no. 6); 14 N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O- {[4-(propan-2-y])phenyl]carbamoyl} homoserine (Compound no. 7); 16 N-(4'-Ethylbiphenyl-4-yl)-O-[(3-fluorophenyl)carbamoyl]- N-formylhomoserine 17 (Compound no. 8); 18 O-[(2,4-Difluorophenyl)carbamoyl]-N-(4'-ethylbiphenyl-4-yl)-N- 19 formylhomoserine (Compound no. 9); N-(4'-Ethylbiphenyl-4-yl)-O-[(2-fluorophenyl)carbamoyl]- N-formylhomoserine 21 (Compound no. 10); 22 N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O- {[4-trifluoromethyl)phenyl|carbamoyl} 23 homoserine (Compound no. 11); 24 N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O-[(2-methylphenyl)carbamoyl homoserine (Compound no. 12); 26 N-(4'-Ethylbiphenyl-4-yl)-O-[(4-ethylphenyl)carbamoyl]-N-formylhomoserine 27 (Compound no. 13); 28 N-(4'-Ethylbiphenyl-4-yl)-N-formyl-O-[ (4-methoxyphenyl)carbamoyl] homoserine 29 (Compound no. 14); O-[(2,6-Dichlorophenyl)carbamoyl]-N-(4'-ethylbiphenyl-4-y1)- N- 31 formylhomoserine (Compound no. 15); 32 2-[Biphenyl-4-yl(methylsulfonyl)amino]-4-(1,3-dioxo-1,3-dihydro-2 H-isoindol-2- 33 yDbutanoic acid (Compound no. 16); 34 4-(1,3-Dioxo- 1,3-dihydro-2 H-isoindol-2-yl)-2- {[4-(6-methoxypyridin-3-yl)phenyl] (methyl sulfonyl)amino } butanoic acid (Compound no. 17); 36 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-y1)-2-[(4'-methoxybiphenyl-4yl) 37 (methylsulfonyl) amino |butanoic acid (Compound no. 18);38 2-{[4-(6-Methoxypyridin-3-yl)phenyl](methylsulfonyl)amino} -4-(4-oxo0-1,2,3- 39 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 19); 40 4-(7-Methoxy-4-0x0-1,2,3-benzotriazin-3(4H)-yl)-2- {[4-(6-methoxypyridin-3- 41 yl)phenyl](methylsulfonyl)amino} butanoic acid (Compound no. 20); 42 2-{[4-(6-Methoxypyridin-3-yl)phenyl](methylsulfonyl)amino} -4-[4-ox0-7- 43 (trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]butanoic acid (Compound no. 21); 44 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-yl)-2- {[4-(6-methoxypyridin-3- 45 yl)phenyl](methyl sulfonyl)amino } butanoic acid (Compound no. 22); 46 4-(6-Methoxy-4-oxo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {[4-(4- 47 methylphenoxy)phenyl](methyl sulfonyl)amino } butanoic acid (Compound no. 23); 48 4-(7-Methyl-4-oxo0-1,2,3-benzotriazin-3(4H)-yl)-2- {[4-(4-methylphenoxy) 49 phenyl](methyl sulfonyl) amino} butanoic acid (Compound no. 24); 50 2-{[4-(4-Methylphenoxy)phenyl](methylsulfonyl)amino } -4-[4-oxo-7- 51 (trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]butanoic acid (Compound no. 25); 52 2- {[4-(4-Methylphenoxy)phenyl](methylsulfonyl)amino} -4-(4-o0xo0-1,2,3- 53 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 26); 54 2-[(3',4'-Difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 55 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 27); 56 2-[(4'-Ethylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin- 57 3(4H)-yl)butanoic acid (Compound no. 28); 58 2-{[4-(2-Methoxypyrimidin-5-yl)phenyl](methylsulfonyl)amino} -4-(4-oxo0-1,2,3- 59 benzotriazin -3(4H)-yl)butanoic acid (Compound no. 29); 60 2-[(3'-Fluoro-4'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 61 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 30); 62 2-[(2',4'-Dimethoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 63 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 31); 64 2-[(4-Methoxyphenyl)(methylsulfonyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)- 65 yDbutanoic acid (Compound no. 32); 66 4-(7-Methoxy-4-o0x0-1,2,3-benzotriazin-3(4 H)-yl)-2-[ (4-methoxyphenyl) 67 (methylsulfonyl)amino]butanoic acid (Compound no. 33); 68 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-y1)-2-[(4- 69 methoxyphenyl)methylsulfonyl)amino]butanoic acid (Compound no. 34); 70 2-[(4-Methoxyphenyl)(methylsulfonyl)amino]-4-(5-methyl-1,3-dioxo-1,3-dihydro- 71 2H-isoindo-2-yl)butanoic acid (Compound no. 35); 72 4-(7-Methoxy-4-oxo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {[4-(4- 73 methylphenoxy)phenyl](methyl sulfonyl)amino} butanoic acid (Compound no. 36); 74 4-(5-Methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2- {[4-(4-methylphenoxy) 75 phenyl](methylsulfonyl)amino } butanoic acid (Compound no. 37);76 2-[(3'-Methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin- 77 3(4H)-yl)butanoic acid (Compound no. 38); 78 2-[(4'-Fluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3-benzotriazin- 79 3(4H)-yl)butanoic acid (Compound no. 39); 80 2- {(Methylsulfonyl)[4'-(propan-2-yl)biphenyl-4-yl]Jamino } -4-(4-ox0-1,2,3- 81 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 40); 82 2-[Biphenyl-4-yl(methylsulfonyl)amino]-4-(4-oxo-1,2,3-benzotriazin-3(4 H)- 83 yDbutanoic acid (Compound no. 41); 84 2-{[4-(6-Methylpyridin-3-yl)phenyl]|(methylsulfonyl)amino} -4-(4-oxo0-1,2,3- 85 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 42); 86 2-{(Methylsulfonyl)[4-(pyrimidin-5-yl)phenyl]amino } -4-(4-0xo0-1,2,3- 87 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 43); 88 2- {(Methylsulfonyl)[4-(pyridin-3-yl)phenyl]amino} -4-(4-ox0-1,2,3-benzotriazin- 89 3(4H)-yl)butanoic acid (Compound no. 44); 90 2- {(Methylsulfonyl)[4'-(trifluoromethyl)biphenyl-4-yl]amino} -4-(4-oxo0-1,2,3- 91 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 45); 92 2- {(Methylsulfonyl)[4-(pyridin-4-yl)phenyl]amino} -4-(4-ox0-1,2,3-benzotriazin- 93 3(4H)-yl)butanoic acid (Compound no. 46); 94 2-[(3',4'-Dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- 95 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 47); 96 2-[(4'-tert-Butylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 97 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 48); 98 2-[(2',3"-Difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 99 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 49); 100 2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- 101 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 50); 102 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-y1)-2- {(methylsulfonyl)[4-(propan-2- 103 yl)phenyl]amino } butanoic acid (Compound no. 51); 104 4-(6-Methoxy-4-o0xo0-1,2,3-benzotriazin-3(4 H)-yl)-2- {(methylsulfonyl)[4-(propan- 105 2-yl)phenyl]amino } butanoic acid (Compound no. 52); 106 4-(7-Methyl-4-oxo0-1,2,3-benzotriazin-3(4H)-yl)-2- {(methylsulfonyl)[4-(propan-2- 107 yl)phenyl]amino } butanoic acid (Compound no. 53); 108 4-(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-y1)-2-[(4- 109 ethylphenyl)(methylsulfonyl)amino]butanoic acid (Compound no. 54); 110 2-[(4-Ethylphenyl)(methylsulfonyl)amino]-4-(5-methyl-1,3-dioxo-1,3-dihydro-2 H- 111 isoindol-2-yl)butanoic acid (Compound no. 55); 112 2-[(4-Ethylphenyl)(methylsulfonyl)amino]-4-(7-methyl-4-oxo0-1,2,3-benzotriazin- 113 3(4H)-yl)butanoic acid (Compound no. 56);114 2-[(4-Ethylphenyl)(methylsulfonyl)amino]-4-(6-methoxy-4-oxo0-1,2,3- 115 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 57); 116 2-[(Methylsulfonyl)(phenyl)amino]-4-(4-oxo- 1,2,3-benzotriazin-3(4H)-yl)butanoic 117 acid (Compound no. 58); 118 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-methyl- 1,3-dioxo-1,3- 119 dihydro-2H-isoindol-2-yl)butanoic acid (Compound no. 59); 120 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-chloro-4-oxo-1,2,3- 121 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 60); 122 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(7-chloro-4-oxo-1,2,3- 123 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 61); 124 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(7-methyl-4-oxo0-1,2,3- 125 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 62); 126 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-[4-oxo-7-(trifluoromethyl)- 127 1,2,3-benzotriazin-3(4H)-yl]butanoic acid (Compound no. 63); 128 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-methoxy-4-oxo-1,2,3- 129 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 64); 130 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(5-fluoro-4-oxo-1,2,3- 131 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 65); 132 2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(1-methyl-2.,4-dioxo-1,4- 133 dihydroquinazolin-3(2H)-yl)butanoic acid (Compound no. 66); 134 4-{(Methylsulfonyl)[ 1-ox0-4-(4-0x0-1,2,3-benzotriazin-3(4 H)-yl)-1-(prop-2-en-1- 135 yloxy)butan-2-yl] amino} benzoic acid (Compound no. 67); 136 2-[ {4-[(4-Methylphenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 137 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 68); 138 2-[ {4-[(4-Chlorophenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 139 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 69); 140 2-{(Methylsulfonyl)[4-(phenylcarbamoyl)phenyl]amino} -4-(4-ox0-1,2,3- 141 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 70); 142 2-[{4-[(3-Fluorophenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 143 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 71); 144 2-[(Methylsulfonyl)(4- {[4-(propan-2-yl)phenyl] carbamoyl} phenyl)amino]-4-(4- 145 0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 72); 146 2-[{4-[(4-Methoxyphenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 147 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 73); 148 2-[{4-[(4-Fluorophenyl)carbamoyl]phenyl} (methylsulfonyl)amino]-4-(4-oxo- 149 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 74); 150 2-[(Methylsulfonyl)(4- {[4-(trifluoromethyl)phenyl]carbamoyl} phenyl )amino]-4- 151 (4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 75);152 (2R)-2-[(4'-Fluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 153 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 76); 154 (2R)-2- {(Methylsulfonyl)[4-(pyrimidin-5-yl)phenyl]amino} -4-(4-oxo0-1,2,3- 155 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 77); 156 (2R)-2- {(Methylsulfonyl)[4'-(propan-2-yl)biphenyl-4-yl]amino} -4-(4-0xo0-1,2,3- 157 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 78); 158 (2R)-2-[(3',4'-Dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 159 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 79); 160 (2R)-2-[(3',4'-Difluorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 161 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 80); 162 (2R)-2-[(3'-Fluoro-4'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 163 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 81); 164 (2R)-2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- 165 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 82); 166 (2R)-2-[(3'-Methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- 167 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 83); 168 (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo- 169 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 84); 170 (2R)-2-[Biphenyl-4-yl(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin-3(4 H)- 171 yl)butanoic acid (Compound no. 85); 172 (2R)-2- {[4-(6-Methoxypyridin-3-yl)phenyl](methylsulfonyl)amino} -4-(4-oxo- 173 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 86); 174 (25)-2-[(4'-Chlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- 175 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 87); 176 (25)-2-[(3',4'-Dichlorobiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 177 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 88); 178 (25)-2-[(3'-Fluoro-4'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3- 179 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 89); 180 (28)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo- 181 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 90); 182 (2R)-2-[(3',4'-Dimethoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 183 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 91); 184 (2R)-2-{[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)phenyl] (methylsulfonyl)amino } -4- 185 (4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 92); 186 (2R)-2-[(4'-Methoxy-3'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo- 187 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 93); 188 (2R)-2-[(4'-Fluoro-3'-methylbiphenyl-4-yl)(methylsulfonyl)amino]-4-(4-oxo-1,2,3- 189 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 94);190 (2R)-2- {(Methylsulfonyl)[4'-(trifluoromethoxy)biphenyl-4-ylJamino } -4-(4-oxo- 191 1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 95); 192 (2R)-2- {[4'-Chloro-3'-(trifluoromethyl)biphenyl-4-yl](methylsulfonyl)amino } -4- 193 (4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 96); 194 (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-[4-oxo-7- 195 (trifluoro methyl)-1,2,3-benzotriazin-3(4H)-yl]butanoic acid (Compound no. 97); 196 (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(8-methyl- 197 4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 98); 198 (2R)-4-(7-Chloro-4-ox0-1,2,3-benzotriazin-3(4H)-yl)-2-[(3'-fluoro-4'- 199 methoxybiphenyl-4-yl)(methylsulfonyl)amino]butanoic acid (Compound no. 99); 200 (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(7- 201 methoxy-4-o0xo0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 100); 202 (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(6-methyl- 203 4-0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 101); 204 (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(8- 205 methoxy-4-o0xo0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 102); 206 (2R)-2-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]-4-(6-fluoro-4- 207 0x0-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound no. 103); 208 4-(5-Chloro-4-o0x0-1,2,3-benzotriazin-3(4H)-yl)-2-[ (4- 209 chlorophenyl)(methylsulfonyl)amino]butanoic acid (Compound no. 104); 210 2-[(4-Bromophenyl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin-3(4H)- 211 yDbutanoic acid (Compound no. 105); 212 2-[(4-Chlorophenyl)(methylsulfonyl)amino]-4-(4-oxo0-1,2,3-benzotriazin-3(4H)- 213 yDbutanoic acid (Compound no. 106); 214 2-[(4-Chlorophenyl)(methylsulfonyl)amino]-4-(7-methyl-4-oxo-1,2,3- 215 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 107); 216 2-[(4-Chlorophenyl)(methylsulfonyl)amino]-4-(6-methoxy-4-oxo-1,2,3- 217 benzotriazin-3(4H)-yl)butanoic acid (Compound no. 108) 218 including racemates or diastereomers thereof; or a pharmaceutically acceptable salt thereof. 1 3 A pharmaceutical composition comprising a therapeutically effective amount of a 2 compound according to claims 1 and 2, together with one or more pharmaceutically 3 acceptable carriers, excipients or diluents. 1 4 A compound according to claims 1 and 2, for use in the treatment or prophylaxis of 2 an animal or a human suffering from an inflammatory or allergic disease.1 5. A compound according to claim 4, wherein the inflammatory or allergic disease is 2 asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis,3 pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, 4 perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation associated with restenosis and ischemic heart failure, stroke, renal disease, 6 tumor metastasis.1 6. A pharmaceutical composition according to claim 3, further comprising one or 2 more of additional active ingredients selected from: 3 a) Anti-inflammatory agents, selected from (i) the nonsteroidal anti- 4 inflammatory agents piroxicam, diclofenac, propionic acids, fenamates, 5 pyrazolones, salicylates, PDE-4 inhibitors, p38 MAP Kinase/Cathepsin 6 inhibitors, (ii) leukotrienes LTC4/LTD4/LTE4/LTB4-Inhibitors, 5- 7 lipoxygenase inhibitor and PAF-receptor antagonists, (iii) Cox-2 inhibitors, 8 (iv) other MMP inhibitors, and (v) interleukin-I inhibitors; 9 b) antihypertensive agents, selected from (i) the ACE inhibitors, like enalapril, lisinopril, valsartan, telmisartan and quinapril (ii) the angiotensin II receptor 11 antagonists and agonists-. losartan, candesartan, irbesartan, valsartan, and 12 eprosartan, (iii) B-blockers, and (iv) calcium channel blockers. 13 ¢) immunosuppressive agents selected from cyclosporine, azathioprine and 14 methotrexate, and anti inflammatory corticosteroids.1 7. A process for preparing a compound of Formula 10 (Formula 1 when RY is 2 heteroaryl, L' is bond, R? is CHO and R' is substituted aryl or heteroaryl) and Formula 13 3 (Formula I when R® is -OCONHR’, L' is bond R? is CHO and R' is substituted aryl or 4 heteroaryl) comprising: 5 a) reacting 4-bromo-4-nitrobenzene with a compound of Formula 2 HO OH Ng” 6 Re 7 Formula 2 8 to give a compound of Formula 3;NO, 9 Formula 3 b) reducing a compound of Formula 3 to give a compound of Formula 4 ° NH, R6 11 Formula 4 12 ¢) reacting a compound of Formula 4 with alpha-bromolactone, to give a 13 compound of Formula 5 I oO Lv RS 14 Formula 5 d) formylating a compound of Formula 5 to give a compound of Formula 6 H © Tad RS 16 Formula 6 17 ¢) ring opening of a compound of Formula 6 to give a compound of Formula 7 HO RS OH 18 Formula 7 19 f) reacting a compound of Formula 7 with a compound of Formula 8H N RS 20 Formula 8 21 to give a compound of Formula 9 H +0 RS ® Het29 Formula 9 R 23 g) deprotecting a compound of Formula 9 to give a compound of Formula 10 Hp WH OH 24 R Formula 10 26 or 27 h) reacting a compound of Formula 7 with a compound of Formula 11 pO N 28 RS OH RNCO 29 Formula 7 Formula 11 to give a compound of Formula 12H._.O 5s N RSLo 31 NHR’ 32 Formula 12 33 i) deprotecting a compound of Formula 12 to give a compound of Formula 13 hp? 7 OH RS ALo 34 NHR’ Formula 13 36 wherein, 37 5 is aryl or heteroaryl ring; 38 R®is hydrogen, alkyl, halogen, alkoxy or halogeno-C;-Cs alkyl; 39 R; is carboxy protecting group, such as methyl, ethyl, allyl, benzyl, t-butyl, 40 silyl, BOC anhydride; 41 is a heteroaryl ring; 42 R’ is C6-Cp aryl, heteroaryl, cycloalkyl, heterocyclyl, arylalkyl, 43 heteroarylalkyl, cycloalkylalkyl, heterocyclylalkyl each of which is 44 optionally substituted by one or more substitutents independently selected 45 from R’; 46 R’ is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C-Cs alkyl, 47 halogeno-Ci-Cs alkoxy, azido, thiol, alkylthiol, -(CH2),-OR;, -C(=0)-R¢, - 48 COORy, -NRR, -(CH,),-C(=O)NRR, -(CH,),-NHC(=0)-R, -(CH,),-O- 49 C(=0)-NRR,, (CH) NHC(=O)NRR,, -(CHy),-O-C(=0)- Rs, -(CH,),-NH-50 C(=0)-Rror -(CH2)nS(=0)n-NRR {whereinRrand Rare independently 51 selected from hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, 52 alkylaryl, alkylheteroaryl and alkylheterocyclyl; n can be zero or an integer 53 between 1 and 2 and m is an integer 0-2}.1 8. A process for preparing a compound of Formula 20 (Formula 1 when RY is 2 heteroaryl, L! is bond, R* is SO,-C)¢-alkyl and R' is substituted aryl or heteroaryl) 3 comprising: 4 a) halogenating a compound of Formula 14 at alpha position RS {eck ~My 6 Formula 14 7 to give a compound of Formula 15 8 Hal 9 Formula 15 b) protecting a compound of Formula 15 to give a compound of Formula 16 RS firaX ok, 11 ~ Hal 12 Formula 16 13 Cc) reacting a compound of Formula 16 with a compound of Formula 17 (where 14 Ry is halogen) to give a compound of Formula 18 Ak 80, 0 OC Hal H N: Re Re16 Formula 17 Formula 18 17 d) coupling of a compound of Formula 18 with a compound of Formula 2 to 18 give a compound of Formula 19AkSo,HO OH re oH } 4 © 19 RS R? Formula 2 Formula 19 21 e) deprotecting a compound of Formula 19 to give a compound of Formula 20 Ak 0, ov N (9) 22 Re 23 Formula 20 24 or f) reacting a compound of Formula 16, with a compound of Formula 17 (where 26 Ry is aryl/heteroaryl substituted with R%) Naso -Ak rd OT27 Hal R, 28 Formula 16 Formula 17 29 to give a compound of Formula 19Ak $0, v9 A R® N re 31 Formula 19 32 g) deprotecting a compound of Formula 19 to give a compound of Formula 20 Ak 50, EO) Sa R® N 33 Re 34 Formula 20 wherein, 36 is a heteroaryl ring; 37 R; is carboxy protecting group such as methyl, ethyl, allyl, benzyl, t-butyl, 38 silyl, BOC anhydride; 39 R’ is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C,-Cs alkyl, 40 halogeno-C;-Cs alkoxy, azido, thiol, alkylthiol, -(CH,),-OR; -C(=0)-Rg, - 41 COORy, -NRRy, -(CH»),-C(=O)NRR, -(CH»),-NHC(=0)-Rs, -(CH»),- O- 42 C(=0)-NRR,, (CH)x NHC(=O)NRR,, -(CH,),-O-C(=0)- Ry, -(CH,),-NH- 43 C(=0)-Rt or -(CH2)nS(=0)n-NRR, {wherein Rand Rare independently 44 selected from hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, 45 alkylaryl, alkylheteroaryl and alkylheterocyclyl; n can be zero or an integer 46 between 1 and 2 and m is an integer 0-2}; 47 Hal is F, Cl, Br, I;48 Ak is Cygalkyl; 49 & is aryl or heteroaryl ring; 50 R®is hydrogen, alkyl, halogen, alkoxy or halogeno-C;-Cg alkyl. 1 9 A process for preparing a compound of Formula 26b (Formula 1 when R? is 2 heteroaryl, L' is bond, R? is SO,-C ¢-alkyl and R' is aryl/heteroaryl substituted with 3 OR®) and Formula 29 (Formula 1 when R? is heteroaryl, L'is bond, R? is S0,-C;¢-alkyl 4 and R'is halogen/hydrogen, alkoxy/aryloxy) comprising: a) reacting a compound of Formula 17a with alpha hydroxy lactone, to give a 6 compound of Formula 21 Ak { A oe OM 7 Ry Ry. 8 Formula 17a Formula 21 9 b) ring opening of a compound of Formula 21 to give a compound of Formula 22 i SO, N Oy 11 OH 12 Formula 22 13 ¢) protecting a compound of Formula 22 at carboxyl group to give a compound 14 of Formula 23Ak 50, Hy oyR. 16 K OH 17 Formula 23 18 d) protecting a compound of Formula 23 (when Ry is halogen) at hydroxyl 19 group to give a compound of Formula 24 Ak I SO, N oy Hal ORp' 21 Formula 24 22 ¢) coupling of a compound of Formula 24 with a compound of Formula 24a , to 23 give a compound of Formula 25 Ak HO OH Ng s0, Sd iho O« RY 24 RS ~0 ORp Formula 24a Formula 25 26 f) deprotecting a compound of Formula 25 to give a compound of Formula 26 Ak SO, Q N ORp 0 OH 27 Formula 2628 g) reacting a compound of Formula 26 with a compound of Formula 27, to give 29 a compound of Formula 26a Ak 1 SO, N I RY N & “0 RS IS ns 31 Formula 27 Formula 26a 32 h) deprotecting a compound of Formula 26a to give a compound of Formula 33 26b Ak 50, N OH Waves 0 N 34 R Formula 26b 36 or 37 i) reacting a compound of Formula 23 (when Ry is 38 alkoxy/aryloxy/halogen/hydrogen) with a compound of Formula 27 Ak 50, Y oryR,. 5 He 39 ‘ on R SS 40 Formula 23 Formula 27 41 to give a compound of Formula 28Ak [ SO, N oryR,. c N ® 42 R? 43 Formula 28 44 j) deprotecting a compound of Formula 28 to give a compound of Formula 29; Ak SO co N oyR,. K N ® 45 Re 46 Formula 29 47 wherein, 48 Ak is Cy galkyl: 49 R; is carboxy protecting group such as methyl, ethyl, allyl, benzyl, t-butyl, 50 silyl, BOC anhydride; 51 Ry: is hydroxyl protecting group such as benzoyl , silyl groups fert- 52 butyldimethylsilyl, trimethylsilyl, ferz-butyldimethylsilyloxymethyl, 53 triisopropylsilyl; 54 rk is a heteroaryl ring; 55 Ry is hydrogen, halogen, alkoxy, aryloxy, aryl, carboxy; 56 R’ is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C,-Cs alkyl, 57 halogeno-C;-Cs alkoxy, azido, thiol, alkylthiol, -(CH,),-OR; -C(=0)-Rg, -58 COORy, -NRRy, -(CH»),-C(=O)NRR, -(CH»),-NHC(=0)-Rs, -(CH»),- O- 59 C(=0)-NRR,, (CH), NHC(=O)NRR, -(CH3),-O-C(=0)- Ry, -(CH>),-NH- 60 C(=0)-Rt or -(CH2)aS(=0)m-NRR, {wherein Rr and Rg are independently 61 selected from hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, 62 alkylaryl, alkylheteroaryl and alkylheterocyclyl; n can be zero or an integer 63 between 1 and 2 and m is an integer 0-2}. 64 CC is aryl or heteroaryl ring; 65 OR" wherein R® is hydrogen, alkyl, halogen, alkoxy or halogeno-C;-C 66 alkyl. 1 10. A process for preparing a compound of Formula 31 (Formula 1 when R” is 2 heteroaryl, L' is bond, R? is SO,-C ¢-alkyl and R' is aryl/heteroaryl substituted with 3 halogen) and Formula 36 (Formula 1 when R’ is heteroaryl, L' is -CONH-, R” is SO»-Ak 4 and R! is aryl/heteroaryl) comprising: a) reacting a compound of Formula 23 (when Ry is aryl/heteroaryl substituted 6 with halogen and Rp is allyl) with a compound of Formula 27 Ak 50, 5 oyR,. c 8 Formula 23 Formula 27 9 to give a compound of Formula 30 Ak 50, oy Hal N re11 Formula 30 12 b) deprotecting a compound of Formula 30 to give a compound of Formula 31; Ak 1 SO; N oo ; Hal N 13 Re 14 Formula 31 15 or 16 ¢) reacting a compound of Formula 23 (when Ry is -COORp) with a compound 17 of Formula 27 Ak 50,ory He 18 fe OH rR hu 19 Formula 23 Formula 27 to give a compound of Formula 32; Ak 1 SO, o N oy RpOOC N (x) 21 Re 22 Formula 3223 d) deprotecting a compound of Formula 32 to give a compound of Formula 33; Ak oy N ory HOOC Y N 24 rR? Formula 33 26 ¢) coupling of a compound of Formula 33 with a compound of Formula 34 NH, 27 Re 28 Formula 34 29 to give a compound of Formula 35 Ak SO, [ N N oO N Re 31 Formula 3532 f) deprotecting a compound of Formula 35 to give a compound of Formula 36; Ak SO, 0 RS N Se yoN. 0 N ® 33 rR 34 Formula 36 wherein, 36 Ak is Cygalkyl; 37 Hal is F, Cl, Br, I; 38 R; is carboxy protecting group such as methyl, ethyl, allyl, benzyl, t-butyl, 39 silyl, BOC anhydride; 40 & is aryl or heteroaryl ring; 41 is a heteroaryl ring; 42 R’ is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C,-Cs alkyl, 43 halogeno-C;-Cs alkoxy, azido, thiol, alkylthiol, -(CH,),-OR; -C(=0)-Rg, - 44 COORg, -NRR, -(CH2)n-C(=O)NRRg, -(CH2),-NHC(=0)-Ry, -(CHz),- O- 45 C(=0)-NRR,, (CH)x NHC(=O)NRR,, -(CHy),-0-C(=0)- Ry, -(CH,),-NH- 46 C(=0)-Rs or -(CH2):S(=0)n-NRRy {wherein Rr and Ry are independently 47 selected from hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, 48 alkylaryl, alkylheteroaryl and alkylheterocyclyl; n can be zero or an integer 49 between 1 and 2 and m is an integer 0-2}; 50 Ris hydrogen, alkyl, halogen, alkoxy or halogeno-C;-Cs alkyl. 1 11. A process for preparing a compound of Formula 43 (Formula 1 when R” is 2 heteroaryl, L' is bond, Ris SO,-Ci¢-alkyl and R'is aryl/heteroaryl) comprising:3 a) protecting a compound of Formula 37, to give compound of Formula 38 0 oO yo Oyo 4 OH OR, Formula 37 Formula 38 6 ¢) reacting a compound of Formula 38 with a compound of Formula 39 to give 7 a compound of Formula 40 Ak SO, 0 RS £y yo so Ak RE OR 8 FP 9 Formula 39 Formula 40 d) deprotecting a compound of Formula 40 to give a compound of Formula 41 Ak 50, RS Oyo 11 OH 12 Formula 41 13 e) reacting a compound of Formula 41 with a compound of Formula 27 to give 14 a compound of Formula 42 Ak [ 0 rk yo N © ® R54 Het NH Re 16 Formula 27 Formula 4217 f) deprotecting a compound of Formula 42 to give a compound of Formula 43Ak or ,RS £Y yor N (=)18 Re 19 Formula 43 wherein, 21 Ak is Cigalkyl: 22 & is aryl or heteroaryl ring; 23 R; is carboxy protecting group such as methyl, ethyl, allyl, benzyl, t-butyl, 24 silyl, BOC anhydride; R;: is hydroxyl protecting group such as benzoyl , silyl groups fert- 26 butyldimethylsilyl, trimethylsilyl, ferz-butyldimethylsilyloxymethyl, 27 triisopropylsilyl; 28 (ak is a heteroaryl ring; 29 R’ is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C,-Cg alkyl, halogeno-C;-Cs alkoxy, azido, thiol, alkylthiol, -(CH,),-OR; -C(=0)-Rg, - 31 COORy, -NRRy, -(CH»),-C(=O)NRR, -(CH»),-NHC(=0)-Rs, -(CH»),- O- 32 C(=0)-NRR,, (CH)x NHC(=O)NRR,, -(CH,),-O-C(=0)- Ry, -(CH,),-NH- 33 C(=0)-Rt or -(CH2)nS(=0)n-NRR, {wherein Rand Rare independently 34 selected from hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl; n can be zero or an integer 36 between 1 and 2 and m is an integer 0-2}; 37 Ris hydrogen, alkyl, halogen, alkoxy or halogeno-C;-Cs alkyl.1 12. A process for preparing a compound of Formula 52 (Formula 1 when R” is 2 heteroaryl, L'is bond, R* is SO,-Cy¢-alkyl and R' is substituted aryl/heteroaryl) 3 comprising: 4 a) reacting a compound of Formula 44 with 4-(2-hydroxyethyl)-2,2-dimethyl 1,3-dioxolane to give a compound of Formula 45 Sp ; 4 N N Het (i) 6 7 Formula 44 Formula 45 8 b) ring opening of a compound of Formula 45 to give a compound of Formula 9 46 HQ OH N11 Formula 46 12 ¢) protecting a compound of Formula 46 to give a compound of Formula 47 Rp'Q OH N 13 14 Formula 47 d) reacting a compound of Formula 47 with a compound of Formula 48 to give 16 a compound of Formula 49SO, Ak NHSO,-Ak \ Fe 0 Hal N Het 17 Hal © 18 Formula 48 Formula 49 19 ¢) coupling of a compound of Formula 49 with a compound of Formula 2 to give a compound of Formula 50 SO,-Ak [ OH B ® \ 21 RS Re 22 Formula 2 Formula 50 23 f) deprotecting a compound of Formula 50 to give a compound of Formula 51 S0,-Ak Yon 7 \ D7 24 R Formula 51 26 g) oxidizing a compound of Formula 51 to give a compound of Formula 52 SO,-Ak N 0 FE N Het . (0) 28 Formula 52 29 wherein, Ak is Cigalkyl:31 Ss is aryl or heteroaryl ring; 32 Ry: is hydroxyl protecting group such as benzoyl, silyl including terz- 33 butyldimethylsilyl, trimethylsilyl, ferz-butyldimethylsilyloxymethyl, 34 triisopropylsilyl; 35 S is a heteroaryl ring; 36 Hal is F, Cl, Br, I; and 37 R® is hydrogen, alkyl, halogen, alkoxy or halogeno-C;-C alkyl. 1 13. A process for preparing a compound of Formula 61 (Formula 1 when Ris 2 heteroaryl, L' is bond, R? is SO,-C¢-alkyl and R' is substituted aryl/heteroaryl) 3 comprising: 4 a) protecting 4-(2-hydroxyethyl)-2,2-dimethyl 1,3-dioxolane to give a compound of Formula 53; & 6 ORp' 7 Formula 53 8 b) ring opening of a compound of Formula 53 to give a compound of Formula 9 54; = ORp’ 11 Formula 54 12 ¢) protecting a compound of Formula 54 to give a compound of Formula 55; Rp"Q OH 13 ORp' 14 Formula 55 d) reacting a compound of Formula 55 with a compound of Formula 48 to give 16 a compound of Formula 56;AkSO,Rp"0 Hal 0,Ak oi 17 Hal ORp' 18 Formula 48 Formula 56 19 ¢) coupling of a compound of Formula 56 with a compound of Formula 2 to give a compound of Formula 57 Ak $0, HO_ ,OH § SOT 21 R RS ORp' 22 Formula 2 Formula 57 23 f) deprotecting a compound of Formula 57 to give a compound of Formula 58 Ak I SO, LG24 RE oH Formula 58 26 g) reacting a compound of Formula 58 with a compound of Formula 27 to give 27 a compound of Formula 59Ak SO, N ORp" H N N 28 Re Re 29 Formula 27 Formula 59 h) deprotecting a compound of Formula 59 to give a compound of Formula 60 Ak 50, SIL N R¢ (2) 31 Re 32 Formula 60 33 i) oxidizing a compound of Formula 60 to give a compound of Formula 61 Ak SO, RS N 34 Re Formula 61 36 wherein, 37 Ak is Cigalkyl: 38 > is aryl or heteroaryl ring;39 Ry: and Ry» is hydroxyl protecting group such as benzoyl, silyl groups tert- 40 butyldimethylsilyl, trimethylsilyl, ferz-butyldimethylsilyloxymethyl, 41 triisopropylsilyl; 42 is a heteroaryl ring; 43 R’ is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C;-Cg alkyl, 44 halogeno-C;-Cs alkoxy, azido, thiol, alkylthiol, -(CH»),-OR¢ -C(=0)-R¢, - 45 COOR;y, -NRR, -(CH,),-C(=O)NRR, -(CH;),-NHC(=0)-Ry, (CHy),- O- 46 C(=0)-NRR,, (CH)x NHC(=O)NRR,, -(CHy),-0-C(=0)- Ry, -(CH,),-NH- 47 C(=0)-Rt or -(CH2)nS(=0)n-NRR, {wherein Rand Rare independently 48 selected from hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, 49 alkylaryl, alkylheteroaryl and alkylheterocyclyl; n can be zero or an integer 50 between 1 and 2 and m is an integer 0-2}; 51 Hal is F, Cl, Br, I; and 52 Ris hydrogen, alkyl, halogen, alkoxy or halogeno-C;-Cs alkyl.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2279DE2010 | 2010-09-24 | ||
PCT/IB2011/054229 WO2012038944A1 (en) | 2010-09-24 | 2011-09-26 | Matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG188641A1 true SG188641A1 (en) | 2013-04-30 |
Family
ID=44903306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013021654A SG188641A1 (en) | 2010-09-24 | 2011-09-26 | Matrix metalloproteinase inhibitors |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2619179A1 (en) |
JP (1) | JP2013538821A (en) |
KR (1) | KR20140045287A (en) |
CN (1) | CN103249719A (en) |
AU (1) | AU2011306398A1 (en) |
BR (1) | BR112013008008A2 (en) |
CA (1) | CA2812362A1 (en) |
MX (1) | MX2013003362A (en) |
SG (1) | SG188641A1 (en) |
WO (1) | WO2012038944A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
WO2013166408A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
EP4008355A1 (en) | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
ES2831625T3 (en) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Therapeutic compounds and their uses |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
JP6426194B2 (en) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | Crystalline forms of therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
BR112019004463A2 (en) | 2016-09-08 | 2019-05-28 | Kala Pharmaceuticals Inc | crystalline forms of therapeutic compounds, their processes for obtaining and their methods of use |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
JP2024508794A (en) | 2021-02-19 | 2024-02-28 | スドー バイオサイエンシーズ リミテッド | TYK2 inhibitors and their uses |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0766665T3 (en) | 1994-06-22 | 1999-12-06 | British Biotech Pharm | metalloproteinase |
US5863915A (en) * | 1996-05-15 | 1999-01-26 | Bayer Corporation | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease |
AU758619B2 (en) | 1998-07-30 | 2003-03-27 | Warner-Lambert Company | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
US6366675B1 (en) | 1999-05-21 | 2002-04-02 | Kohji Toda | Sound pressure detecting system |
GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
-
2011
- 2011-09-26 WO PCT/IB2011/054229 patent/WO2012038944A1/en active Application Filing
- 2011-09-26 BR BR112013008008A patent/BR112013008008A2/en not_active Application Discontinuation
- 2011-09-26 CN CN2011800564244A patent/CN103249719A/en active Pending
- 2011-09-26 CA CA2812362A patent/CA2812362A1/en not_active Abandoned
- 2011-09-26 SG SG2013021654A patent/SG188641A1/en unknown
- 2011-09-26 AU AU2011306398A patent/AU2011306398A1/en not_active Abandoned
- 2011-09-26 MX MX2013003362A patent/MX2013003362A/en unknown
- 2011-09-26 JP JP2013529763A patent/JP2013538821A/en not_active Withdrawn
- 2011-09-26 EP EP11776885.3A patent/EP2619179A1/en not_active Withdrawn
- 2011-09-26 KR KR1020137010369A patent/KR20140045287A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR112013008008A2 (en) | 2016-06-21 |
WO2012038944A1 (en) | 2012-03-29 |
EP2619179A1 (en) | 2013-07-31 |
MX2013003362A (en) | 2013-06-05 |
CA2812362A1 (en) | 2012-03-29 |
JP2013538821A (en) | 2013-10-17 |
CN103249719A (en) | 2013-08-14 |
KR20140045287A (en) | 2014-04-16 |
AU2011306398A1 (en) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG188641A1 (en) | Matrix metalloproteinase inhibitors | |
AU2011306396A1 (en) | Matrix metalloproteinase inhibitors | |
US7645784B2 (en) | Benzimidazole derivatives | |
AU2006217615B2 (en) | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases | |
SG188644A1 (en) | Matrix metalloproteinase inhibitors | |
SG187654A1 (en) | Matrix metalloproteinase inhibitors | |
EP1147095B1 (en) | 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors | |
JP2003525203A (en) | Hydroxam and carboxylic acid derivatives | |
CA2317546A1 (en) | 2,3,4,5-tetrahydro-1h-¬1,4|-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors | |
JP4209659B2 (en) | Amidino derivative and anticoagulant and thrombosis therapeutic agent using the same | |
US6544984B1 (en) | 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids | |
KR20090121329A (en) | Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors | |
RAUF et al. | International Bureau |